Fused-ring compound, pharmaceutical composition comprising same, use of fused-ring compound, and method
By developing novel GPR6 receptor modulator compounds, the side effects of existing levodopa compounds in the treatment of Parkinson's disease have been addressed, providing an effective treatment option for GPR6 receptor-mediated diseases and reducing cardiovascular risks.
Patent Information
- Application Number
- PCT/CN2026/095855
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2026-02-09
- Filing Date
- 2026-05-09
- Publication Date
- 2026-11-19
AI Technical Summary
Existing levodopa compounds have serious side effects when used to treat Parkinson's disease, such as movement disorders, impulse control disorders, psychotic symptoms and sleep disorders, and have inhibitory activity on hERG, which may lead to QT interval prolongation and arrhythmia.
Develop novel GPR6 receptor modulator compounds, including cyclic compounds with structures as shown in Formula I and Formula I', for regulating the G protein-coupled receptor GPR6, and prepare corresponding pharmaceutical compositions to treat GPR6 receptor-mediated diseases or disorders.
Effectively prevents and treats GPR6 receptor-mediated diseases or disorders, such as Parkinson's disease, levodopa-induced dyskinesia, Huntington's disease, drug addiction, eating disorders, cognitive impairment, schizophrenia, and depression, reducing side effects and avoiding hERG inhibition.
Smart Images

Figure CN2026095855_19112026_PF_FP_ABST
Abstract
Description
Cyclic compounds, pharmaceutical compositions comprising them, and their uses and methods
[0001] Citation of relevant applications
[0002] This disclosure claims the following patent applications filed with the State Intellectual Property Office on May 16, 2025, application number 202510638478.5, entitled "A Cyclic Compound, a Pharmaceutical Composition Containing the Same, and Uses and Methods Thereof"; filed with the State Intellectual Property Office on May 16, 2025, application number 202510638667.2, entitled "A Cyclic Compound, a Pharmaceutical Composition Containing the Same, and Uses and Methods Thereof"; filed with the State Intellectual Property Office on August 22, 2025, application number 202511182096.2, entitled "A Cyclic Compound, a Pharmaceutical Composition Containing the Same, and Uses and Methods Thereof"; and filed with the State Intellectual Property Office on November 2025. The priority of the following patent applications is hereby granted by reference in their entirety: Application No. 202511626244.5, entitled "Cyclic Compounds, Pharmaceutical Compositions Containing the Same, and Uses and Methods Thereof"; Application No. 202511936601.8, entitled "Cyclic Compounds, Pharmaceutical Compositions Containing the Same, and Uses and Methods Thereof"; and Application No. 202610192210.8, entitled "Cyclic Compounds, Pharmaceutical Compositions Containing the Same, and Uses and Methods Thereof". Technical Field
[0003] This disclosure pertains to the pharmaceutical field, specifically relating to cyclic compounds, pharmaceutical compositions thereof, preparation methods, and their uses and methods. Background Technology
[0004] GPR6 is a highly active G-protein-coupled receptor that can stimulate cellular adenylate cyclase activity and cyclic adenosine monophosphate (cAMP) accumulation in vitro. The GPR6 receptor is highly expressed in the dopamine D2-MSN (moderately spinous neurons) indirect pathway, but less expressed in the direct pathway of MSNs expressing D1 dopamine receptors, other brain regions, and peripheral tissues. GPR6 knockout mice also show reduced cAMP levels in the striatum, consistent with in vivo GPR6-Gs protein coupling and cAMP signaling. In vitro studies show that GPR6 and Gs (stimulatory G proteins) coupling can stimulate cellular adenylate cyclase activity and cAMP accumulation, thereby activating the indirect pathway. In the D2-type MSN indirect pathway, antagonism or inverse activation of GRP6 can reduce excessive activity of the indirect pathway and improve Parkinson's motor symptoms. Preclinical studies have shown that GRP6-deficient PD rodent models exhibit increased motor activity and reduced abnormal involuntary movements.
[0005] Existing levodopa compounds are commonly used to treat Parkinson's disease, but these compounds have common and serious side effects, including inducing motor disorders, impulse control disorders, psychotic symptoms, and sleep disturbances. Patent applications WO2014028479A1 and WO2015095728A1 disclose GPR6 modulators for the treatment of Parkinson's disease. These compounds exhibit significant inhibitory activity against hERG, and hERG inhibition is considered a potential factor related to QT interval prolongation and arrhythmias. This disclosure, through extensive research, develops a novel compound with promising efficacy for treating GPR6 receptor-mediated diseases or disorders. Summary of the Invention
[0006] The purpose of this disclosure is to provide compounds as modulators of the G protein-coupled receptor GPR6, pharmaceutical compositions comprising the same, methods of preparation, and their use in the prevention and / or treatment of diseases or disorders mediated by the GPR6 receptor, such as movement disorders including Parkinson's disease, levodopa-induced dyskinesia, Huntington's disease, drug addiction, eating disorders, cognitive impairment, schizophrenia, bipolar disorder, and depression.
[0007] On the one hand, this disclosure provides a compound, or a stereoisomer, tautomer, polymorph, solvate, N-oxide, isotopically labeled compound, or a metabolite, prodrug, or pharmaceutically acceptable salt or ester thereof, wherein the compound has a structure as shown in Formula I:
[0008] Wherein, ring A is selected from 3-14 membered heterocycles and 3-14 membered carbocycles, wherein the heterocycle or carbocycle is optionally selected by one or more of the following groups: H, D, halogen, hydroxyl, amino, cyano, nitro, C. 1-6 Alkyl, C 3-6Cycloalkyl, 3-12 membered heterocyclic, 5-10 membered heteroaryl, C 6-10 Aryl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy groups, -C 1-6 Alkyl-OR a -C(=O)-(CH2) p -OR a -C(=O)-(CH2) p -NR a R b and -C 1-6 Alkylene-NR a R b Substituents of the substituents;
[0009] Y is selected from -CR a R b -、-O-、-NR a -、-S-、-S(O)- and -S(O)2-;
[0010] X 1 X 2 Each is independently selected from CR and N;
[0011] R is independently selected from H, D, halogen, hydroxyl, cyano, nitro, amino, C 1-6 Alkyl, 3-12 membered heterocyclic, 5-10 membered heteroaryl, C 6-10 Aryl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Halogenated alkyl groups and C 3-10 Cycloalkyl; preferably, R is independently selected from H, halogen, hydroxyl, cyano, nitro, amino, C 1-6 Alkyl, 3-12 membered heterocyclic, 5-10 membered heteroaryl, C 6-10 Aryl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Halogenated alkyl groups and C 3-10 cycloalkyl;
[0012] L is selected from 4-8 membered carbocyclic rings, 3-10 membered heterocyclic groups, and 5-10 membered heteroaryl groups, wherein the carbocyclic ring, heterocyclic group, or heteroaryl group is optionally selected by one or more independently from H, D, halogen, hydroxyl, amino, cyano, nitro, C 1-6 Alkyl, C 3-6 Cycloalkyl, 3-12 membered heterocyclic, 5-10 membered heteroaryl, C 6-10 Aryl, C 2-6alkenyl, C 2-6 alkynyl group, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy groups, -C 1-6 Alkyl-OR a -C(=O)-(CH2) p -OR a -C(=O)-(CH2) p -NR a R b and -C 1-6 Alkylene-NR a R b The substituents are preferably selected from one or more groups, each independently chosen from H, halogen, hydroxyl, amino, cyano, nitro, C. 1-6 Alkyl, C 3-6 Cycloalkyl, 3-12 membered heterocyclic, 5-10 membered heteroaryl, C 6-10 Aryl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy groups, -C 1-6 Alkyl-OR a -C(=O)-(CH2) p -OR a -C(=O)-(CH2) p -NR a R b and -C 1-6 Alkylene-NR a R b Substituents of the substituents;
[0013] Z is selected from covalent bond, =C(R) a )-、-CR a R b -、-O-CR a R b -、C(=NSO2R b ), C(=O)NR b -NR a -, -O-, -S-, -C(=O)-, -S(=O)-, -S(=O)2-, S(=O)(=NR b ) and S(=NR b )2;
[0014] R 1 Selected from H, D, halogen, cyano, C 1-6 Alkyl, C 3-6 cycloalkyl, C1-6 Haloalkyl, C 1-6 Haloalkoxy, -C(=O)R c -C 1-6 Alkyl-C(=O)-NR a R b NR a R b OR a SR a -NR a C(=O)R b -C(=O)-OR a -SOR a -SO2R a C 6-10 Aryl, 5-10-membered heteroaryl, and 3-12-membered heterocyclic groups, wherein the alkyl, cycloalkyl, aryl, heteroaryl, or heterocyclic group is optionally selected by one or more groups, each independently selected from H, D, =O, halogen, hydroxyl, amino, cyano, nitro, C 1-6 Alkyl, C 3-6 cycloalkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Hydroxyalkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy group, -C(=O)-(CH2) p -OR a -C(=O)-(CH2) p -NR a R b -C 1-6 Alkylene-NR a R b Substituents; preferably, R 1 Selected from H, halogen, cyano, C 1-6 Alkyl, C 3-6 cycloalkyl, C 1-6 Haloalkyl, C 1-6 Haloalkoxy, -C(=O)R c -C 1-6 Alkyl-C(=O)-NR a R b NR a R b OR a SR a -NR a C(=O)R b -C(=O)-OR a -SOR a -SO2R a C6-10 Aryl, 5-10-membered heteroaryl, and 3-12-membered heterocyclic groups, wherein the alkyl, cycloalkyl, aryl, heteroaryl, or heterocyclic group is optionally selected by one or more groups, each independently selected from H, =O, halogen, hydroxyl, amino, cyano, nitro, C 1-6 Alkyl, C 3-6 cycloalkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Hydroxyalkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy group, -C(=O)-(CH2) p -OR a -C(=O)-(CH2) p -NR a R b and -C 1-6 Alkylene-NR a R b The substituents are preferably selected from one or more groups, each independently chosen from H, halogen, hydroxyl, amino, cyano, nitro, C. 1-6 Alkyl, C 3-6 cycloalkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Hydroxyalkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy group, -C(=O)-(CH2) p -OR a -C(=O)-(CH2) p -NR a R b and -C 1-6 Alkylene-NR a R b Substituents of the substituents;
[0015] R a and R b Each is independently selected from H, D, halogen, hydroxyl, cyano, 3-12 membered heterocyclic group, 5-10 membered heteroaryl, C 6-10 Aryl, C 1-6 Alkyl, C 3-6 cycloalkyl, C 3-6 cycloalkyl-OR c C 1-6 Alkoxy, C 1-6 Haloalkyl, C 1-6 Haloalkoxy, -C(=O)R c -C 1-6 Alkyl-C(=O)-NRc R d NR c R d -NR c C(=O)R d -C(=O)-OR c -OR c -SR c -SOR c and -SO2R c The alkyl, cycloalkyl, alkoxy, haloalkyl, haloalkoxy, heterocyclic, heteroaryl, or aryl group is optionally selected by one or more groups, each independently selected from H, D, halogen, hydroxyl, amino, cyano, C 1-6 Alkyl, C 3-6 cycloalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkyl groups and C 1-6 Substituents of haloalkoxy groups; preferably, R a and R b Each is independently selected from H, halogen, hydroxyl, cyano, 3-12 membered heterocyclic group, 5-10 membered heteroaryl, C 6-10 Aryl, C 1-6 Alkyl, C 3-6 cycloalkyl, C 3-6 cycloalkyl-OR c C 1-6 Alkoxy, C 1-6 Haloalkyl, C 1-6 Haloalkoxy, -C(=O)R c -C 1-6 Alkyl-C(=O)-NR c R d NR c R d -NR c C(=O)R d -C(=O)-OR c -OR c -SR c -SOR c and -SO2R c The alkyl, cycloalkyl, alkoxy, haloalkyl, haloalkoxy, heterocyclic, heteroaryl, or aryl group is optionally selected by one or more groups, each independently selected from H, halogen, hydroxyl, amino, cyano, C 1-6 Alkyl, C 3-6 cycloalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkyl groups and C 1-6 Substituents of haloalkoxy groups;
[0016] Or, Ra R b The atoms bonded thereto form 3-8 membered carbon rings, 3-12 membered heterocyclic groups, or 5-10 membered heteroaryl groups, wherein the carbon ring, heterocyclic group, or heteroaryl group is optionally composed of one or more elements independently selected from H, D, halogen, hydroxyl, amino, cyano, =O, C. 1-6 Alkyl, C 3-6 cycloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkyl, C 1-6 The alkyl halogen is preferably substituted by one or more groups, each independently selected from H, halogen, hydroxyl, amino, cyano, =O, C. 1-6 Alkyl, C 3-6 cycloalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkyl groups and C 1-6 Substituents of haloalkoxy groups;
[0017] R c and R d Each is independently selected from H, D, halogen, hydroxyl, cyano, 3-12 membered heterocyclic group, 5-10 membered heteroaryl, C 6-10 Aryl, C 1-6 Alkyl, C 3-6 cycloalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkyl groups and C 1-6 The alkyl, cycloalkyl, alkoxy, haloalkyl, haloalkoxy, heterocyclic, heteroaryl, or aryl group is optionally selected by one or more groups, each independently selected from H, D, halogen, hydroxyl, amino, cyano, C. 1-6 Alkyl, C 3-6 cycloalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkyl groups and C 1-6 Substituents of haloalkoxy groups; preferably, R c and R d Each is independently selected from H, halogen, hydroxyl, cyano, 3-12 membered heterocyclic group, 5-10 membered heteroaryl, C 6-10 Aryl, C 1-6 Alkyl, C 3-6 cycloalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkyl groups and C 1-6 The alkyl, cycloalkyl, alkoxy, haloalkyl, haloalkoxy, heterocyclic, heteroaryl, or aryl group is optionally selected by one or more groups, each independently selected from H, halogen, hydroxyl, amino, cyano, C. 1-6 Alkyl, C 3-6 cycloalkyl, C 1-6 Alkoxy, C1-6 Halogenated alkyl groups and C 1-6 Substituents of haloalkoxy groups;
[0018] Or, R c R d The N atom attached thereto forms a 3-8 membered heterocyclic group or a 5-10 membered heteroaryl group, wherein the heterocyclic group or heteroaryl group is optionally composed of one or more elements independently selected from H, D, halogen, hydroxyl, amino, cyano, =O, C. 1-6 Alkyl, C 3-6 cycloalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkyl groups and C 1-6 The alkyl halogen is preferably substituted by one or more groups, each independently selected from H, halogen, hydroxyl, amino, cyano, =O, C. 1-6 Alkyl, C 3-6 cycloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkyl, C 1-6 Substituents of haloalkoxy groups;
[0019] Ar is selected from C 6-10 Aryl and 5-10 heteroaryl, wherein the aryl or heteroaryl is optionally surrounded by one or more R 2 replace;
[0020] R 2 Each is independently selected from H, D, halogen, amino, cyano, nitro, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Haloalkyl, C 1-4 Alkoxy, C 3-10 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-10 Aryl and 5-10 heteroaryl groups, wherein the alkyl, cycloalkyl, heterocyclic, aryl, or heteroaryl group is optionally composed of one or more groups each independently selected from H, D, halogen, hydroxyl, amino, cyano, and C. 1-6 Alkyl substituents; preferably, R 2 Each is independently selected from H, halogen, amino, cyano, nitro, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Haloalkyl, C 1-4 Alkoxy, C 3-10 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-10 Aryl and 5-10 quinone heteroaryl groups, preferably H, halogen, amino, cyano, nitro, or C. 1-6 Alkyl, C 2-6 alkenyl, C2-6 alkynyl group, C 1-6 Haloalkyl, C 3-10 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-10 Aryl and 5-10-membered heteroaryl groups, wherein the alkyl, cycloalkyl, heterocyclic, aryl, and heteroaryl groups are optionally surrounded by one or more groups selected from H, halogen, hydroxyl, amino, cyano, and C. 1-6 Alkyl substituents;
[0021] p is independently selected from 0, 1, 2, 3, 4, 5 and 6;
[0022] The compound of formula I may optionally be substituted at any position with one or more of the following substituents: D, halogen, -OH, -CN, -COOH, -NH2, C 1-6 Alkyl and C 1-6 Halogenated alkyl groups.
[0023] This disclosure also provides compounds, or stereoisomers, tautomers, polymorphs, solvates, N-oxides, isotopically labeled compounds, or metabolites, prodrugs, or pharmaceutically acceptable salts or esters thereof, wherein said compounds have a structure as shown in Formula I':
[0024] Among them, ring A' is selected from C. 6-14 Aromatic rings and 3-14 membered heteroaromatic rings, wherein the aromatic rings or heteroaromatic rings are optionally selected by one or more groups, each independently selected from H, D, halogen, hydroxyl, amino, cyano, nitro, C 1-6 Alkyl, C 3-6 Cycloalkyl, 3-12 membered heterocyclic, 5-10 membered heteroaryl, C 6-10 Aryl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy groups, -C 1-6 Alkyl-OR a -C(=O)-(CH2) p -OR a -C(=O)-(CH2) p -NR a R b and -C 1-6 Alkylene-NR a R b The substituents are substituted; the heteroaromatic ring contains 1-3 heteroatoms, each independently selected from N, O and S;
[0025] X 1 X 2 L, Z, Ar, R1 R a and R b As defined in Equation I.
[0026] Another aspect of this disclosure provides a pharmaceutical composition comprising a preventive or therapeutically effective amount of the compound described in this disclosure, or a stereoisomer, tautomer, polymorph, solvate, N-oxide, isotopically labeled compound, or a metabolite or prodrug or pharmaceutically acceptable salt or ester thereof, and one or more pharmaceutically acceptable carriers.
[0027] Another aspect of this disclosure provides the use of the compounds described herein, or stereoisomers, tautomers, polymorphs, solvates, N-oxides, isotopically labeled compounds, or metabolites or prodrugs or pharmaceutically acceptable salts or esters thereof, or pharmaceutical compositions described herein, in the preparation of medicaments for the prevention and / or treatment of diseases, particularly for the prevention and / or treatment of GPR6 receptor-mediated diseases.
[0028] Another aspect of this disclosure provides the use of the compounds described herein, or stereoisomers, tautomers, polymorphs, solvates, N-oxides, isotopically labeled compounds, or metabolites or prodrugs or pharmaceutically acceptable salts or esters thereof, or pharmaceutical compositions described herein, in the context of medicaments for the prevention and / or treatment of diseases, particularly for the prevention and / or treatment of GPR6 receptor-mediated diseases.
[0029] Another aspect of this disclosure provides methods for preventing and / or treating diseases, particularly methods for preventing and / or treating GPR6 receptor-mediated diseases, said methods comprising administering to an individual in need an effective amount of the compound described in this disclosure, or a stereoisomer, tautomer, polymorph, solvate, N-oxide, isotopically labeled compound, or a metabolite or prodrug or pharmaceutically acceptable salt or ester thereof, or a pharmaceutical composition described in this disclosure.
[0030] The GPR6 receptor-mediated diseases described in this disclosure are selected from: movement disorders, including Parkinson's disease, levodopa-induced movement disorder, Huntington's disease, drug addiction, eating disorders, cognitive impairment, schizophrenia, bipolar disorder, and depression.
[0031] Another aspect of this disclosure provides a method for preparing compounds of formula I. Detailed Implementation
[0032] Terminology Definition
[0033] Unless otherwise defined below, all technical and scientific terms used herein are intended to have the same meaning as commonly understood by one of ordinary skill in the art. References to technical terms herein refer to techniques commonly understood in the art, including variations or equivalent substitutions of techniques that are obvious to one of ordinary skill in the art. While it is believed that the following terms will be well understood by one of ordinary skill in the art, the following definitions are set forth to better interpret this disclosure.
[0034] The terms “comprising,” “including,” “having,” “containing,” or “involving,” and their other forms herein, are inclusive or open-ended and do not exclude other unlisted elements or method steps.
[0035] The term "carbocyclic ring" refers to a saturated or unsaturated non-aromatic ring, which can be a 3- to 14-membered monocyclic ring, a 4- to 12-membered bicyclic ring, or a 10- to 15-membered tricyclic system. The carbocyclic ring can be connected with fused rings, bridged rings, or spirocyclic rings, such as 3-12-membered, 3-10-membered, 3-8-membered, and 3-6-membered carbocyclic rings. Non-limiting examples include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclodecyl, and cyclododecyl; cyclohexene. The carbocyclic ring may optionally be further substituted by one or more (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12) groups selected from F, Cl, Br, I, =O, hydroxyl, mercapto, nitro, cyano, amino, alkylamino, amide, alkenyl, alkynyl, alkyl, hydroxyalkyl, alkoxy, carbocyclic, heterocyclic, carbocyclic oxy, heterocyclic oxy, carboxyl, or carboxylic acid ester groups.
[0036] The term "heterocyclic" or "heterocyclic group" refers to a 3- to 14-membered non-aromatic cyclic group consisting of 2 to 13 carbon atoms and 1 to 6 heteroatoms selected from nitrogen, oxygen, and sulfur, such as 3-14-membered heterocycles, 3-12-membered heterocycles, 3-10-membered heterocycles, 3-8-membered heterocycles, 3-6-membered heterocycles, and 4-6-membered heterocycles. Heterocyclic groups can be saturated or partially unsaturated. Unless otherwise specifically indicated in this specification, heterocyclic groups can be monocyclic, bicyclic, tricyclic, or more ring systems, which may include fused ring systems, fused ring systems, bridged ring systems, or spirocyclic systems. For example, a heterocycle can be associated with a carbon atom. 6-10 Aryl, C 3-10 Cycloalkyl groups, 3-12-membered heterocyclic groups, and 5-10-membered heteroaryl groups can form fused ring systems, fused ring systems, or spirocyclic systems. Non-adjacent atoms in the heterocycle can also form bridged ring systems, which can also contain 1-5 heteroatoms such as N, O, and S.
[0037] The heterocyclic group disclosed herein is preferably a 3- to 14-membered non-aromatic monocyclic or bicyclic group comprising 1 to 5 heteroatoms selected from nitrogen, oxygen, and sulfur, such as a 3- to 8-membered non-aromatic monocyclic group comprising 1 to 5 heteroatoms selected from nitrogen, oxygen, and sulfur, or a 3- to 6-membered non-aromatic monocyclic group comprising 1 to 5 heteroatoms selected from nitrogen and oxygen; or a 3- to 14-membered non-aromatic polycyclic group, including fused bicyclic, fused, bridged, or spirocyclic rings. The nitrogen, carbon, or sulfur atom in the heterocyclic group may optionally be oxidized; the nitrogen atom may optionally be quaternized; and the heterocyclic group may be partially unsaturated or fully saturated. The heterocyclic group may be connected to the rest of the molecule via a carbon atom or heteroatom and through a single bond. Examples of heterocyclic groups include, but are not limited to: azirrobutyl, pyranyl, tetrahydropyranyl, thiaranyl, tetrahydrofuranyl, morpholinyl, thiomorpholinyl, pyrazolyl, dihydropyrazolyl, piperazinyl, piperidinyl, pyrrolidinyl, oxazinyl, dioxocyclopentyl, tetrahydroisoquinolinyl, decahydroisoquinolinyl, imidazolinyl, imidazoalkyl, quinazinyl, thiazoalkyl, isothiazolyl, isoxazolyl, dihydroindolyl, octahydroindolyl, octahydroisoindolyl, pyrazolyl, phthalimide, azirrobicyclo[3.1.0]hexyl, azirrocyclo[2.4]heptyl, and groups of the following formula:
[0038] The "heterocyclic" or "heterocyclic group" may optionally be substituted by one or more (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12) groups selected from F, Cl, Br, I, =O, hydroxyl, mercapto, nitro, cyano, amino, alkylamino, amide, alkenyl, alkynyl, alkyl, hydroxyalkyl, alkoxy, carbocyclic, heterocyclic, carbocyclicoxy, heterocyclicoxy, carboxyl or carboxylic ester group.
[0039] The term "alkyl" refers to a saturated aliphatic hydrocarbon group, including straight-chain and branched groups with 1 to 20 carbon atoms, preferably alkyl groups containing 1 to 6 carbon atoms. Non-limiting examples include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, sec-butyl, n-pentyl, 1,1-dimethylpropyl, 1,2-dimethylpropyl, 2,2-dimethylpropyl, 1-ethylpropyl, 2-methylbutyl, 3-methylbutyl, n-hexyl, 1-ethyl-2-methylpropyl, 1,1,2-trimethylpropyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 2,2-dimethylbutyl, 1,3-dimethylbutyl, 2-ethylbutyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl, 2,3-dimethylbutyl, and various branched isomers thereof. The alkyl group may be substituted or unsubstituted. When substituted, the substituent may be substituted at any usable connection point, preferably one or more of the following groups, independently selected from alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylamino, halogen, mercapto, hydroxyl, nitro, cyano, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkoxy, heterocycloalkoxy, cycloalkylthio, heterocycloalkylthio, oxo, etc.
[0040] The term "cycloalkyl" refers to a saturated cyclic hydrocarbon group, including but not limited to monocycloalkyl and bicycloalkyl groups (such as spirocycloalkyl, fused cycloalkyl, and bridged cycloalkyl). The term "C" 3-10 "Cycloalkyl" refers to a cycloalkyl group having 3 to 10 (e.g., 3-8, 3-6, 3-4) cyclic carbon atoms, such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, etc. The cycloalkyl group may be substituted or unsubstituted, wherein the cycloalkyl group may be independently unsubstituted or substituted by one or more substituents described in this disclosure, such as F, Cl, Br, I, =O, hydroxyl, mercapto, nitro, cyano, amino, alkylamino, amide, alkenyl, alkynyl, alkyl, hydroxyalkyl, alkoxy, carbocyclic, heterocyclic, carbocyclicoxy, heterocyclicoxy, carboxyl, or carboxylic acid ester.
[0041] The term "halogenated" or "halogenated" is defined as including F, Cl, Br, or I.
[0042] The term "halogenated alkyl" refers to the aforementioned alkyl group that has been substituted with a halogen. For example, "C 1-6 "Halogenated alkyl" refers to a C-shaped alkyl group that has been substituted with one or two halogens. 1-6 alkyl.
[0043] The term "hydroxyalkyl" refers to the alkyl group described above that has been substituted with a hydroxyl group. For example, "C 1-6 "Hydroxyalkyl" refers to a C-shaped carbonyl group that has been substituted with one or more hydroxyl groups. 1-6 alkyl.
[0044] The term "alkoxy group" refers to an alkyl group, as defined above, that is attached to a parent molecule via an oxygen atom. C 1-6 Representative examples of alkoxy groups include, but are not limited to, methoxy, ethoxy, propoxy, n-butoxy, isobutoxy, tert-butoxy, pentoxy, and hexoxy.
[0045] The term "haloalkoxy" refers to the alkoxy group described above, such as C10. 1-6 An alkoxy group is a group obtained by substituting one or more (e.g., 1, 2, 3, or 4) hydrogen atoms with a halogen (e.g., fluorine, chlorine, bromine, or iodine), such as C. 1-2 Halogenated alkoxy, halogenated methoxy, halogenated ethoxy, C3-halogenated alkoxy, C4-halogenated alkoxy, C 1-2 Fluoroalkoxy, fluoromethoxy, fluoroethoxy, C3 fluoroalkoxy, C4 fluoroalkoxy, C 1-2 Chloroalkoxy, chloromethoxy, chloroethoxy, C3 chloroalkoxy, C4 chloroalkoxy. Specific examples include, but are not limited to, fluoromethoxy, difluoromethoxy, trifluoromethoxy, trifluoroethoxy, chloroethoxy, etc.
[0046] The term "alkenyl" refers to an aliphatic hydrocarbon group containing at least one carbon-carbon double bond and in which one hydrogen atom is replaced by a bond. The alkenyl group can be straight-chain or branched and contains from about 2 to about 15 carbon atoms. In one embodiment, the alkenyl group contains from about 2 to about 12 carbon atoms. In another embodiment, the alkenyl group contains from about 2 to about 6 carbon atoms. The term "C 2-6 "Alkenyl" refers to an alkenyl group with 2 to 6 carbon atoms. Non-limiting examples of alkenyl groups include vinyl, propenyl, n-butenyl, 3-methylbut-2-enyl, and n-pentenyl. The alkenyl group can be unsubstituted or substituted with one or more of the same or different substituents, each substituent being independently selected from halogens, alkenyl, alkynyl, aryl, cycloalkyl, cyano, hydroxyl, -O-alkyl, -O-aryl, -alkylene-O-alkyl, alkylthio, -NH2, -NH(alkyl), -N(alkyl)2, -NH(cycloalkyl), -OC(O)-alkyl, -OC(O)-aryl, -OC(O)-cycloalkyl, -C(O)OH, and -C(O)O-alkyl.
[0047] Term "C" 2-6 "Alkyne" refers to a linear or branched monovalent hydrocarbon group that contains one or more triple bonds and has 2, 3, 4, 5, or 6 carbon atoms, particularly 2 or 3 carbon atoms ("C"). 2-3 The C group ("alkynyl group"). 2-6Alkynyl groups include, for example, ethynyl, prop-1-ynyl, prop-2-ynyl, but-1-ynyl, but-2-ynyl, but-3-ynyl, pent-1-ynyl, pent-2-ynyl, pent-3-ynyl, pent-4-ynyl, hex-1-ynyl, hex-2-ynyl, hex-3-ynyl, hex-4-ynyl, hex-5-ynyl, 1-methylprop-2-ynyl, 2-methylbut-3-ynyl, 1-methylbut-3-ynyl, 1-methylbut-2-ynyl, 3-methylbut-1-ynyl, 1-ethylprop-2-ynyl, 3-methylpent-4-ynyl, 2-methylpent-4-ynyl The alkynyl group includes 1-methylpentan-4-alkynyl, 2-methylpentan-3-alkynyl, 1-methylpentan-3-alkynyl, 4-methylpentan-2-alkynyl, 1-methylpentan-2-alkynyl, 4-methylpentan-1-alkynyl, 3-methylpentan-1-alkynyl, 2-ethylbutan-3-alkynyl, 1-ethylbutan-3-alkynyl, 1-ethylbutan-2-alkynyl, 1-propylpropan-2-alkynyl, 1-isopropylpropan-2-alkynyl, 2,2-dimethylbutan-3-alkynyl, 1,1-dimethylbutan-3-alkynyl, 1,1-dimethylbutan-2-alkynyl, or 3,3-dimethylbutan-1-alkynyl. In particular, the alkynyl group is ethynyl, propan-1-alkynyl, or propan-2-alkynyl.
[0048] The term "aryl" refers to a C group with a conjugated π-electron system. 6-14 All-carbon monocyclic or fused polycyclic (i.e., rings sharing adjacent carbon atom pairs) groups, preferably C 6-10 Aryl groups, such as phenyl and naphthyl, more preferably phenyl. The aryl ring may be fused to a heteroaryl, heterocyclic, or cycloalkyl ring, wherein the ring attached to the parent structure is an aryl ring, and non-limiting examples include:
[0049] The aryl group can be substituted or unsubstituted. When substituted, the substituent is preferably one or more of the following groups, independently selected from alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylamino, halogen, mercapto, hydroxyl, nitro, cyano, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkoxy, heterocycloalkoxy, cycloalkylthio, heterocycloalkylthio, carboxyl or carboxylic acid ester group.
[0050] The terms "5-10-membered heteroaryl" or "5-10-membered heteroaryl ring" refer to an aromatic monocyclic or polycyclic system containing about 5 to about 10 ring atoms, wherein 1 to 4 ring atoms are independently O, N, or S, and the remaining ring atoms are carbon atoms. In another embodiment, the heteroaryl is a monocyclic heteroaryl and has 5 or 6 ring atoms. In another embodiment, the heteroaryl is a bicyclic heteroaryl. The heteroaryl may optionally be substituted by one or more "cyclic substituents," which may be the same or different, and as defined herein. The heteroaryl is linked by ring carbon atoms, and any nitrogen atom of the heteroaryl may optionally be oxidized to the corresponding N-oxide. Any C atom of the heteroaryl may optionally be oxidized or thiolated. The term "heteroaryl" also includes heteroaryls as defined above fused with cycloalkyl groups. Non-limiting examples of heteroaryl groups include: pyridyl, pyrazinyl, furanyl, thiopheneyl, pyrimidinyl, pyridone (including N-substituted pyridones), isoxazolyl, isothiazolyl, oxazolyl, oxadiazolyl, thiazolyl, pyrazolyl, furazolyl, pyrroleyl, triazolyl, 1,2,4-thiadiazolyl, pyrazinyl, pyridazinyl, quinoxalinyl, phthalazinyl, oxindolyl, imidazo[1] [2-a]pyridyl, imidazo[2,1-b]thiazolyl, benzofurazanyl, indolyl, azaindolyl, benzimidazolyl, benzothiophene, quinolinyl, imidazolyl, benzimidazolyl, thiophene-pyridyl, quinazolinyl, thiophene-pyrimidinyl, pyrrolopyridyl, imidazopyridyl, isoquinolinyl, benzoazaindolyl, 1,2,4-triazinyl, benzothiazolyl, etc., and all their isomers. In one embodiment, the heteroaryl group is a 5-membered heteroaryl group. In another embodiment, the heteroaryl group is a 6-membered heteroaryl group, such as a 6-membered nitrogen-containing heteroaryl group.
[0051] The term "substitution" refers to the selective replacement of one or more (e.g., one, two, three, or four) hydrogen atoms on a specified atom by a specified group, provided that the substitution does not exceed the normal valence of the specified atom in the present case and the substitution forms a substantially stable compound. Combinations of substituents and / or variables are permitted only if such combinations form a substantially stable compound.
[0052] The term “optionally” means that the groups or substituents described herein may be unsubstituted or substituted by specific groups or radicals.
[0053] The term "one or more" means one or more under reasonable conditions, such as two, three, four, five or ten.
[0054] When the bond of a substituent is such that it passes through the ring and connects two atoms, then such a substituent can be bonded to any cyclic atom in the substituted ring.
[0055] If a compound, group or substituent described herein is described as being "optionally" substituted with a specified group or radical, it means that the compound, group or substituent may be (1) unsubstituted or (2) substituted with the specified group or radical.
[0056] If a substituent or number is described as being “independently selected” from a set of groups or numbers, then each substituent or number is selected independently of the others. Therefore, each substituent or number may be the same as or different from another (other) substituent or number.
[0057] This disclosure also includes all pharmaceutically acceptable isotopically labeled compounds identical to those of this disclosure, except that one or more atoms are replaced by atoms having the same atomic number but with an atomic mass or mass number different from the dominant atomic mass or mass number in nature. Examples of isotopes suitable for inclusion in the compounds of this disclosure include, but are not limited to, isotopes of hydrogen (e.g., 2 H, 3 H, deuterium (D), tritium (T); carbon isotopes (e.g., H, deuterium (D), tritium (T)); 11 C 13 C and 14 C); isotopes of chlorine (e.g.) 37 Cl); isotopes of fluorine (e.g., Cl); 18 F); isotopes of iodine (e.g., F); 123 I and 125 I); nitrogen isotopes (e.g.) 13 N and 15 N); isotopes of oxygen (e.g., N); 15 O、 17 O and 18 O); isotopes of phosphorus (e.g., O); phosphorus isotopes ... 32 P); and isotopes of sulfur (e.g., ... 35 S). Certain isotope-labeled compounds of this disclosure (e.g., those doped with radioisotopes) can be used in drug and / or substrate tissue distribution studies (e.g., analysis). Radioisotope tritium (i.e. 3 H) and carbon-14 (i.e. 14 C) It is particularly suitable for this purpose due to its ease of incorporation and detection. Using positron-emitting isotopes (e.g.) 11 C 18 F, 15 O and 13Substitution of N) can be used in positron emission tomography (PET) studies to examine substrate acceptor occupancy. Isotopically labeled compounds of this disclosure can be prepared by methods similar to those described in the accompanying routes and / or examples and preparations, by replacing previously used unlabeled reagents with appropriate isotopically labeled reagents. Pharmaceutically acceptable solvates of this disclosure include those in which the crystallization solvent can be isotopically substituted, for example, D2O, acetone-d6, or DMSO-d6.
[0058] As used herein, the term "suitable substituent" refers to modifications of a compound that can be made by those skilled in the art to suit the needs of the compound's substituents. "Suitable substituents" include oxo (=O), halogen, cyano, and NR. a R b Carboxyl, thiol, hydroxyl, ester group (e.g., -C) 1-6 Alkyl-C(=O)-OC 1-6 Alkyl), C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Alkyl-OC 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 3-6 Cycloalkyl, 3-10 membered heterocyclic, 5-10 membered heteroaryl, C 6-10 Aryl, benzyl, hydroxy-substituted benzyl, indolylmethylene and C 1-6 Haloalkoxy, R a R b As described in this article.
[0059] Whether explicitly stated or not, all numerical values in this disclosure are modified by the term “about”. The term “about” means within ±20%, ±10%, ±5%, or ±2% of the stated numerical value.
[0060] The term "stereoisomer" refers to isomers formed due to the presence of at least one asymmetric center in a compound. In compounds having one or more (e.g., one, two, three, or four) asymmetric centers, racemic mixtures, single enantiomers, mixtures of diastereomers, and individual diastereomers can be produced. Specific individual molecules may also exist as geometric isomers (cis / trans). Similarly, the compounds of this disclosure can exist as mixtures of two or more structurally different forms in rapid equilibrium (commonly referred to as tautomers). Representative examples of tautomers include keto-enol tautomers, phenol-keto tautomers, nitroso-oxime tautomers, imine-enamine tautomers, etc. It is to be understood that the scope of this disclosure covers all such isomers or mixtures thereof in any proportion (e.g., 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%).
[0061] This disclosure covers all possible crystalline forms or polymorphs of the compounds disclosed herein, which may be a single polymorph or a mixture of more than one polymorph in any proportion.
[0062] It should also be understood that certain compounds of this disclosure may exist in their free form for therapeutic purposes, or, where appropriate, in their pharmaceutically acceptable derivative forms. According to this disclosure, pharmaceutically acceptable derivatives include, but are not limited to, pharmaceutically acceptable salts, esters, solvates, metabolites, isotope-labeled substances, or prodrugs, which, upon administration to a patient in need, can directly or indirectly provide the compounds of this disclosure or their metabolites or residues. Therefore, when referring to “compounds of this disclosure” herein, it is also intended to cover the various derivative forms of the compounds described above.
[0063] Pharmaceutically acceptable salts of the compounds disclosed herein include their acid-addition salts and base-addition salts.
[0064] Suitable acid addition salts are formed by acids that form pharmaceutically acceptable salts. Suitable base addition salts are formed by bases that form pharmaceutically acceptable salts.
[0065] Pharmaceutically acceptable salts of the compounds disclosed herein include their acid addition salts and base addition salts. Suitable acid addition salts are formed by acids that form pharmaceutically acceptable salts. Suitable base addition salts are formed by bases that form pharmaceutically acceptable salts. A review of suitable salts can be found in Stahl and Wermuth's "Handbook of Pharmaceutical Salts: Properties, Selection, and Use" (Wiley-VCH, 2002). Methods for preparing pharmaceutically acceptable salts of the compounds disclosed herein are known to those skilled in the art.
[0066] The term "ester" refers to an ester derived from the various general formula compounds of this disclosure, including physiologically hydrolyzable esters that can be hydrolyzed under physiological conditions to release the compounds of this disclosure in the form of free acids or alcohols. The compounds of this disclosure may themselves be esters.
[0067] The compounds disclosed herein may exist as solvates (preferably hydrates), wherein the compounds of this disclosure contain a polar solvent as a structural element of the compound's crystal lattice. The amount of the polar solvent, particularly water, may be stoichiometric or non-stoichiometric.
[0068] Those skilled in the art will understand that not all nitrogen-containing heterocycles can form N-oxides because nitrogen requires available lone pairs of electrons to be oxidized into oxides; those skilled in the art will identify nitrogen-containing heterocycles that can form N-oxides. Those skilled in the art will also recognize that tertiary amines can form N-oxides. Synthetic methods for preparing N-oxides of heterocycles and tertiary amines are well known to those skilled in the art, including the oxidation of heterocycles and tertiary amines with peroxy acids such as peracetic acid and m-chloroperoxybenzoic acid (MCPBA), hydrogen peroxide, alkyl peroxides such as tert-butyl peroxide, sodium perborate, and dioxiranes such as dimethyldioxirane. These methods for preparing N-oxides have been extensively described and reviewed in the literature, see, for example: T.L. Gilchrist, Comprehensive Organic Synthesis, vol. 7, pp. 748-750; A.R. Katritzky and A.J. Boulton, Eds., Academic Press; and G.W. H. Heeseman and E.S. G. Wierstiuk, Advances in Heterocyclic Chemistry, vol. 22, pp. 390-392, A.R. Katritzky and A.J. Boulton, Eds., Academic Press.
[0069] The scope of this disclosure also includes metabolites of the compounds of this disclosure, i.e., substances formed in the body upon administration of the compounds of this disclosure. Such products can be generated, for example, by oxidation, reduction, hydrolysis, amidation, deamidation, esterification, enzymatic hydrolysis, etc., of the administered compound. Therefore, this disclosure includes metabolites of the compounds of this disclosure, including compounds prepared by methods that expose the compounds of this disclosure to mammals for a time sufficient to produce their metabolites.
[0070] This disclosure further includes, within its scope, prodrugs of the compounds of this disclosure, which are certain derivatives of the compounds of this disclosure that may themselves have little or no pharmacological activity, and which, when administered to or onto the body, can be converted, for example, by hydrolysis and cleavage into the compounds of this disclosure having the desired activity. Typically, such prodrugs are functional group derivatives of the compounds that are readily converted in vivo into the compounds with the desired therapeutic activity. Further information regarding the use of prodrugs can be found in “Pro-drugs as Novel Delivery Systems,” Vol. 14, ACS Symposium Series (T. Higuchi and V. Stella) and “Bioreversible Carriers in Drug Design,” Pergamon Press, 1987 (EB Roche, editor, American Pharmaceutical Association). Prodrugs of this disclosure can be prepared, for example, by replacing suitable functional groups present in the compounds of this disclosure with certain portions known to those skilled in the art as “pro-moiety” (e.g., as described in “Design of Prodrugs,” H. Bundgaard (Elsevier, 1985)).
[0071] In any process of preparing the compounds of this disclosure, protection of sensitive or reactive groups on any relevant molecule may be necessary and / or desirable, thereby forming a form of chemical protection for the compounds of this disclosure. This can be achieved by conventional protecting groups, for example, those described in Protective Groups in Organic Chemistry, ed. JFW McOmie, Plenum Press, 1973; and TW Greene & P. GMWuts, Protective Groups in Organic Synthesis, John Wiley & Sons, 1991, which are incorporated herein by reference. Protecting groups can be removed at appropriate subsequent stages using methods known in the art.
[0072] compound
[0073] In one embodiment, this disclosure provides a compound, or a stereoisomer, tautomer, polymorph, solvate, N-oxide, isotopically labeled compound, or a metabolite, prodrug, or pharmaceutically acceptable salt or ester thereof, wherein said compound has a structure as shown in Formula I:
[0074] Wherein, ring A is selected from 3-14 membered heterocycles and 3-14 membered carbocycles, wherein the heterocycle or carbocycle is optionally selected by one or more of the following groups: H, D, halogen, hydroxyl, amino, cyano, nitro, C. 1-6 Alkyl, C 3-6 Cycloalkyl, 3-12 membered heterocyclic, 5-10 membered heteroaryl, C 6-10 Aryl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy groups, -C 1-6 Alkyl-OR a -C(=O)-(CH2) p -OR a -C(=O)-(CH2) p -NR a R b and -C 1-6 Alkylene-NR a R b Substituents of the substituents;
[0075] Y is selected from -CR a R b -、-O-、-NR a -、-S-、-S(O)- and -S(O)2-;
[0076] X 1 X 2 Each is independently selected from CR and N;
[0077] R is selected from H, D, halogen, hydroxyl, cyano, nitro, amino, C. 1-6 Alkyl, 3-12 membered heterocyclic, 5-10 membered heteroaryl, C 6-10 Aryl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Halogenated alkyl groups and C 3-10 cycloalkyl;
[0078] L is selected from 4-8 membered carbocyclic rings, 3-10 membered heterocyclic groups, and 5-10 membered heteroaryl groups, wherein the carbocyclic ring, heterocyclic group, or heteroaryl group is optionally selected by one or more independently from H, D, halogen, hydroxyl, amino, cyano, nitro, C 1-6 Alkyl, C 3-6 Cycloalkyl, 3-12 membered heterocyclic, 5-10 membered heteroaryl, C 6-10 Aryl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Haloalkyl, C 1-6 Alkoxy, C1-6 Halogenated alkoxy groups, -C 1-6 Alkyl-OR a -C(=O)-(CH2) p -OR a -C(=O)-(CH2) p -NR a R b and -C 1-6 Alkylene-NR a R b Substituents of the substituents;
[0079] Z is selected from covalent bond, =C(R) a )-、-CR a R b -、-O-CR a R b -、-C(=NSO2R b )-、-C(=O)N(R b )-、-N(R a ), -O-, -S-, -C(=O)-, -S(=O)-, -S(=O)2-, -S(=O)(=NR b - and -S(=NR) b )2-;
[0080] R 1 Selected from H, D, halogen, cyano, C 1-6 Alkyl, C 3-6 cycloalkyl, C 1-6 Haloalkyl, C 1-6 Haloalkoxy, -C(=O)R c -C 1-6 Alkyl-C(=O)-NR a R b NR a R b OR a SR a -NR a C(=O)R b -C(=O)-OR a -SOR a -SO2R a C 6-10 Aryl, 5-10-membered heteroaryl, and 3-12-membered heterocyclic groups, wherein the alkyl, cycloalkyl, aryl, heteroaryl, or heterocyclic group is optionally selected by one or more groups, each independently selected from H, D, =O, halogen, hydroxyl, amino, cyano, nitro, C 1-6 Alkyl, C 3-6 cycloalkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C1-6 Hydroxyalkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy group, -C(=O)-(CH2) p -OR a -C(=O)-(CH2) p -NR a R b and -C 1-6 Alkylene-NR a R b Substituents of the substituents;
[0081] R a and R b Each is independently selected from H, D, halogen, hydroxyl, cyano, 3-12 membered heterocyclic group, 5-10 membered heteroaryl, C 6-10 Aryl, C 1-6 Alkyl, C 3-6 cycloalkyl, C 3-6 cycloalkyl-OR c C 1-6 Alkoxy, C 1-6 Haloalkyl, C 1-6 Haloalkoxy, -C(=O)R c -C 1-6 Alkyl-C(=O)-NR c R d NR c R d -NR c C(=O)R d -C(=O)-OR c -OR c -SR c -SOR c and -SO2R c The alkyl, cycloalkyl, alkoxy, haloalkyl, haloalkoxy, heterocyclic, heteroaryl, or aryl group is optionally selected by one or more groups, each independently selected from H, D, halogen, hydroxyl, amino, cyano, C 1-6 Alkyl, C 3-6 cycloalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkyl groups and C 1-6 Substituents of haloalkoxy groups;
[0082] Or, R a R bThe atoms bonded thereto form 3-8 membered carbon rings, 3-12 membered heterocyclic groups, or 5-10 membered heteroaryl groups, wherein the carbon ring, heterocyclic group, or heteroaryl group is optionally composed of one or more elements independently selected from H, D, halogen, hydroxyl, amino, cyano, =O, C. 1-6 Alkyl, C 3-6 cycloalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkyl groups and C 1-6 Substituents of haloalkoxy groups;
[0083] R c and R d Each is independently selected from H, D, halogen, hydroxyl, cyano, 3-12 membered heterocyclic group, 5-10 membered heteroaryl, C 6-10 Aryl, C 1-6 Alkyl, C 3-6 cycloalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkyl groups and C 1-6 The alkyl, cycloalkyl, alkoxy, haloalkyl, haloalkoxy, heterocyclic, heteroaryl, or aryl group is optionally selected by one or more groups, each independently selected from H, D, halogen, hydroxyl, amino, cyano, C. 1-6 Alkyl, C 3-6 cycloalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkyl groups and C 1-6 Substituents of haloalkoxy groups;
[0084] Or, R c R d The N atom attached thereto forms a 3-8 membered heterocyclic group or a 5-10 membered heteroaryl group, wherein the heterocyclic group or heteroaryl group is optionally composed of one or more elements independently selected from H, D, halogen, hydroxyl, amino, cyano, =O, C. 1-6 Alkyl, C 3-6 cycloalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkyl groups and C 1-6 Substituents of haloalkoxy groups;
[0085] Ar is selected from C 6-10 Aryl and 5-10 heteroaryl, wherein the aryl or heteroaryl is optionally surrounded by one or more R 2 replace;
[0086] R 2 Each is independently selected from H, D, halogen, amino, cyano, nitro, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Haloalkyl, C1-4 Alkoxy, C 3-10 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-10 Aryl and 5-10 heteroaryl groups, wherein the alkyl, cycloalkyl, heterocyclic, aryl, or heteroaryl group is optionally selected by one or more groups independently chosen from H, D, halogen, hydroxyl, amino, cyano, and C. 1-6 Alkyl substituents;
[0087] p is independently selected from 0, 1, 2, 3, 4, 5 and 6;
[0088] The compound of formula I may optionally be substituted at any position with one or more of the following substituents: D, halogen, -OH, -CN, -COOH, -NH2, C 1-6 Alkyl and C 1-6 Halogenated alkyl groups.
[0089] In some embodiments, ring A is selected from 3-14 membered heterocycles and 3-14 membered carbocycles, wherein the heterocycle or carbocycle is optionally selected by one or more of the following groups, each independently selected from H, D, halogen, hydroxyl, amino, cyano, nitro, C. 1-6 Alkyl, C 3-6 Cycloalkyl, 3-12 membered heterocyclic, 5-10 membered heteroaryl, C 6-10 Aryl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy groups, -C 1-6 Alkyl-OR a -C(=O)-(CH2) p -OR a -C(=O)-(CH2) p -NR a R b and -C 1-6 Alkylene-NR a R b Substituents of the substituents;
[0090] Y is selected from -CR a R b -、-O-、-NR a -、-S-、-S(O)- and -S(O)2-;
[0091] X 1 X 2 Each is independently selected from CR and N;
[0092] R is selected from H, halogen, hydroxyl, cyano, nitro, amino, C 1-6Alkyl, 3-12 membered heterocyclic, 5-10 membered heteroaryl, C 6-10 Aryl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Halogenated alkyl groups and C 3-10 cycloalkyl;
[0093] L is selected from 4-8 membered carbocyclic rings, 3-10 membered heterocyclic groups, and 5-10 membered heteroaryl groups, wherein the carbocyclic ring, heterocyclic group, or heteroaryl group is optionally selected by one or more independently from H, halogen, hydroxyl, amino, cyano, nitro, C 1-6 Alkyl, C 3-6 Cycloalkyl, 3-12 membered heterocyclic, 5-10 membered heteroaryl, C 6-10 Aryl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy groups, -C 1-6 Alkyl-OR a -C(=O)-(CH2) p -OR a -C(=O)-(CH2) p -NR a R b and -C 1-6 Alkylene-NR a R b Substituents of the substituents;
[0094] Z is selected from covalent bonds, -C(R) a )-、-CR a R b -、-O-CR a R b -、-C(=NSO2R b )-、-C(=O)N(R b )-、-N(R a ), -O-, -S-, -C(=O)-, -S(=O)-, -S(=O)2-, -S(=O)(=NR b - and -S(=NR) b )2-;
[0095] R 1 Selected from H, halogen, cyano, C 1-6 Alkyl, C 3-6 cycloalkyl, C 1-6 Haloalkyl, C 1-6 Haloalkoxy, -C(=O)R c -C 1-6 Alkyl-C(=O)-NRa R b NR a R b OR a SR a -NR a C(=O)R b -C(=O)-OR a -SOR a -SO2R a C 6-10 Aryl, 5-10-membered heteroaryl, and 3-12-membered heterocyclic groups, wherein the alkyl, cycloalkyl, aryl, heteroaryl, or heterocyclic group is optionally selected by one or more groups, each independently selected from H, =O, halogen, hydroxyl, amino, cyano, nitro, C 1-6 Alkyl, C 3-6 cycloalkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Hydroxyalkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy group, -C(=O)-(CH2) p -OR a -C(=O)-(CH2) p -NR a R b and -C 1-6 Alkylene-NR a R b Substituents of the substituents;
[0096] R a and R b Each is independently selected from H, halogen, hydroxyl, cyano, 3-12 membered heterocyclic group, 5-10 membered heteroaryl, C 6-10 Aryl, C 1-6 Alkyl, C 3-6 cycloalkyl, C 3-6 cycloalkyl-OR c C 1-6 Alkoxy, C 1-6 Haloalkyl, C 1-6 Haloalkoxy, -C(=O)R c -C 1-6 Alkyl-C(=O)-NR c R d NR c R d -NR c C(=O)R d -C(=O)-OR c -OR c -SRc -SOR c and -SO2R c The alkyl, cycloalkyl, alkoxy, haloalkyl, haloalkoxy, heterocyclic, heteroaryl, or aryl group is optionally selected by one or more groups, each independently selected from H, halogen, hydroxyl, amino, cyano, C 1-6 Alkyl, C 3-6 cycloalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkyl groups and C 1-6 Substituents of haloalkoxy groups;
[0097] Or, R a R b The atoms bonded thereto form 3-8 membered carbon rings, 3-12 membered heterocyclic groups, or 5-10 membered heteroaryl groups, wherein the carbon ring, heterocyclic group, or heteroaryl group is optionally composed of one or more elements independently selected from H, halogen, hydroxyl, amino, cyano, =O, C. 1-6 Alkyl, C 3-6 cycloalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkyl groups and C 1-6 Substituents of haloalkoxy groups;
[0098] R c and R d Each is independently selected from H, halogen, hydroxyl, cyano, 3-12 membered heterocyclic group, 5-10 membered heteroaryl, C 6-10 Aryl, C 1-6 Alkyl, C 3-6 cycloalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkyl groups and C 1-6 The alkyl, cycloalkyl, alkoxy, haloalkyl, haloalkoxy, heterocyclic, heteroaryl, or aryl group is optionally selected by one or more groups, each independently selected from H, halogen, hydroxyl, amino, cyano, C. 1-6 Alkyl, C 3-6 cycloalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkyl groups and C 1-6 Substituents of haloalkoxy groups;
[0099] Or, R c R d The N atom attached thereto forms a 3-8 membered heterocyclic group or a 5-10 membered heteroaryl group, wherein the heterocyclic group or heteroaryl group is optionally composed of one or more atoms each independently selected from H, halogen, hydroxyl, amino, cyano, =O, C. 1-6 Alkyl, C 3-6 cycloalkyl, C 1-6 Alkoxy, C1-6 Halogenated alkyl groups and C 1-6 Substituents of haloalkoxy groups;
[0100] Ar is selected from C 6-10 Aryl and 5-10 heteroaryl, wherein the aryl or heteroaryl is optionally surrounded by one or more R 2 replace;
[0101] R 2 Each is independently selected from H, halogen, amino, cyano, nitro, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Haloalkyl, C 1-4 Alkoxy, C 3-10 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-10 Aryl and 5-10 heteroaryl groups, wherein the alkyl, cycloalkyl, heterocyclic, aryl, or heteroaryl group is optionally selected by one or more groups, each independently selected from H, halogen, hydroxyl, amino, cyano, and C. 1-6 Alkyl substituents;
[0102] p is independently selected from 0, 1, 2, 3, 4, 5 and 6.
[0103] In some embodiments, ring A is selected from 3-14 membered heterocycles and 3-14 membered carbocycles, wherein the heterocycle or carbocycle is optionally selected by one or more of the following groups, each independently selected from H, D, halogen, hydroxyl, amino, cyano, nitro, C. 1-6 Alkyl, C 3-6 Cycloalkyl, 3-12 membered heterocyclic, 5-10 membered heteroaryl, C 6-10 Aryl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy groups, -C 1-6 Alkyl-OR a -C(=O)-(CH2) p -OR a -C(=O)-(CH2) p -NR a R b and -C 1-6 Alkylene-NR a R b Substituents are substituted.
[0104] In some embodiments, ring A is selected from 3-14 membered heterocycles and 3-14 membered carbocycles, wherein the heterocycle or carbocycle is optionally selected by one or more groups, each independently selected from H, halogen, hydroxyl, amino, cyano, nitro, C.1-6 Alkyl, C 3-6 Cycloalkyl, 3-12 membered heterocyclic, 5-10 membered heteroaryl, C 6-10 Aryl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy groups, -C 1-6 Alkyl-OR a -C(=O)-(CH2) p -OR a -C(=O)-(CH2) p -NR a R b and -C 1-6 Alkylene-NR a R b Substituents are substituted.
[0105] In some embodiments, ring A is a 3-14 membered heterocycle (e.g., a 3-12 membered heterocycle, a 7-10 membered heterocycle), wherein the heterocycle is optionally composed of one or more members independently selected from H, D, halogen, hydroxyl, amino, cyano, nitro, C. 1-4 Alkyl, C 3-6 Cycloalkyl, 3-10 membered heterocyclic, 5-10 membered heteroaryl, C 6-10 Aryl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-4 Haloalkyl, C 1-4 Alkoxy, C 1-4 Halogenated alkoxy groups, -C 1-4 Alkyl-OR a -C(=O)-(CH2) p -OR a -C(=O)-(CH2) p -NR a R b and -C 1-4 Alkylene-NR a R b Substituents are substituted.
[0106] In some embodiments, ring A is a 3-14 membered heterocycle (e.g., a 3-12 membered heterocycle, a 7-10 membered heterocycle), wherein the heterocycle is optionally composed of one or more elements each independently selected from H, halogen, hydroxyl, amino, cyano, nitro, C. 1-4 Alkyl, C 3-6 Cycloalkyl, 3-10 membered heterocyclic, 5-10 membered heteroaryl, C 6-10 Aryl, C 2-6 alkenyl, C2-6 alkynyl group, C 1-4 Haloalkyl, C 1-4 Alkoxy, C 1-4 Halogenated alkoxy groups, -C 1-4 Alkyl-OR a -C(=O)-(CH2) p -OR a -C(=O)-(CH2) p -NR a R b and -C 1-4 Alkylene-NR a R b Substituents are substituted.
[0107] In some embodiments, ring A is a 3-10 membered heterocycle, wherein the heterocycle is optionally composed of one or more elements each independently selected from H, D, hydroxyl, C. 1-4 Alkyl, 3-8 membered heterocyclic, 5-10 membered heteroaryl, C 1-4 Haloalkyl, C 1-4 Alkoxy and -C 1-4 Substitution of alkyl-OH groups.
[0108] In some embodiments, ring A is a 3-10 membered heterocycle, wherein the heterocycle is optionally composed of one or more members, each independently selected from H, hydroxyl, C. 1-4 Alkyl, 3-8 membered heterocyclic, 5-10 membered heteroaryl, C 1-4 Haloalkyl, C 1-4 Alkoxy and -C 1-4 Substitution of alkyl-OH groups.
[0109] In some embodiments, ring A is a 3-10 membered heterocycle, wherein the heterocycle is optionally composed of one or more members, each independently selected from H, hydroxyl, C. 1-4 Alkyl groups, 3-8 membered heterocyclic groups (e.g., 3-8 membered nitrogen- or oxygen-containing heterocyclic groups), 5-10 membered nitrogen-containing heteroaryl groups, C 1-4 Fluoroalkyl, C 1-4 Chloroalkyl, C 1-4 Alkoxy and -C 1-4 Substitution of alkyl-OH groups.
[0110] In some embodiments, ring A is a 3-10 membered heterocycle, wherein the heterocycle is optionally composed of one or more groups, each independently selected from H, D, hydroxyl, methyl, ethyl, propyl, isopropyl, 3-6 membered heterocyclic groups (e.g., 4 membered oxygen-containing heterocyclic groups), pyrazolyl, -CF3, -CHF2, -CH2CH2F, C 1-4 Substitution with chloroalkyl, methoxy and -CH2CH2OH groups.
[0111] In some embodiments, ring A is a 3-10 membered heterocycle, wherein the heterocycle is optionally composed of one or more groups, each independently selected from H, hydroxyl, methyl, ethyl, propyl, isopropyl, 3-6 membered heterocyclic groups (e.g., 4 membered oxygen-containing heterocyclic groups), pyrazolyl, -CF3, -CHF2, -CH2CH2F, C 1-4 Substitution with chloroalkyl, methoxy and -CH2CH2OH groups.
[0112] In some embodiments, the A ring is a 3- to 10-membered heterocycle; preferably, the heterocycle contains one or more of N, O, or S atoms.
[0113] In some embodiments, ring A is selected from 4-membered heterocycles, 5-membered heterocycles, 6-membered heterocycles, 7-membered heterocycles, 8-membered heterocycles, 9-membered heterocycles, and 10-membered heterocycles, wherein the heterocycle is optionally substituted by one or more substituents, each independently selected from H, D, hydroxyl, methyl, ethyl, isopropyl, 4-membered oxygen-containing heterocyclic group, pyrazolyl, -CF3, -CHF2, -CH2CH2F, methoxy, and -CH2CH2OH; preferably, the heterocycle contains one or more N, O, or S atoms.
[0114] In some embodiments, ring A is selected from 4-membered heterocycles, 5-membered heterocycles, 6-membered heterocycles, 7-membered heterocycles, 8-membered heterocycles, 9-membered heterocycles, and 10-membered heterocycles, wherein the heterocycle is optionally substituted by one or more substituents, each independently selected from H, hydroxyl, methyl, ethyl, isopropyl, 4-membered oxygen-containing heterocyclic group, pyrazolyl, -CF3, -CHF2, -CH2CH2F, methoxy, and -CH2CH2OH; preferably, the heterocycle contains one or more N, O, or S atoms.
[0115] In some embodiments, ring A is a 3- to 10-membered carbon ring, wherein the carbon ring is optionally composed of one or more elements each independently selected from H, D, halogen, hydroxyl, amino, cyano, nitro, C. 1-6 Alkyl, C 3-6 Cycloalkyl, 3-12 membered heterocyclic, 5-10 membered heteroaryl, C 6-10 Aryl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy groups, -C 1-6 Alkyl-OR a -C(=O)-(CH2) p -OR a -C(=O)-(CH2) p -NR a R b and -C 1-6Alkylene-NR a R b Substituents are substituted.
[0116] In some embodiments, ring A is a 3- to 10-membered carbon ring, wherein the carbon ring is optionally composed of one or more elements each independently selected from H, halogen, hydroxyl, amino, cyano, nitro, C. 1-6 Alkyl, C 3-6 Cycloalkyl, 3-12 membered heterocyclic, 5-10 membered heteroaryl, C 6-10 Aryl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy groups, -C 1-6 Alkyl-OR a -C(=O)-(CH2) p -OR a -C(=O)-(CH2) p -NR a R b and -C 1-6 Alkylene-NR a R b Substituents are substituted.
[0117] In some embodiments, ring A is a 3- to 10-membered carbon ring, wherein the carbon ring is optionally composed of one or more elements each independently selected from H, D, halogen, hydroxyl, amino, cyano, nitro, and C. 1-6 Alkyl substituents.
[0118] In some embodiments, ring A is a 3- to 10-membered carbon ring, wherein the carbon ring is optionally composed of one or more elements each independently selected from H, halogen, hydroxyl, amino, cyano, nitro, and C. 1-6 Alkyl substituents. In some embodiments, Selected from
[0119] In some implementations, Selected from
[0120] In some implementations, Selected from
[0121] In some implementations, Selected from
[0122] In some implementations, Selected from
[0123] In some embodiments, the compound of formula I has the structure shown in formula I-01:
[0124] Y, X 1 X 2 L, Z, Ar, R 1 As defined in this article; R 3 Selected from H, D, halogen, hydroxyl, amino, cyano, nitro, C 1-6 Alkyl, C 3-6 Cycloalkyl, 3-12 membered heterocyclic, 5-10 membered heteroaryl, C 6-10 Aryl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy groups, -C 1-6 Alkyl-OR a -C(=O)-(CH2) p -OR a -C(=O)-(CH2) p -NR a R b and -C 1-6 Alkylene-NR a R b r, m and n are each independently selected from 0, 1, 2, 3 and 4, and q is selected from 0-8 (e.g. 0-4, 0, 1, 2 and 3).
[0125] In some embodiments, the compound of formula I has the structure shown in formula I-01-1, I-01-2 or I-01-3:
[0126] Y, L, Z, Ar, R 1 R a and R b As defined in this article; R 3 Selected from H, D, halogen, hydroxyl, amino, cyano, nitro, C 1-6 Alkyl, C 3-6 Cycloalkyl, 3-12 membered heterocyclic, 5-10 membered heteroaryl, C 6-10 Aryl, C 2-6 alkenyl, C 2-6alkynyl group, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy groups, -C 1-6 Alkyl-OR a -C(=O)-(CH2) p -OR a -C(=O)-(CH2) p -NR a R b and -C 1-6 Alkylene-NR a R b r, m and n are each independently selected from 0, 1, 2, 3 and 4, and q is selected from 0-8 (e.g. 0-4, 0, 1, 2 and 3).
[0127] In some embodiments, the compound of formula I has the structure shown in formula I-02-1, I-02-2 or I-02-3:
[0128] Y, L, Z, Ar, R 1 As defined in this article; R 3 Selected from H, D, halogen, hydroxyl, amino, cyano, nitro, C 1-6 Alkyl, C 3-6 Cycloalkyl, 3-12 membered heterocyclic, 5-10 membered heteroaryl, C 6-10 Aryl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy groups, -C 1-6 Alkyl-OR a -C(=O)-(CH2) p -OR a -C(=O)-(CH2) p -NR a R b and -C 1-6 Alkylene-NR a R b r, m and n are each independently selected from 0, 1, 2, 3 and 4, and q is selected from 0-8 (e.g. 0-4, 0, 1, 2 and 3).
[0129] In some embodiments, the compound of formula I has the structure shown in formulas I-01-1-A to I-01-1-F, I-01-2-A to I-01-2-F, or I-01-3-A to I-01-3-F:
[0130] L, Z, Ar, R 1 R a and R b As defined in this article, m and n are each independently selected from 0, 1, 2, 3, and 4.
[0131] In some embodiments, the compound of formula I has the structure shown in formula I-1:
[0132] Y, X 1 X 2 L, Z, Ar, R 1 As defined in this article, m and n are each independently selected from 0, 1, 2, 3, and 4.
[0133] In some embodiments, the compound of formula I has the structure shown in formula I-1-A, I-1-B, I-1-C, I-1-D, I-1-E, I-1-F, I-1-G, I-1-H or I-1-J:
[0134] X 1 X 2 L, Z, Ar, R 1 As defined in this article; Y is independently selected from -CR a R b -、-O-、-NR a -、-S-、-S(O)- and -S(O)2-.
[0135] In some embodiments, the compound of formula I has the structure shown in formula I-1-A, I-1-B, I-1-C, I-1-D, I-1-E, or I-1-F:
[0136] Y, X 1 X 2 L, Z, Ar, R 1 As defined in this article.
[0137] In some embodiments, the compound of formula I has the structure shown in formula I-2:
[0138] Y, L, Z, Ar, R 1 As defined in this article, m and n are each independently selected from 0, 1, 2, 3, and 4.
[0139] In some embodiments, the compound of formula I has the structure shown in formula I-2-A or formula I-2-B:
[0140] Y, L, Z, Ar, R1 As defined in this article.
[0141] In some embodiments, the compound of formula I has the structure shown in formula I-3-A, I-3-B, I-3-C, I-3-D, I-3-E or I-3-F:
[0142] L, Z, Ar, R 1 and R a As defined in this article, m and n are each independently selected from 0, 1, 2, 3, and 4.
[0143] In some embodiments, the compound of formula I has the structures shown in formulas I-4-1 to I-4-22:
[0144] X 1 X 2 L, Z, Ar, R 1 R a and R b As defined in this article; R 3 Selected from H, D, halogen, hydroxyl, amino, cyano, nitro, C 1-6 Alkyl, C 3-6 Cycloalkyl, 3-12 membered heterocyclic, 5-10 membered heteroaryl, C 6-10 Aryl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy groups, -C 1-6 Alkyl-OR a -C(=O)-(CH2) p -OR a -C(=O)-(CH2) p -NR a R b and -C 1-6 Alkylene-NR a R b Or two Rs 3 The atoms connected to it form C 3-6 Cycloalkyl or 3-8 membered heterocyclic group; q is selected from 0-8 (e.g., 0-4, 0, 1, 2, 3).
[0145] In some embodiments, the compound of formula I has the structure shown in formulas I-4-1 to I-4-19:
[0146] X 1 X2 L, Z, Ar, R 1 R a and R b As defined in this article; R 3 Selected from H, D, halogen, hydroxyl, amino, cyano, nitro, C 1-6 Alkyl, C 3-6 Cycloalkyl, 3-12 membered heterocyclic, 5-10 membered heteroaryl, C 6-10 Aryl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy groups, -C 1-6 Alkyl-OR a -C(=O)-(CH2) p -OR a -C(=O)-(CH2) p -NR a R b and -C 1-6 Alkylene-NR a R b ;q is selected from 0-8 (e.g., 0-4, 0, 1, 2, 3).
[0147] In some embodiments, the compound of formula I has the structure shown in formula I-5:
[0148] Among them, rings A, Y, and X 1 X 2 L, Ar, R 1 and R a As defined in this article.
[0149] In some embodiments, the compound of formula I has the structure shown in formula I-5-A or I-5-B:
[0150] Among them, rings A, Y, and X 1 X 2 ,L,Ar and R 1 As defined in this article.
[0151] In some embodiments, the compound of formula I has the structures shown in formulas I-5-1 to I-5-22:
[0152] X 1 X 2 L, Z, Ar, R 1 R a and R bAs defined in this article; R 3 Selected from H, D, halogen, hydroxyl, amino, cyano, nitro, C 1-6 Alkyl, C 3-6 Cycloalkyl, 3-12 membered heterocyclic, 5-10 membered heteroaryl, C 6-10 Aryl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy groups, -C 1-6 Alkyl-OR a -C(=O)-(CH2) p -OR a -C(=O)-(CH2) p -NR a R b and -C 1-6 Alkylene-NR a R b Or two Rs 3 The atoms connected to it form C 3-6 Cycloalkyl or 3-8 membered heterocyclic group; q is selected from 0-8 (e.g., 0-4, 0, 1, 2, 3).
[0153] In some embodiments, the compound of formula I has the structure shown in formula I-6-A or formula I-6-B:
[0154] Y is selected independently from -CR a R b -、-O-、-NR a -、-S-、-S(O)- and -S(O)2-;
[0155] The B ring is a 3-8 membered heterocyclic group, wherein the heterocyclic group contains 1-2 heteroatoms each independently selected from N, O and S and contains at least 1 nitrogen atom;
[0156] X 1 X 2 L, Z, Ar, R 1 R a and R b As defined in this article.
[0157] In some embodiments, the compound of formula I has the structure shown in formula I-6-1 or formula I-6-2:
[0158] R 2 Each is independently selected from H, halogen, C 1-6 Alkyl, C 1-6 Halogenated alkyl groups and C1-4 Alkoxy, preferably halogen, more preferably F;
[0159] t is selected from 0-5, preferably 1-3, and more preferably 2;
[0160] X 1 and X 2 Each is independently selected from CR and N;
[0161] R is independently selected from H, halogen, cyano, C 1-6 Alkyl and C 3-10 Cycloalkyl, preferably H;
[0162] R 1 Selected from C 1-6 Alkyl, C 3-6 cycloalkyl, NR a R b OR a SR a 5-10-membered heteroaryl and 3-12-membered heterocyclic groups, wherein the alkyl, cycloalkyl, heteroaryl or heterocyclic group is optionally selected by one or more of each independently selected from H, D, =O, halogen, C 1-6 Alkyl, C 1-6 Hydroxyalkyl, C 1-6 Halogenated alkyl groups and C 1-6 Substitution of alkoxy groups;
[0163] R a and R b Each is independently selected from H, D, halogen, hydroxyl, 3-12 membered heterocyclic group, 5-10 membered heteroaryl group, C 1-6 Alkyl, C 3-6 cycloalkyl and C 1-6 Halogenated alkyl groups.
[0164] In some implementations, in formula I-6-1 or formula I-6-2, for
[0165] In some implementations, in formula I-6-1 or formula I-6-2, R 1 for
[0166] In some embodiments, the compound of formula I has the structure shown in formulas I-7-A to I-7-D:
[0167] C ring is C 3-6 cycloalkyl;
[0168] R a Selected from H, D, halogens, hydroxyl groups, C 1-6 Alkyl, C3-6 cycloalkyl, C 1-6 Haloalkyl, -C(=O)R c and -SO2R c ;
[0169] X 1 X 2 L, Z, Ar, R 1 and R c As defined in this article.
[0170] In some embodiments, the compound of formula I has the structure shown in formulas I-7-1 to I-7-4:
[0171] R 2 Each is independently selected from H, halogen, C 1-6 Alkyl, C 1-6 Halogenated alkyl groups and C 1-4 Alkoxy, preferably halogen, more preferably F;
[0172] t is selected from 0-5, preferably 1-3, and more preferably 2;
[0173] X 1 and X 2 Each is independently selected from CR and N;
[0174] R is independently selected from H, halogen, cyano, C 1-6 Alkyl and C 3-10 Cycloalkyl, preferably H;
[0175] R a Selected from H, D, halogens, hydroxyl groups, C 1-6 Alkyl, C 3-6 cycloalkyl, C 1-6 Haloalkyl, -C(=O)R c and -SO2R c R c Selected from C 1-6 Alkyl and C 3-6 cycloalkyl; preferably, R a C 1-6 Alkyl; more preferably, R a It is methyl;
[0176] C ring is C 3-6 Cycloalkyl, preferably cyclopropyl, cyclobutyl or cyclopentyl, more preferably cyclopropyl or cyclobutyl.
[0177] In some implementations, in formulas I-7-1 to I-7-4, for
[0178] In some embodiments, the compound of formula I has the structure shown in formulas I-8-A to I-8-E, preferably the structure shown in formulas I-8-A to I-8-C, and more preferably I-8-A:
[0179] Y is selected independently from -CR a R b -、-O-、-NR a -, -S-, -S(O)- and -S(O)2-, preferably -O-, -N(CH3)-, -N(isopropyl)-, -N(COCH3)- and -S(O)-, more preferably -O-, -N(CH3)- and -N(isopropyl)-, and even more preferably -O-;
[0180] X 1 and X 2 Each is independently selected from CR and N;
[0181] R is independently selected from H, halogen, cyano, C 1-6 Alkyl and C 3-10 Cycloalkyl, preferably H;
[0182] Z is selected from covalent bonds, =CH-, -CR a R b -, -O-, -S- and -C(=O)-, preferably =CH- and -CR a R b - and -O-, more preferably -CF2-, -CHF-, -O- and =CH-, and even more preferably -CF2-, -CHF- and -O-;
[0183] R 1 Selected from C 1-6 Alkyl, C 3-6 cycloalkyl, NR a R b OR a SR a 5-10-membered heteroaryl and 3-12-membered heterocyclic groups, wherein the alkyl, cycloalkyl, heteroaryl or heterocyclic group is optionally selected by one or more of each independently selected from H, D, =O, halogen, C 1-6 Alkyl, C 1-6 Hydroxyalkyl, C 1-6 Halogenated alkyl groups and C 1-6 Alkyl group substitution; preferably, R 1 Selected from NR a R b OR a and SR a More preferably, R 1 For NR a R b ;
[0184] R a Selected from halogens, hydroxyl groups, 3-12 membered heterocyclic groups, 5-10 membered heteroaryl groups, C 1-6 Alkyl, C 3-6 cycloalkyl, C 1-6 Haloalkyl, -C(=O)R c and -SO2R c Preferably, R a Selected from halogens, hydroxyl groups, 3-12 membered heterocyclic groups, C 1-6 Alkyl, C 3-6 cycloalkyl, C 1-6 Halogenated alkyl groups and -C(=O)R c More preferably, R a Selected from halogens, 3-12 membered heterocyclic groups, C 1-6 Alkyl groups and -C(=O)R c ;
[0185] R c Selected from C 1-6 Alkyl and C 3-6 cycloalkyl;
[0186] R b Selected from H, D, halogens, hydroxyl groups, 3-12 membered heterocyclic groups, 5-10 membered heteroaryl groups, C 1-6 Alkyl, C 3-6 cycloalkyl and C 1-6 Haloalkyl groups, preferably H, D, halogens, 3-12 membered heterocyclic groups, C 1-6 Alkyl, C 3-6 cycloalkyl and C 1-6 Halogenated alkyl groups, more preferably H, D, halogens and 3-12 membered heterocyclic groups.
[0187] In some implementations, in formulas I-8-A to I-8-E, R 1 for
[0188] In some implementations, X 1 and X 2 At least one of them is CR.
[0189] In some implementations, X 1 and X 2 All are CR. In some implementations, Y is selected from -CR. a R b -、-O-、-NR a -、-S-、-S(O)- and -S(O)2-, where R a and R b Each is independently selected from H, D, halogen, hydroxyl, cyano, C1-6 Alkyl, C 1-6 Haloalkyl, C 3-6 Cycloalkyl, -C(=O)R c and -SO2R c R c Selected from C 1-6 Alkyl and C 3-6 Cycloalkyl.
[0190] In some implementations, Y is selected from -CR a R b -、-O-、-NR a -、-S-、-S(O)- and -S(O)2-, where R a and R b Each is independently selected from H, halogen, hydroxyl, cyano, C 1-6 Alkyl, C 1-6 Haloalkyl, C 3-6 Cycloalkyl, -C(=O)R c and -SO2R c R c Selected from C 1-6 Alkyl and C 3-6 Cycloalkyl.
[0191] In some implementations, Y is selected from -CR a R b -、-O-、-NR a -、-S-、-S(O)- and -S(O)2-, where R a and R b Each is independently selected from H, halogen, hydroxyl, cyano, C 1-6 Alkyl, -C(=O)R c and -SO2R c R c Selected from C 1-6 Alkyl and C 3-6 Cycloalkyl.
[0192] In some implementations, Y is selected from -CR a R b -、-O-、-NR a -、-S-、-S(O)- and -S(O)2-, where R a and R b Each is independently selected from H, D, halogen, hydroxyl, cyano, and C. 1-6 alkyl.
[0193] In some implementations, Y is selected from -CR a R b -、-O-、-NR a-、-S-、-S(O)- and -S(O)2-, where R a and R b Each is independently selected from H, halogen, hydroxyl, cyano, and C. 1-6 Alkyl group. In some embodiments, Y is selected from -C(CH3)(OH)-, -O-, -NH-, -S-, -S(O)-, -S(O)2-, -N(COCH3)-, -N(COCH2CH3)-, -N(C(O)isopropyl)-, -N(CH3)-, -N(COcyclopropyl)-, -N(S(O)2CH3)-, -N(isopropyl)-, -N(cyclobutyl)- and -N(CH2CF3)-.
[0194] In some embodiments, Y is selected from -C(CH3)(OH)-, -O-, -NH-, -S-, -S(O)-, -S(O)2-, -N(COCH3)-, -N(COCH2CH3)-, -N(C(O)isopropyl)-, -N(CH3)-, -N(COcyclopropyl)- and -N(S(O)2CH3)-.
[0195] In some embodiments, Y is selected from -C(CH3)(OH)-, -O-, -NH-, -S-, -S(O)- and -S(O)2-.
[0196] In some embodiments, L is selected from 4-8 membered carbocyclic rings, 3-10 membered nitrogen-containing heterocyclic rings, and 5-10 membered nitrogen-containing heteroaromatic rings, wherein the carbocyclic ring, heterocyclic group, or heteroaromatic group is optionally selected by one or more independently from H, halogen, hydroxyl, amino, cyano, nitro, C 1-6 Alkyl, C 3-6 Cycloalkyl, 3-12 membered heterocyclic, 5-10 membered heteroaryl, C 6-10 Aryl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy groups, -C 1-6 Alkyl-OR a -C(=O)-(CH2) p -OR a -C(=O)-(CH2) p -NR a R b and -C 1-6 Alkylene-NR a R b Substituents are substituted.
[0197] In some embodiments, L is selected from 4-8 membered carbocyclic rings, 3-10 membered nitrogen-containing heterocyclic rings, and 5-10 membered nitrogen-containing heteroaromatic rings, wherein the carbocyclic ring, heterocyclic group, or heteroaromatic group is optionally selected by one or more independently from H, halogen, hydroxyl, amino, cyano, nitro, C 1-6 Alkyl and C 3-6 Substitution of cycloalkyl groups.
[0198] In some embodiments, L is selected from 4-8 membered carbocyclic rings, 3-10 membered nitrogen-containing heterocyclic rings, and 5-10 membered nitrogen-containing heteroaromatic rings, wherein the carbocyclic ring, heterocyclic group, or heteroaromatic ring is optionally selected by one or more of H, halogen, hydroxyl, amino, C, ... 1-6 Alkyl substituents.
[0199] In some embodiments, L is selected from 4-8 membered carbocyclic rings, 3-10 membered nitrogen-containing heterocyclic rings, and 5-10 membered nitrogen-containing heteroaromatic rings, wherein the carbocyclic ring, heterocyclic group, or heteroaromatic ring is optionally selected by one or more of H, halogen, hydroxyl, amino, and C. 1-6 Alkyl substituents.
[0200] In some embodiments, L is selected from 4-8 membered carbon rings, 3-10 membered nitrogen-containing heterocycles, and 5-10 membered nitrogen-containing heteroaromatic rings.
[0201] In some embodiments, L is selected from 4-8 membered carbon rings and 3-10 membered nitrogen-containing heterocycles, wherein the carbon ring or heterocycle is optionally substituted by one or more substituents, each independently selected from H, F, Cl, Br, hydroxyl, amino, methyl, ethyl, n-propyl and isopropyl.
[0202] In some implementations, L is selected from 4-8 membered carbon rings and 3-10 membered nitrogen-containing heterocycles.
[0203] In some embodiments, L is selected from 4-8 membered carbon rings, 3-6 membered nitrogen-containing monoheterocycles, 3-6 membered nitrogen-containing heterocycles with 3-6 membered nitrogen-containing heterocycles, and 3-6 membered nitrogen-containing heterocycles with C. 3-6 Carbon rings, 3-6 nucleotide nitrogen-containing heterocyclic spirochetes, 3-6 nucleotide nitrogen-containing heterocyclic spirochetes, 3-6 nucleotide nitrogen-containing heterocyclic spirochetes, and 6-10 nucleotide nitrogen-containing bridged heterocyclic rings, wherein the carbon rings or heterocyclic rings are optionally selected by one or more elements independently selected from H, halogens, hydroxyl groups, amino groups, and C. 1-6 Alkyl substituents.
[0204] In some embodiments, L is selected from 4-8 membered carbon rings, 3-6 membered nitrogen-containing monoheterocycles, 3-6 membered nitrogen-containing heterocycles with 3-6 membered nitrogen-containing heterocycles, and 3-6 membered nitrogen-containing heterocycles with C. 3-6 Carbon ring.
[0205] In some implementations, L is selected from
[0206] In some implementations, L is selected from
[0207] In some embodiments, L is selected from 4-8 membered monocyclic rings, 3-10 membered heterocyclic rings, and 5-10 membered heteroaromatic rings, wherein the monocyclic ring, heterocyclic ring, or heteroaromatic ring is optionally selected by one or more groups, each independently selected from D, halogen, hydroxyl, amino, cyano, nitro, C. 1-6 Alkyl, C 3-6 Cycloalkyl, 3-12 membered heterocyclic, 5-10 membered heteroaryl, C 6-10 Aryl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy groups, -C 1-6 Alkyl-OR a -C(=O)-(CH2) p -OR a -C(=O)-(CH2) p -NR a R b and -C 1-6 Alkylene-NR a R b Substituents are substituted.
[0208] In some embodiments, L is selected from 4-8 membered monocyclic rings, 3-10 membered heterocyclic rings, and 5-10 membered heteroaromatic rings, wherein the monocyclic ring, heterocyclic ring, or heteroaromatic ring is optionally selected by one or more of the following groups, each independently selected from halogen, hydroxyl, amino, cyano, nitro, C 1-6 Alkyl, C 3-6 Cycloalkyl, 3-12 membered heterocyclic, 5-10 membered heteroaryl, C 6-10 Aryl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy groups, -C 1-6 Alkyl-OR a -C(=O)-(CH2) p -OR a -C(=O)-(CH2) p -NR a R b and -C 1-6 Alkylene-NR a R b Substituents are substituted.
[0209] In some embodiments, L is selected from 4-8 membered monocyclic rings, 3-10 membered heterocyclic rings, and 5-10 membered heteroaromatic rings, wherein the monocyclic ring, heterocyclic ring, or heteroaromatic ring is optionally selected by one or more groups, each independently selected from D, halogen, hydroxyl, amino, cyano, nitro, C. 1-6 Alkyl, C 3-6 Cycloalkyl, 3-12 membered heterocyclic, 5-10 membered heteroaryl, C 6-10 Aryl, C 1-6 Haloalkyl, C 1-6 Alkoxy and C 1-6 Substituents of haloalkoxy groups.
[0210] In some embodiments, L is selected from 4-8 membered monocyclic rings, 3-10 membered heterocyclic rings, and 5-10 membered heteroaromatic rings, wherein the monocyclic ring, heterocyclic ring, or heteroaromatic ring is optionally selected by one or more of the following groups, each independently selected from halogen, hydroxyl, amino, cyano, nitro, C 1-6 Alkyl, C 3-6 Cycloalkyl, 3-12 membered heterocyclic, 5-10 membered heteroaryl, C 6-10 Aryl, C 1-6 Haloalkyl, C 1-6 Alkoxy and C 1-6 Substituents of haloalkoxy groups.
[0211] In some embodiments, L is selected from 4-8 membered monocyclic rings, 3-10 membered heterocyclic rings, and 5-10 membered heteroaromatic rings, wherein the monocyclic ring, heterocyclic ring, or heteroaromatic ring is optionally selected by one or more groups, each independently selected from D, halogen, hydroxyl, amino, cyano, nitro, and C. 1-6 Alkyl substituents.
[0212] In some embodiments, L is selected from 4-8 membered monocyclic rings, 3-10 membered heterocyclic rings, and 5-10 membered heteroaromatic rings, wherein the monocyclic ring, heterocyclic ring, or heteroaromatic ring is optionally selected by one or more of the following groups: halogen, hydroxyl, amino, cyano, nitro, and C. 1-6 Alkyl substituents.
[0213] In some embodiments, L is selected from 4-8 membered monocyclic rings and 3-8 membered heterocyclic rings, wherein the monocyclic ring or heterocyclic ring is optionally selected by one or more groups, each independently selected from halogen, hydroxyl, amino, cyano, nitro, and C. 1-6 Alkyl substituents.
[0214] In some embodiments, L is selected from 4-8 membered monocyclic carbon rings and 3-6 membered nitrogen-containing mono-heterocyclic rings, wherein the monocyclic carbon ring or mono-heterocyclic ring is optionally selected by one or more of the following groups: halogen, hydroxyl, amino, cyano, nitro, and C. 1-6 Alkyl substituents.
[0215] In some embodiments, L is selected from 4-6 membered monocyclic rings and 3-6 membered nitrogen-containing mono-heterocyclic rings, wherein the monocyclic ring or mono-heterocyclic ring is optionally selected by one or more groups, each independently selected from D, halogen, hydroxyl, amino, cyano, nitro, and C. 1-6 Alkyl substituents.
[0216] In some embodiments, L is selected from 4-6 membered monocyclic rings and 3-6 membered nitrogen-containing mono-heterocyclic rings, wherein the monocyclic ring or mono-heterocyclic ring is optionally selected by one or more of the following groups: halogen, hydroxyl, amino, cyano, nitro, and C. 1-6 Alkyl substituents.
[0217] In some implementations, L is selected from Where s is any integer selected from 1 to 10.
[0218] In some implementations, L is selected from
[0219] In some implementations, L is selected from
[0220] In some implementations, L is selected from
[0221] In some implementations, L is selected from
[0222] In some implementations, L is
[0223] In some implementations, Z is selected from covalent bonds, =C(R) a )-、-C(R a R b -, -O-, -S-, -N(R) a )-, -C(=O)-, -S(=O)- and -S(=O)2-.
[0224] In some implementations, Z is selected from covalent bonds, -C(R) a R b -, -O-, -S-, -N(R) a )-, -C(=O)-, -S(=O)- and -S(=O)2-.
[0225] In some implementations, Z is selected from covalent bonds, -CF2-, -CH2-, -CH(CH3)-, -CHF-, -O-, -C(=O)-, -S(=O)2-, =CH-, =CF-, -CD2-, -CDF-, =CD-,
[0226] In some implementations, Z is selected from covalent bonds, -CF2-, -CH2-, -CHF-, -O-, -C(=O)-, -S(=O)2-, =CH-, =CF-, -CD2-, -CDF-, =CD-,
[0227] In some implementations, Z is selected from covalent bonds, -CF2-, -CH2-, -CHF-, -O-, -C(=O)-, -S(=O)2-, =CH-, =CF-,
[0228] In some implementations, Z is selected from covalent bonds, -CF2-, -CH2-, -CHF-, -O-, -C(=O)-, and -S(=O)2-.
[0229] In some implementations, Z is selected from covalent bonds, -CF2-, -CH2-, -CHF-, -O-, and -C(=O)-.
[0230] In some implementations, Z is -O-.
[0231] In some implementations, Z is selected from =CH- and =CF-.
[0232] In some implementations, Z is selected from -CD2-, -CDF-, and =CD-.
[0233] In some implementations, R a and R b Each is independently selected from H, halogen, hydroxyl, cyano, 3-10 membered heterocyclic group, 5-10 membered heteroaryl, C 6-10 Aryl, C 1-4 Alkyl, C 3-6 cycloalkyl, C 3-6 cycloalkyl-OR c C 1-4 Alkoxy, C 1-4 Haloalkyl, C 1-4 Haloalkoxy, -C(=O)R c -C 1-4 Alkyl-C(=O)-NR c R d NR c R d -NR c C(=O)Rd -C(=O)-OR c -OR c -SR c -SOR c and -SO2R c The alkyl, cycloalkyl, alkoxy, haloalkyl, haloalkoxy, heterocyclic, heteroaryl, or aryl group is optionally selected by one or more groups, each independently selected from H, halogen, hydroxyl, amino, cyano, C 1-6 Alkyl, C 3-6 cycloalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkyl groups and C 1-6 Substituents of haloalkoxy groups;
[0234] Or, R a R b The atoms bonded thereto form 3-8 membered carbon rings, 3-10 membered heterocyclic groups, or 5-10 membered heteroaryl groups, wherein the carbon ring, heterocyclic group, or heteroaryl group is optionally composed of one or more elements each independently selected from H, halogen, hydroxyl, amino, cyano, =O, C. 1-4 Alkyl, C 3-6 cycloalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkyl groups and C 1-6 Substituents of haloalkoxy groups.
[0235] In some implementations, R a and R b Each is independently selected from H, D, halogen, hydroxyl, cyano, 3-10 membered heterocyclic group, 5-10 membered heteroaryl, C 6-10 Aryl, C 1-4 Alkyl, C 3-6 cycloalkyl, C 3-6 cycloalkyl-OR c C 1-4 Alkoxy, C 1-4 Haloalkyl, C 1-4 Haloalkoxy, -C(=O)R c -C 1-4 Alkyl-C(=O)-NR c R d NR c R d -NR c C(=O)R d -C(=O)-OR c -OR c -SR c -SOR c and -SO2R cThe alkyl, cycloalkyl, alkoxy, haloalkyl, haloalkoxy, heterocyclic, heteroaryl, or aryl group is optionally selected by one or more groups, each independently selected from H, D, halogen, hydroxyl, amino, cyano, C 1-4 Alkyl, C 3-6 cycloalkyl, C 1-4 Alkoxy, C 1-4 Halogenated alkyl groups and C 1-4 Substituents of haloalkoxy groups;
[0236] Or, R a R b The atoms bonded thereto form 3-8 membered carbon rings, 3-8 membered heterocyclic groups, or 5-10 membered heteroaryl groups, wherein the carbon ring, heterocyclic group, or heteroaryl group is optionally composed of one or more elements independently selected from H, D, halogen, hydroxyl, amino, cyano, =O, C. 1-6 Alkyl, C 3-6 cycloalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkyl groups and C 1-6 Substituents of haloalkoxy groups.
[0237] In some implementations, R a and R b Each is independently selected from H, halogen, hydroxyl, cyano, 3-10 membered heterocyclic group, 5-10 membered heteroaryl, C 6-10 Aryl, C 1-4 Alkyl, C 3-6 cycloalkyl, C 3-6 cycloalkyl-OR c C 1-4 Alkoxy, C 1-4 Haloalkyl, C 1-4 Haloalkoxy, -C(=O)R c -C 1-4 Alkyl-C(=O)-NR c R d NR c R d -NR c C(=O)R d -C(=O)-OR c -OR c -SR c -SOR c and -SO2R c The alkyl, cycloalkyl, alkoxy, haloalkyl, haloalkoxy, heterocyclic, heteroaryl, or aryl group is optionally selected by one or more groups, each independently selected from H, halogen, hydroxyl, amino, cyano, C 1-4 Alkyl, C 3-6 cycloalkyl, C 1-4 Alkoxy, C1-4 Halogenated alkyl groups and C 1-4 Substituents of haloalkoxy groups;
[0238] Or, R a R b The atoms bonded to it form a 3-8 membered carbon ring, a 3-8 membered heterocyclic group, or a 5-10 membered heteroaryl group, wherein the carbon ring, heterocyclic group, or heteroaryl group is optionally composed of one or more elements independently selected from H, halogen, hydroxyl, amino, cyano, =O, C. 1-6 Alkyl, C 3-6 cycloalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkyl groups and C 1-6 Substituents of haloalkoxy groups.
[0239] In some implementations, R a and R b Each is independently selected from H, D, halogens, 3-6 membered heterocyclic groups, and C. 1-4 Alkyl, C 3-6 cycloalkyl and C 3-6 cycloalkyl-OR c The alkyl, cycloalkyl, or heterocyclic group is optionally substituted by one or more substituents, each independently selected from H, D, halogens, and hydroxyl groups;
[0240] Or, R a R b The atoms attached thereto form 3-6 membered carbon rings (e.g., cyclopropyl ring, cyclobutyl ring, cyclopentyl ring, cyclohexyl ring), 3-8 membered heterocyclic groups (e.g., nitrogen-containing heterocyclic groups or oxygen-containing heterocyclic groups), or 5-10 membered heteroaryl groups, wherein the heterocyclic group or heteroaryl group is optionally composed of one or more elements each independently selected from H, halogen, hydroxyl, =O, and C. 1-6 Alkyl substituents.
[0241] In some implementations, R a and R b Each is independently selected from H, halogens, 3-6 membered heterocyclic groups, and C. 1-4 Alkyl, C 3-6 cycloalkyl and C 3-6 cycloalkyl-OR c The alkyl, cycloalkyl, or heterocyclic group is optionally substituted by one or more substituents, each independently selected from H, halogens, and hydroxyl groups;
[0242] Or, R a R bThe atoms attached thereto form 3-6 membered carbon rings (e.g., cyclopropyl ring, cyclobutyl ring, cyclopentyl ring, cyclohexyl ring), 3-8 membered heterocyclic groups (e.g., nitrogen-containing heterocyclic groups or oxygen-containing heterocyclic groups), or 5-10 membered heteroaryl groups, wherein the heterocyclic group or heteroaryl group is optionally composed of one or more elements each independently selected from H, halogen, hydroxyl, =O, and C. 1-6 Alkyl substituents.
[0243] In some implementations, R 1 Selected from H, halogen, cyano, C 1-6 Alkyl, C 3-6 cycloalkyl, C 1-6 Haloalkyl, C 1-6 Haloalkoxy, -C(=O)R c -C 1-6 Alkyl-C(=O)-NR a R b NR a R b OR a SR a -NR a C(=O)R b -C(=O)-OR a -SOR a -SO2R a C 6-10 Aryl, 5-10-membered heteroaryl, and 3-12-membered heterocyclic groups, wherein the alkyl, cycloalkyl, aryl, heteroaryl, or heterocyclic group is optionally selected by one or more groups, each independently selected from H, halogen, hydroxyl, amino, cyano, nitro, C 1-6 Alkyl, C 3-6 cycloalkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Hydroxyalkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy group, -C(=O)-(CH2) p -OR a -C(=O)-(CH2) p -NR a R b and -C 1-6 Alkylene-NR a R b Substituents are substituted.
[0244] In some implementations, R 1 Selected from H, halogen, cyano, C 1-6 Alkyl, C 3-6 cycloalkyl, C 1-6 Haloalkyl, C1-6 Haloalkoxy, -C(=O)R c -C 1-6 Alkyl-C(=O)-NR a R b NR a R b OR a SR a -NR a C(=O)R b -C(=O)-OR a -SOR a -SO2R a C 6-10 Aryl, 5-10-membered heteroaryl, and 3-12-membered heterocyclic groups, wherein the alkyl, cycloalkyl, aryl, heteroaryl, or heterocyclic group is optionally selected by one or more groups, each independently selected from H, =O, halogen, hydroxyl, amino, cyano, nitro, C 1-6 Alkyl, C 3-6 cycloalkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Hydroxyalkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy group, -C(=O)-(CH2) p -OR a -C(=O)-(CH2) p -NR a R b and -C 1-6 Alkylene-NR a R b Substituents are substituted.
[0245] In some implementations, R 1 Selected from H, halogen, cyano, C 1-6 Alkyl, C 3-6 cycloalkyl, C 1-6 Haloalkyl, C 1-6 Haloalkoxy, -C(=O)R c -C 1-6 Alkyl-C(=O)-NR a R b NR a R b OR a SR a -NR a C(=O)R b -C(=O)-OR a -SOR a -SO2Ra C 6-10 Aryl, 5-10-membered heteroaryl, and 3-12-membered heterocyclic groups, wherein the alkyl, cycloalkyl, aryl, heteroaryl, or heterocyclic group is optionally selected by one or more groups, each independently selected from H, halogen, hydroxyl, amino, cyano, nitro, C 1-6 Alkyl, C 3-6 cycloalkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Hydroxyalkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy group, -C(=O)-(CH2) p -OR a -C(=O)-(CH2) p -NR a R b and -C 1-6 Alkylene-NR a R b Substituents are substituted.
[0246] In some implementations, R 1 Selected from C 1-6 Alkyl, C 3-6 cycloalkyl, NR a R b OR a SR a 5-10-membered heteroaryl and 3-12-membered heterocyclic groups, wherein the alkyl, cycloalkyl, heteroaryl or heterocyclic group is optionally selected by one or more independently from =O, halogen, hydroxyl, amino, cyano, nitro, C 1-6 Alkyl, C 3-6 cycloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy and C 1-6 Substitution of haloalkoxy groups; R a and R b Each is independently selected from H, halogens, 3-6 membered heterocyclic groups, and C. 1-6 Alkyl, C 3-6 cycloalkyl and C 3-6 Cycloalkyl-OH, wherein the heterocyclic or cycloalkyl group is optionally selected by one or more groups, each independently selected from halogen, hydroxyl, amino, cyano, nitro, C 1-6 Alkyl, C 3-6 cycloalkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy and C 1-6 Substituents of haloalkoxy groups.
[0247] In some implementations, R 1 Selected from C 1-6 Alkyl, C 3-6 cycloalkyl, NR a R b OR a SR a 5-10-membered heteroaryl and 3-12-membered heterocyclic groups, wherein the alkyl, cycloalkyl, heteroaryl or heterocyclic group is optionally selected by one or more of the following groups, each independently selected from halogen, hydroxyl, amino, cyano, nitro, C 1-6 Alkyl, C 3-6 cycloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy and C 1-6 Substitution of haloalkoxy groups, R a and R b Each is independently selected from H, halogens, 3-6 membered heterocyclic groups, and C. 1-6 Alkyl, C 3-6 cycloalkyl and C 3-6 Cycloalkyl-OH.
[0248] In some implementations, R 1 Selected from C 1-6 Alkyl, C 3-6 cycloalkyl, NR a R b OR a SR a 5-6-membered heteroaryl and 3-6-membered heterocyclic groups, wherein the alkyl, cycloalkyl, heteroaryl or heterocyclic group is optionally selected by one or more groups independently selected from =O, halogen, hydroxyl, amino, cyano, nitro, C 1-6 Alkyl, C 3-6 cycloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy and C 1-6 Substitution of haloalkoxy groups, R a and R b Each is independently selected from H, halogens, 3-6 membered heterocyclic groups, and C. 1-6 Alkyl, C 3-6 cycloalkyl and C 3-6 Cycloalkyl-OH; the heterocyclic or cycloalkyl group is optionally selected by one or more groups, each independently selected from halogen, hydroxyl, amino, cyano, nitro, C 1-6 Alkyl, C 3-6 cycloalkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy and C 1-6 Substituents of haloalkoxy groups.
[0249] In some implementations, R 1 Selected from C 1-6 Alkyl, C 3-6 cycloalkyl, NR a R b OR a SR a 5-6-membered heteroaryl and 3-6-membered heterocyclic groups, wherein the alkyl, cycloalkyl, heteroaryl or heterocyclic group is optionally selected by one or more independently from halogen, hydroxyl, amino, cyano, nitro, C 1-6 Alkyl, C 3-6 cycloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy and C 1-6 Substitution of haloalkoxy groups, R a and R b Each is independently selected from H, halogens, 3-6 membered heterocyclic groups, and C. 1-6 Alkyl, C 3-6 cycloalkyl and C 3-6 Cycloalkyl-OH.
[0250] In some implementations, R 1 Selected from -cyclopropyl-CH2-OH, -NH-CH(CH3)2, -O-CH(CH3)2, -NH-cyclopropyl, -NH-cyclobutyl, -NH-CH(CH3)-CH2-OH, -NH-cyclopropyl-OH, -CH2-CH(CH3)2. -S-CH(CH3)2、
[0251] In some implementations, R 1 Selected from -cyclopropyl-CH2-OH, -NH-CH(CH3)2, -O-CH(CH3)2, -NH-cyclopropyl, -NH-cyclobutyl, -NH-CH(CH3)-CH2-OH, -NH-cyclopropyl-OH, -CH2-CH(CH3)2. -S-CH(CH3)2、
[0252] In some implementations, R 1 Selected from -cyclopropyl-CH2-OH, -NH-CH(CH3)2, -O-CH(CH3)2, -NH-cyclopropyl, -NH-cyclobutyl, -NH-CH(CH3)-CH2-OH, -NH-cyclopropyl-OH -S-CH(CH3)2、 and -CH2-CH(CH3)2.
[0253] In some implementations, R 1 Selected from -cyclopropyl-CH2-OH, -NH-CH(CH3)2, -O-CH(CH3)2, -NH-cyclopropyl, -NH-CH(CH3)-CH2-OH, -NH-cyclopropyl-OH -S-CH(CH3)2、 and -CH2-CH(CH3)2.
[0254] In some implementations, R 1 Selected from -cyclopropyl-CH2-OH and
[0255] In some implementations, R c and R d Each is independently selected from H, D, F, Cl, Br, hydroxyl, cyano, C 1-4 Alkyl, C 1-4 Alkoxy, C 1-4 Halogenated alkyl groups and C 1-4 The alkyl, alkoxy, haloalkyl, or haloalkoxy group is optionally selected from one or more groups, each independently chosen from H, D, halogen, hydroxyl, amino, cyano, and C. 1-4 Alkyl substituents;
[0256] Or, R c R d The N atom attached thereto forms a 4-8 membered heterocyclic group or a 5-8 membered heteroaryl group, wherein the heterocyclic group or heteroaryl group is optionally composed of one or more atoms each independently selected from H, D, halogen, hydroxyl, amino, cyano, =O, C. 1-4 Alkyl, C 3-6 cycloalkyl, C 1-4 Alkoxy, C 1-4 Halogenated alkyl groups and C 1-4 Substituents of haloalkoxy groups.
[0257] In some implementations, R c and R d Each is independently selected from H, F, Cl, Br, hydroxyl, cyano, C 1-4 Alkyl, C 1-4Alkoxy, C 1-4 Halogenated alkyl groups and C 1-4 The alkyl, alkoxy, haloalkyl, or haloalkoxy group is optionally selected from one or more groups, each independently chosen from H, halogen, hydroxyl, amino, cyano, and C. 1-4 Alkyl substituents;
[0258] Or, R c R d The N atom attached thereto forms a 4-8 membered heterocyclic group or a 5-8 membered heteroaryl group, wherein the heterocyclic group or heteroaryl group is optionally composed of one or more atoms, each independently selected from H, halogen, hydroxyl, amino, cyano, =O, C. 1-4 Alkyl, C 3-6 cycloalkyl, C 1-4 Alkoxy, C 1-4 Halogenated alkyl groups and C 1-4 Substituents of haloalkoxy groups.
[0259] In some implementations, R c and R d Each is independently selected from H, D, F, Cl, Br, hydroxyl, cyano, C 1-4 Alkyl, C 1-4 Alkoxy, C 1-4 Halogenated alkyl groups and C 1-4 The alkyl, alkoxy, haloalkyl, or haloalkoxy group is optionally selected from one or more groups, each independently chosen from H, D, F, Cl, Br, hydroxyl, amino, cyano, and C. 1-4 Alkyl substituents;
[0260] Or, R c R d The N atom attached thereto forms a 4-8 membered heterocyclic group or a 5-8 membered heteroaryl group, wherein the heterocyclic group or heteroaryl group is optionally composed of one or more atoms, each independently selected from H, D, F, Cl, Br, hydroxyl, amino, cyano, =O, C. 1-4 Alkyl, C 3-6 cycloalkyl, C 1-4 Alkoxy, C 1-4 Halogenated alkyl groups and C 1-4 Substituents of haloalkoxy groups.
[0261] In some implementations, R c and R d Each is independently selected from H, F, Cl, Br, hydroxyl, cyano, C 1-4 Alkyl, C 1-4 Alkoxy, C 1-4 Halogenated alkyl groups and C 1-4Haloalkoxy, wherein the alkyl, alkoxy, haloalkyl or haloalkoxy group is optionally selected by one or more groups, each independently selected from H, F, Cl, Br, hydroxyl, amino, cyano and C. 1-4 Alkyl substituents;
[0262] Or, R c R d The N atom attached thereto forms a 4-8 membered heterocyclic group or a 5-8 membered heteroaryl group, wherein the heterocyclic group or heteroaryl group is optionally composed of one or more atoms, each independently selected from H, F, Cl, Br, hydroxyl, amino, cyano, =O, C. 1-4 Alkyl, C 3-6 cycloalkyl, C 1-4 Alkoxy, C 1-4 Halogenated alkyl groups and C 1-4 Substituents of haloalkoxy groups.
[0263] In some implementations, Ar is selected from C 6-10 Aryl and 5-10 nitrogen-containing heteroaryl groups, wherein the aryl or heteroaryl group is optionally surrounded by one or more R groups. 2 replace.
[0264] In some implementations, R 2 Each is independently selected from H, D, halogen, amino, cyano, nitro, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Haloalkyl, C 3-10 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-10 Aryl and 5-10 heteroaryl groups, wherein the alkyl, cycloalkyl, heterocyclic, aryl, or heteroaryl group is optionally selected by one or more groups independently chosen from H, D, halogen, hydroxyl, amino, cyano, and C. 1-6 Alkyl substituents.
[0265] In some implementations, R 2 Each is independently selected from H, halogen, amino, cyano, nitro, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Haloalkyl, C 3-10 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-10 Aryl and 5-10 heteroaryl groups, wherein the alkyl, cycloalkyl, heterocyclic, aryl, or heteroaryl group is optionally selected by one or more groups, each independently selected from H, halogen, hydroxyl, amino, cyano, and C. 1-6 Alkyl substituents.
[0266] In some implementations, R 2Each is independently selected from H, D, F, Cl, Br, amino, cyano, nitro, C 1-4 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-4 Haloalkyl, C 1-4 Alkoxy, C 3-8 Cycloalkyl, 3-10 membered heterocyclic groups, C 6-10 Aryl and 5-10 heteroaryl groups, wherein the alkyl, cycloalkyl, heterocyclic, aryl, or heteroaryl group is optionally composed of one or more groups each independently selected from H, D, F, Cl, Br, hydroxyl, amino, cyano, and C. 1-4 Alkyl substituents.
[0267] In some implementations, R 2 Each is independently selected from H, F, Cl, Br, amino, cyano, nitro, C 1-4 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-4 Haloalkyl, C 1-4 Alkoxy, C 3-8 Cycloalkyl, 3-10 membered heterocyclic groups, C 6-10 Aryl and 5-10 heteroaryl groups, wherein the alkyl, cycloalkyl, heterocyclic, aryl, or heteroaryl group is optionally composed of one or more groups each independently selected from H, F, Cl, Br, hydroxyl, amino, cyano, and C. 1-4 Alkyl substituents.
[0268] In some implementations, R 2 Each is independently selected from H, D, F, Cl, Br, amino, cyano, nitro, C 1-4 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-4 Haloalkyl, C 3-8 Cycloalkyl, 3-10 membered heterocyclic groups, C 6-10 Aryl and 5-10 heteroaryl groups, wherein the alkyl, cycloalkyl, heterocyclic, aryl, or heteroaryl group is optionally composed of one or more groups each independently selected from H, D, F, Cl, Br, hydroxyl, amino, cyano, and C. 1-4 Alkyl substituents.
[0269] In some implementations, R 2 Each is independently selected from H, F, Cl, Br, amino, cyano, nitro, C 1-4 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-4 Haloalkyl, C 3-8 Cycloalkyl, 3-10 membered heterocyclic groups, C6-10 Aryl and 5-10 heteroaryl groups, wherein the alkyl, cycloalkyl, heterocyclic, aryl, or heteroaryl group is optionally composed of one or more groups each independently selected from H, F, Cl, Br, hydroxyl, amino, cyano, and C. 1-4 Alkyl substituents.
[0270] In some implementations, R 2 Each is independently selected from H, F, Cl, amino, cyano, nitro, C 1-4 Alkyl, C 1-4 Haloalkyl, C 1-4 Alkoxy, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 Aryl and 5-10 heteroaryl groups, wherein the alkyl, cycloalkyl, heterocyclic, aryl, or heteroaryl group is optionally composed of one or more groups each independently selected from H, F, Cl, Br, hydroxyl, amino, cyano, and C. 1-4 Alkyl substituents.
[0271] In some implementations, R 2 Each is independently selected from H, F, Cl, amino, cyano, nitro, C 1-4 Alkyl, C 1-4 Haloalkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 Aryl and 5-10 heteroaryl groups, wherein the alkyl, cycloalkyl, heterocyclic, aryl, or heteroaryl group is optionally composed of one or more groups each independently selected from H, F, Cl, Br, hydroxyl, amino, cyano, and C. 1-4 Alkyl substituents.
[0272] In some implementations, R 2 Each is independently selected from H, D, F, Cl, amino, cyano, nitro, C 1-4 Alkyl, C 1-4 Halogenated alkyl groups and C 1-4 Alkyl group.
[0273] In some implementations, R 2 Each is independently selected from H, F, Cl, amino, cyano, nitro, C 1-4 Alkyl, C 1-4 Halogenated alkyl groups and C 1-4 Alkyl group.
[0274] In some implementations, R 2 Each is independently selected from H, D, F, Cl, amino, cyano, nitro, methyl, ethyl, -CF3, CHF2, CH2F-, methoxy, and ethoxy.
[0275] In some implementations, R 2Each is independently selected from H, F, Cl, amino, cyano, nitro, methyl, ethyl, -CF3, CHF2, CH2F-, methoxy, and ethoxy.
[0276] In some implementations, R 2 Each is independently selected from H, D, F, Cl, methyl, and methoxy.
[0277] In some implementations, R 2 Each is independently selected from H, F, Cl, methyl, and methoxy.
[0278] In some embodiments, Ar is selected from phenyl and pyridyl, wherein the phenyl or pyridyl group is optionally substituted by one or more (e.g., 2, 3, 4 or 5) substituents each independently selected from D, F, Cl, methyl and methoxy.
[0279] In some embodiments, Ar is selected from phenyl and pyridyl, wherein the phenyl or pyridyl group is optionally substituted by one or more (e.g., 2, 3, 4 or 5) substituents each independently selected from F, Cl, methyl and methoxy.
[0280] In some embodiments, Ar is a phenyl group, which is optionally substituted by one or more (e.g., 2, 3, 4, or 5) substituents each independently selected from D, F, and Cl.
[0281] In some embodiments, Ar is a phenyl group, which is optionally substituted by one or more (e.g., 2, 3, 4, or 5) substituents each independently selected from F and Cl.
[0282] In some embodiments, Ar is selected from phenyl and pyridyl, wherein the phenyl or pyridyl group is substituted by a plurality of (e.g., 2, 3, 4 or 5) substituents each independently selected from D, F, Cl, methyl and methoxy.
[0283] In some embodiments, Ar is selected from phenyl and pyridyl, wherein the phenyl or pyridyl group is substituted by a plurality of (e.g., 2, 3, 4 or 5) substituents each independently selected from F, Cl, methyl and methoxy.
[0284] In some embodiments, Ar is a phenyl group, which is substituted by a plurality of (e.g., 2, 3, 4 or 5) substituents each independently selected from F and Cl.
[0285] In some implementations, Ar is selected from
[0286] In some implementations, Ar is selected from
[0287] In some implementations, R3 Each is independently selected from H, D, hydroxyl, and C. 1-4 Alkyl, 3-8 membered heterocyclic, 5-10 membered heteroaryl, C 1-4 Haloalkyl, C 1-4 Alkoxy and -C 1-4 Alkyl-OH.
[0288] In some implementations, R 3 Each is independently selected from H, D, hydroxyl, C 1-4 Alkyl groups, 3-8 membered heterocyclic groups (e.g., 3-8 membered nitrogen- or oxygen-containing heterocyclic groups), 5-10 membered nitrogen-containing heteroaryl groups, C 1-4 Fluoroalkyl, C 1-4 Chloroalkyl, C 1-4 Alkoxy and -C 1-4 Alkyl-OH.
[0289] In some implementations, R 3 Each is independently selected from H, D, hydroxyl, methyl, ethyl, propyl, isopropyl, 3-6 membered heterocyclic groups (e.g., 4 membered oxygen-containing heterocyclic groups), pyrazolyl, -CF3, -CHF2, -CH2CH2F, C 1-4 Chloroalkyl, methoxy, and -CH2CH2OH.
[0290] In some implementations, R 3 Each is independently selected from H, D, hydroxyl, methyl, ethyl, isopropyl, 4-membered oxygen-containing heterocyclic group, pyrazolyl, -CF3, -CHF2, -CH2CH2F, methoxy and -CH2CH2OH.
[0291] In some implementations, p is independently selected from 0, 1, 2, and 3.
[0292] In some implementations, X 1 and X 2 Each is independently selected from N and CR, and R is selected from H, D, halogen, hydroxyl, cyano, nitro, amino, and C. 1-4 Alkyl, C 2-4 alkenyl, C 2-4 alkynyl group, C 1-4 Halogenated alkyl groups and C 3-8 Cycloalkyl.
[0293] In some implementations, X 1 and X 2 Each is independently selected from N and CR, and R is selected from H, halogen, hydroxyl, cyano, nitro, amino, C. 1-4 Alkyl, C 2-4 alkenyl, C 2-4 alkynyl group, C 1-4 Halogenated alkyl groups and C 3-8 Cycloalkyl.
[0294] In some implementations, X 1 and X 2 Each is independently selected from N and CR, and R is selected from H, halogen, hydroxyl, cyano, nitro, amino, C. 1-4 Alkyl, C 1-4 Halogenated alkyl groups and C 3-8 Cycloalkyl.
[0295] In some implementations, X 1 and X 2 Each is independently selected from N and CR, and R is selected from H, D, F, Cl, Br, hydroxyl, cyano, nitro, amino, methyl, ethyl, propyl, C. 1-3 Halogenated alkyl groups and C 3-6 Cycloalkyl.
[0296] In some implementations, X 1 and X 2 Each is independently selected from N and CR, and R is selected from H, F, Cl, Br, hydroxyl, cyano, nitro, amino, methyl, ethyl, propyl, C. 1-3 Halogenated alkyl groups and C 3-6 Cycloalkyl.
[0297] In some implementations, X 1 and X 2 Each is independently selected from N and CH.
[0298] In some implementations, X 1 and X 2 Let N be the number of elements in the array.
[0299] In some implementations, X 1 and X 2 At least one of them is CR, and each R is independently selected from H, D, F, Cl, Br, hydroxyl, cyano, nitro, amino, methyl, ethyl, propyl, C 1-3 Halogenated alkyl, cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl.
[0300] In some implementations, X 1 Selected from CH, C(F), C(Cl), C(CH3), C(CN), and C(cyclopropyl), X 2 For CH.
[0301] In some implementations, X 1 For CH, X 2 Selected from CH, C(F), C(Cl), C(CH3), C(CN) and C(cyclopropyl).
[0302] In some implementations, X 1Selected from CH, C(F), C(Cl), C(CH3) and C(CN), X 2 For CH.
[0303] In some implementations, X 1 For CH, X 2 Selected from CH, C(F), C(Cl), C(CH3) and C(CN).
[0304] In some implementations, X 1 Let N, X 2 Selected from CH, C(F), C(Cl), C(CH3), C(CN) and C(cyclopropyl).
[0305] In some implementations, X 1 Let N, X 2 For CH.
[0306] In some implementations, X 1 Selected from CH, C(F), C(Cl), C(CH3), C(CN), and C(cyclopropyl), X 2 Let N be the number of elements in the array.
[0307] In some implementations, X 1 For CH, X 2 Let N be the number of elements in the array.
[0308] In some implementations, m and n are each independently selected from 0, 1, and 2; preferably, m is selected from 0 and 1, and n is selected from 1 and 2.
[0309] In some implementations, q is selected from 0, 1, and 2.
[0310] In some implementations, q is selected from 0 and 1.
[0311] In some implementations, q is selected from 3 and 4.
[0312] In some implementations, r is selected from 0, 1, and 2; preferably, r is selected from 0 and 1.
[0313] In some embodiments, the compounds of this disclosure are substituted at any position with one or more of the following substituents: D, halogen, -OH, -CN, -COOH, -NH2, C 1-6 Alkyl and C 1-6 Halogenated alkyl groups.
[0314] In some embodiments, the compounds of this disclosure are substituted with one or more D molecules at any position.
[0315] In some embodiments, any position of the A ring, L, Z, Ar, and R1 of the compounds disclosed herein is substituted with one or more D atoms.
[0316] In some embodiments, the A ring and L of the compounds disclosed herein are substituted at any position with one or more D rings.
[0317] In some embodiments, the compounds disclosed herein are selected from:
[0318] In some embodiments, the compound is selected from:
[0319] This disclosure also provides compounds, or stereoisomers, tautomers, polymorphs, solvates, N-oxides, isotopically labeled compounds, or metabolites, prodrugs, or pharmaceutically acceptable salts or esters thereof, wherein said compounds have a structure as shown in Formula I':
[0320] Among them, ring A' is selected from C. 6-14 Aromatic rings and 3-14 membered heteroaromatic rings, wherein the aromatic rings or heteroaromatic rings are optionally selected by one or more groups, each independently selected from H, D, halogen, hydroxyl, amino, cyano, nitro, C 1-6 Alkyl, C 3-6 Cycloalkyl, 3-12 membered heterocyclic, 5-10 membered heteroaryl, C 6-10 Aryl, C2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy groups, -C 1-6 Alkyl-OR a -C(=O)-(CH2) p -OR a -C(=O)-(CH2) p -NR a R b and -C 1-6 Alkylene-NR a R b The substituents are substituted; the heteroaromatic ring contains 1-3 heteroatoms, each independently selected from N, O and S;
[0321] X 1 X 2 L, Z, Ar, R 1 R a and R b As defined in Equation I.
[0322] In some implementations, the optionally replaced Selected from
[0323] In some embodiments, the compound of formula I' has the structure shown in formula I'-1-A or formula I'-1-B:
[0324] R' is independently selected from H, D, halogen, hydroxyl, amino, cyano, nitro, C 1-6 Alkyl, C 3-6 Cycloalkyl, 3-12 membered heterocyclic, 5-10 membered heteroaryl, C 6-10 Aryl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy groups, -C 1-6 Alkyl-OR a -C(=O)-(CH2) p -OR a -C(=O)-(CH2) p -NR a R b and -C 1-6 Alkylene-NR a R b ;
[0325] p is selected from 0-3;
[0326] X 1 X 2 L, Z, R 1 R a and R b As defined in Equation I'.
[0327] In some implementations, in formula I'-1-A or formula I'-1-B, R 1 Selected from
[0328] In some embodiments, the compounds disclosed herein are selected from:
[0329] Preferably, the compound is selected from...
[0330] In some embodiments, the compounds described herein may optionally be substituted at suitable positions with one or more suitable substituents.
[0331] The functional groups in all the embodiments described above in this disclosure can be suitably selected and combined in any way to obtain different general formula ranges or specific embodiments. These ranges and embodiments are all included in this disclosure. This disclosure covers compounds obtained by arbitrarily combining the various embodiments.
[0332] Preparation method
[0333] Route 1: Preparation method of formula I-3-A when m is 0
[0334] Where R 1 As defined above, X is a halogen, and R is a halogen. A Selected from C 1-6 Alkyl groups (e.g., methyl, ethyl, isopropyl, tert-butyl) and benzyl groups; preferably, n is selected from 0, 1, 2, and 3; NXS is selected from NCS, NBS, and NIS; preferably, NXS is NBS;
[0335] The preparation method includes:
[0336] Step 1: Compound I-3-A-1 undergoes a substitution reaction or a coupling reaction to generate compound I-3-A-2;
[0337] Preferably, the substitution reaction is a nucleophilic substitution reaction; preferably, the nucleophilic substitution reaction is usually carried out in a basic reagent (such as potassium carbonate, cesium carbonate, triethylamine, DBU, etc.) at a temperature range of -20°C to 120°C.
[0338] The coupling reaction is selected from the Suzuki reaction, the Buchwald cross-coupling reaction, and the Ullman coupling reaction;
[0339] Step 2: Compound I-3-A-2 undergoes a coupling reaction to generate compound I-3-A-3;
[0340] Preferably, the coupling reaction is selected from the Suzuki reaction, the carbonyl insertion reaction, and the Heck reaction;
[0341] Step 3: Compound I-3-A-3 undergoes a reduction reaction to generate compound I-3-A-4;
[0342] Preferably, the reduction reaction is carried out under the conditions of hydrogen metal catalysis (e.g., Pd, Pd(OH)2) and negative hydrogen reagent catalysis (e.g., LAH, DIBAL-H, borane, etc.);
[0343] Step 4: Compound I-3-A-4 undergoes a cyclization reaction to form compound I-3-A-5;
[0344] Preferably, the compound I-3-A-4 undergoes a cyclization reaction in the presence of an acidic reagent (such as trifluoroacetic acid, hydrochloric acid, concentrated sulfuric acid, etc.) and a solvent; preferably, the solvent is selected from polar solvents; more preferably, the solvent is selected from DMSO and DMF.
[0345] Step 5: Compound I-3-A-5 reacts with halogens or NGS to generate compound I-3-A-6;
[0346] Preferably, the reaction is carried out under halogen (e.g., bromine, iodine, etc.) or NGS (e.g., selected from NCS, NBS and NIS; preferably, NGS is selected from NBS) conditions, in a solvent (e.g., dichloromethane, chloroform, toluene, etc.; preferably, the solvent is selected from chloroform), at a temperature of -20°C to 80°C.
[0347] Step 6: Compound I-3-A-6 undergoes a substitution reaction or a coupling reaction to generate compound I-3-A;
[0348] Preferably, the substitution reaction is a nucleophilic substitution reaction; preferably, the nucleophilic substitution reaction is usually carried out in the presence of a basic reagent (such as potassium carbonate, cesium carbonate, triethylamine, DBU, etc.) at a temperature range of -20°C to 120°C.
[0349] The coupling reaction is selected from the Buchwald cross-coupling reaction and the Ullman coupling reaction.
[0350] Route 2: Preparation method of formula I-3-A
[0351] Among them, R 1 As defined above, m, n, L, Z, and Ar are halogens, X is a halogen, and R is a halogen. A and R B Each was independently selected from C 1-6 Alkyl groups (e.g., methyl, ethyl, isopropyl, tert-butyl) and benzyl groups; preferably, n is selected from 0, 1, 2, and 3; m is selected from 0, 1, and 2; NXS is selected from NCS, NBS, and NIS; preferably, NXS is NBS;
[0352] The preparation method includes:
[0353] Step 1: Compound I-3-A-1' undergoes a substitution reaction to generate compound I-3-A-2';
[0354] Preferably, the substitution reaction is a nucleophilic substitution reaction; preferably, the nucleophilic substitution reaction is usually carried out in the presence of a basic reagent (such as potassium carbonate, cesium carbonate, triethylamine, DBU, etc.) at a temperature range of -20°C to 120°C.
[0355] Step 2: Compound I-3-A-2' undergoes a substitution reaction to generate compound I-3-A-3';
[0356] Preferably, the substitution reaction is a nucleophilic substitution reaction; preferably, the nucleophilic substitution reaction is usually carried out in the presence of a basic reagent (such as potassium carbonate, cesium carbonate, triethylamine, DBU, etc.) at a temperature range of -20°C to 120°C; third step: compound I-3-A-3' undergoes a substitution reaction or a coupling reaction to generate compound I-3-A-4';
[0357] Preferably, the substitution reaction is a nucleophilic substitution reaction; preferably, the nucleophilic substitution reaction is usually carried out in the presence of a basic reagent (such as potassium carbonate, cesium carbonate, triethylamine, DBU, etc.) at a temperature range of -20°C to 120°C.
[0358] The coupling reaction is selected from the Suzuki reaction, the Buchwald cross-coupling reaction, and the Ullman coupling reaction;
[0359] Step 4: Compound I-3-A-4' undergoes a reduction reaction to form compound I-3-A-5';
[0360] Preferably, the reduction reaction is carried out under the following conditions: a reducing agent catalyzed system (e.g., LAH, DIBAL-H, borane, etc.), in a solvent (tetrahydrofuran, dichloromethane, diethyl ether, etc., with tetrahydrofuran being the preferred solvent), and at a temperature range of -78°C to 25°C.
[0361] Step 5: Compound I-3-A-5' undergoes a cyclization reaction to form compound I-3-A-6';
[0362] Preferably, the compound I-3-A-5' undergoes a cyclization reaction in the presence of an acidic reagent (such as trifluoroacetic acid, hydrochloric acid, concentrated sulfuric acid, etc.) and a solvent; preferably, the solvent is a polar solvent; more preferably, the solvent is selected from DMSO and DMF.
[0363] Step 6: Compound I-3-A-6' reacts with halogens or NGS to generate compound I-3-A-7';
[0364] Preferably, the reaction is carried out under halogen (such as bromine, iodine, etc.) or NGS (such as NCS, NBS and NIS; preferably NBS) conditions, in a solvent (e.g., the solvent is selected from dichloromethane, chloroform and toluene, etc.; preferably, the solvent is chloroform), at a temperature of -20°C to 80°C.
[0365] Step 7: Compound I-3-A-7' undergoes a substitution reaction or a coupling reaction to generate compound I-3-A;
[0366] Preferably, the substitution reaction is a nucleophilic substitution reaction; preferably, the nucleophilic substitution reaction is usually carried out in the presence of a basic reagent (such as potassium carbonate, cesium carbonate, triethylamine, DBU, etc.) at a temperature range of -20°C to 120°C.
[0367] The coupling reaction is selected from the Suzuki reaction, the Buchwald cross-coupling reaction, and the Ullman coupling reaction.
[0368] Route 3: Preparation methods of Formula I-3-B, Formula I-3-C and Formula I-3-D
[0369] Where R1, m, n, Ra, L, Z, and Ar are as defined above, X is a halogen, and R A and R B Each was independently selected from C 1-6 Alkyl (e.g., methyl, ethyl, isopropyl, tert-butyl) or benzyl, etc.; preferably, m is selected from 0, 1, 2 and 3; n is selected from 0, 1 and 2; NXS is selected from NCS, NBS and NIS; preferably, NXS is selected from NBS.
[0370] The preparation method includes:
[0371] Step 1: Compound I-3-A-5' undergoes a substitution reaction to generate compound I-3-B-1;
[0372] Preferably, the substitution reaction is a nucleophilic substitution reaction; the nucleophilic substitution reaction is usually carried out in the presence of a basic reagent (such as potassium carbonate, cesium carbonate, triethylamine, DBU, etc.) and at a temperature range of 0°C to 25°C, in reaction with a protecting group reagent (TsCl, MsCl, etc.);
[0373] Step 2: Compound I-3-B-1 undergoes a cyclization reaction to generate compound I-3-B-2;
[0374] Preferably, the cyclization reaction is typically carried out in the presence of an alkaline reagent (such as potassium carbonate, cesium carbonate, triethylamine, DBU, etc.) and at a temperature range of 25°C to 125°C, in reaction with a sulfur-containing reagent (Na2S, NaHS, etc.).
[0375] Step 3: Compound I-3-B-2 reacts with halogens or NGS to generate compound I-3-B-3;
[0376] Preferably, the reaction is carried out under halogen (such as bromine, iodine, etc.) or NGS (such as NCS, NBS and NIS; preferably NBS) conditions, in a solvent (e.g., the solvent is selected from dichloromethane, chloroform and toluene, etc.; preferably, the solvent is chloroform), at a temperature of -20°C to 80°C.
[0377] Step 4: Compound I-3-B-3 undergoes a substitution reaction or a coupling reaction to generate compound I-3-B;
[0378] Preferably, the substitution reaction is a nucleophilic substitution reaction; preferably, the nucleophilic substitution reaction is usually carried out in the presence of a basic reagent (such as potassium carbonate, cesium carbonate, triethylamine, DBU, etc.) at a temperature range of -20°C to 120°C.
[0379] The coupling reaction is selected from the Suzuki reaction, the Buchwald cross-coupling reaction, and the Ullman coupling reaction;
[0380] Step 5: Compound I-3-B undergoes oxidation to form compound I-3-C;
[0381] Preferably, the oxidation reaction is typically carried out in the presence of an oxidizing agent (such as m-chloroperoxybenzoic acid, hydrogen peroxide, sodium hypochlorite, sodium periodate, etc.), in a solvent (such as a solvent selected from dichloromethane, chloroform, methanol, etc.; preferably, the solvent is dichloromethane) and at a temperature range of -20°C to 60°C.
[0382] Step 6: Compound I-3-C undergoes oxidation to form compound I-3-D;
[0383] Preferably, the oxidation reaction is typically carried out in the presence of an oxidizing agent (such as m-chloroperoxybenzoic acid, hydrogen peroxide, sodium hypochlorite, sodium periodate, etc.), in a solvent (such as dichloromethane, chloroform, methanol, etc.; preferably, dichloromethane) and at a temperature range of -20°C to 60°C.
[0384] Route 4: m is 0, R a When H is present, the preparation method of formula I-3-E
[0385] Where R 1 n, R a As defined above, L, Z, and Ar, X is a halogen, and R... A Selected from C 1-6 Alkyl groups (e.g., methyl, ethyl, isopropyl, tert-butyl) and benzyl groups; preferably, n is selected from 0, 1, 2, and 3; NXS is selected from NCS, NBS, and NIS; preferably, NXS is NBS;
[0386] The preparation method includes:
[0387] Step 1: Compound I-3-E-1 undergoes a substitution reaction or a coupling reaction to generate compound I-3-E-2;
[0388] Preferably, the substitution reaction is a nucleophilic substitution reaction; preferably, the nucleophilic substitution reaction is usually carried out in the presence of a basic reagent (such as potassium carbonate, cesium carbonate, triethylamine, DBU, etc.) at a temperature range of -20°C to 120°C.
[0389] The coupling reaction is selected from the Suzuki reaction, the Buchwald cross-coupling reaction, and the Ullman coupling reaction;
[0390] Step 2: Compound I-3-E-2 undergoes a coupling reaction to generate compound I-3-E-3;
[0391] Preferably, the coupling reaction is selected from the Suzuki reaction, the carbonyl insertion reaction, and the Heck reaction;
[0392] Step 3: Compound I-3-E-3 undergoes a reduction reaction to generate compound I-3-E-4;
[0393] Preferably, the reduction reaction is carried out under hydrogen metal catalysis (e.g., Pd, Pd(OH)2, Raney nickel, etc.) system;
[0394] Step 4: Compound I-3-E-4 undergoes a cyclization reaction to form compound I-3-E-5;
[0395] Preferably, compound IV-4 undergoes a cyclization reaction in the presence of an alkaline reagent (such as potassium carbonate, cesium carbonate, triethylamine, DBU, etc.) and a solvent; preferably, the solvent is a polar solvent; more preferably, the solvent is selected from methanol and ethanol.
[0396] Step 5: Compound I-3-E-5 reacts with halogens or NGS to generate compound I-3-E-6;
[0397] Preferably, the reaction is carried out under halogen (e.g., bromine, iodine, etc.) or NGS (e.g., selected from NCS, NBS and NIS; preferably, NGS is selected from NBS) conditions, in a solvent (e.g., dichloromethane, chloroform, toluene, etc.; preferably, the solvent is selected from chloroform), at a temperature of -20°C to 80°C.
[0398] Step 6: Compound I-3-E-6 undergoes a substitution reaction or a coupling reaction to generate compound I-3-E-7;
[0399] Preferably, the substitution reaction is a nucleophilic substitution reaction; preferably, the nucleophilic substitution reaction is usually carried out in the presence of a basic reagent (such as potassium carbonate, cesium carbonate, triethylamine, DBU, etc.) at a temperature range of -20°C to 120°C.
[0400] The coupling reaction is selected from the Buchwald cross-coupling reaction and the Ullman coupling reaction;
[0401] Step 7: Compound I-3-E-7 is converted to compound I-3-E via alkylation.
[0402] Route 5: Preparation method of formula I-01-1-A
[0403] Among them, R 1 As defined above, m, n, L, Z, and Ar are halogens, X is a halogen, and R is a halogen. A and R B Each was independently selected from C 1-6 Alkyl groups (e.g., methyl, ethyl, isopropyl, tert-butyl) and benzyl groups; preferably, n is selected from 0, 1, 2, and 3; m is selected from 0, 1, and 2; NXS is selected from NCS, NBS, and NIS; preferably, NXS is NBS;
[0404] The preparation method includes:
[0405] Step 1: Compound I-01-1-A-1' undergoes a substitution reaction to generate compound I-01-1-A-2';
[0406] Preferably, the substitution reaction is a nucleophilic substitution reaction; preferably, the nucleophilic substitution reaction is usually carried out in the presence of a basic reagent (such as potassium carbonate, cesium carbonate, triethylamine, DBU, etc.) at a temperature range of -20°C to 120°C.
[0407] Step 2: Compound I-01-1-A-2' undergoes a substitution reaction to generate compound I-01-1-A-3';
[0408] Preferably, the substitution reaction is a nucleophilic substitution reaction; preferably, the nucleophilic substitution reaction is usually carried out in the presence of a basic reagent (such as potassium carbonate, cesium carbonate, triethylamine, DBU, etc.) at a temperature range of -20°C to 120°C; third step: compound I-01-1-A-3' undergoes a substitution reaction or a coupling reaction to generate compound I-01-1-A-4';
[0409] Preferably, the substitution reaction is a nucleophilic substitution reaction; preferably, the nucleophilic substitution reaction is usually carried out in the presence of a basic reagent (such as potassium carbonate, cesium carbonate, triethylamine, DBU, etc.) at a temperature range of -20°C to 120°C.
[0410] The coupling reaction is selected from the Suzuki reaction, the Buchwald cross-coupling reaction, and the Ullman coupling reaction;
[0411] Step 4: Compound I-01-1-A-4' undergoes a reduction reaction to generate compound I-01-1-A-5';
[0412] Preferably, the reduction reaction is carried out under the following conditions: a reducing agent catalyzed system (e.g., LAH, DIBAL-H, borane, etc.), in a solvent (tetrahydrofuran, dichloromethane, diethyl ether, etc., with tetrahydrofuran being the preferred solvent), and at a temperature range of -78°C to 25°C.
[0413] Step 5: Compound I-01-1-A-5' undergoes a cyclization reaction to generate compound I-01-1-A-6';
[0414] Preferably, the compound II-3-A-5' undergoes a cyclization reaction in the presence of an acidic reagent (such as trifluoroacetic acid, hydrochloric acid, concentrated sulfuric acid, etc.) and a solvent; preferably, the solvent is a polar solvent; more preferably, the solvent is selected from DMSO and DMF.
[0415] Step 6: Compound I-01-1-A-6' reacts with halogens or NGS to generate compound I-01-1-A-7';
[0416] Preferably, the reaction is carried out under halogen (such as bromine, iodine, etc.) or NGS (such as NCS, NBS and NIS; preferably NBS) conditions, in a solvent (e.g., the solvent is selected from dichloromethane, chloroform and toluene, etc.; preferably, the solvent is chloroform), at a temperature of -20°C to 80°C.
[0417] Step 7: Compound I-01-1-A-7' undergoes a substitution reaction or a coupling reaction to generate compound I-01-1-A;
[0418] Preferably, the substitution reaction is a nucleophilic substitution reaction; preferably, the nucleophilic substitution reaction is usually carried out in the presence of a basic reagent (such as potassium carbonate, cesium carbonate, triethylamine, DBU, etc.) at a temperature range of -20°C to 120°C.
[0419] The coupling reaction is selected from the Suzuki reaction, the Buchwald cross-coupling reaction, and the Ullman coupling reaction.
[0420] Route 6: Preparation method of formula I-01-1-E
[0421] Where R 1 n, R a As defined above, L, Z, and Ar, X is a halogen, and R... A Selected from C 1-6 Alkyl groups (e.g., methyl, ethyl, isopropyl, tert-butyl) and benzyl groups; preferably, n is selected from 0, 1, 2, and 3; NXS is selected from NCS, NBS, and NIS; preferably, NXS is NBS;
[0422] The preparation method includes:
[0423] Step 1: Compound I-01-1-E-1 undergoes a substitution reaction or a coupling reaction to generate compound I-01-1-E-2;
[0424] Preferably, the substitution reaction is a nucleophilic substitution reaction; preferably, the nucleophilic substitution reaction is usually carried out in the presence of a basic reagent (such as potassium carbonate, cesium carbonate, triethylamine, DBU, etc.) at a temperature range of -20°C to 120°C.
[0425] The coupling reaction is selected from the Suzuki reaction, the Buchwald cross-coupling reaction, and the Ullman coupling reaction;
[0426] Step 2: Compound I-01-1-E-2 undergoes a coupling reaction to generate compound I-01-1-E-3;
[0427] Preferably, the coupling reaction is selected from the Suzuki reaction, the carbonyl insertion reaction, and the Heck reaction;
[0428] Step 3: Compound I-01-1-E-3 undergoes a reduction reaction to generate compound I-01-1-E-4;
[0429] Preferably, the reduction reaction is carried out under hydrogen metal catalysis (e.g., Pd, Pd(OH)2, Raney nickel, etc.) system;
[0430] Step 4: Compound I-01-1-E-4 undergoes a cyclization reaction to generate compound I-01-1-E-5;
[0431] Step 5: Compound I-01-1-E-5 reacts with halogens or NGS to generate compound I-01-1-E-6;
[0432] Preferably, the reaction is carried out under halogen (such as bromine, iodine, etc.) or NGS (such as NCS, NBS and NIS; preferably NBS) conditions, in a solvent (e.g., the solvent is selected from dichloromethane, chloroform and toluene, etc.; preferably, the solvent is chloroform), at a temperature of -20°C to 80°C.
[0433] Step 6: Compound I-01-1-E-6 undergoes a substitution reaction or a coupling reaction to generate compound I-01-1-E-7;
[0434] Preferably, the substitution reaction is a nucleophilic substitution reaction; preferably, the nucleophilic substitution reaction is usually carried out in the presence of a basic reagent (such as potassium carbonate, cesium carbonate, triethylamine, DBU, etc.) at a temperature range of -20°C to 120°C.
[0435] Step 7: Compound I-01-1-E-7 undergoes a substitution or reduction reaction to generate compound I-01-1-E-8;
[0436] Preferably, the reduction reaction is carried out under the following conditions: catalysis by a reducing agent (e.g., LAH, DIBAL-H, borane, etc.), in a solvent (tetrahydrofuran, dichloromethane, diethyl ether, etc., with tetrahydrofuran being the preferred solvent), and at a temperature range of -78°C to 25°C; Step 8: Compound I-01-1-E-8 undergoes a substitution reaction or a reduction reaction to generate compound I-01-1-E;
[0437] Preferably, the substitution reaction is a nucleophilic substitution reaction; preferably, the nucleophilic substitution reaction is usually carried out in the presence of a basic reagent (such as sodium hydride, potassium carbonate, cesium carbonate, triethylamine, DBU, etc.) at a temperature range of -20°C to 100°C; preferably, the reduction reaction is a reductive amination reaction; preferably, the reductive amination reaction is carried out in a reducing agent catalyzed system (such as sodium borohydride, sodium cyanoborohydride, sodium triacetoxyborohydride) in a solvent (tetrahydrofuran, dichloromethane, methanol, 1,4-dioxane, etc., with methanol being the preferred solvent) at a temperature range of 0°C to 60°C.
[0438] Route 7: Preparation method of formula I-01-2-E
[0439] Where R 1 n, R a As defined above, L, Z, and Ar, X is a halogen, and R... A Selected from C 1-6 Alkyl groups (e.g., methyl, ethyl, isopropyl, tert-butyl) and benzyl groups; preferably, n is selected from 0, 1, 2, and 3; NXS is selected from NCS, NBS, and NIS; preferably, NXS is NBS;
[0440] The preparation method includes:
[0441] Step 1: Compound I-01-2-E-1 undergoes a substitution reaction or a coupling reaction to generate compound I-01-2-E-2;
[0442] Preferably, the substitution reaction is a nucleophilic substitution reaction; preferably, the nucleophilic substitution reaction is usually carried out in the presence of a basic reagent (such as potassium carbonate, cesium carbonate, triethylamine, DBU, etc.) at a temperature range of -20°C to 120°C.
[0443] The coupling reaction is selected from the Suzuki reaction, the Buchwald cross-coupling reaction, and the Ullman coupling reaction;
[0444] Step 2: Compound I-01-2-E-2 undergoes a coupling reaction to generate compound I-01-2-E-3;
[0445] Preferably, the coupling reaction is selected from the Suzuki reaction, the carbonyl insertion reaction, and the Heck reaction;
[0446] Step 3: Compound I-01-2-E-3 undergoes a reduction reaction to generate compound I-01-2-E-4;
[0447] Preferably, the reduction reaction is carried out under hydrogen metal catalysis (e.g., Pd, Pd(OH)2, Raney nickel, etc.) system;
[0448] Step 4: Compound I-01-2-E-4 undergoes a cyclization reaction to generate compound I-01-2-E-5;
[0449] Step 5: Compound I-01-2-E-5 reacts with halogens or NGS to generate compound I-01-2-E-6;
[0450] Preferably, the reaction is carried out under halogen (such as bromine, iodine, etc.) or NGS (such as NCS, NBS and NIS; preferably NBS) conditions, in a solvent (e.g., the solvent is selected from dichloromethane, chloroform and toluene, etc.; preferably, the solvent is chloroform), at a temperature of -20°C to 80°C.
[0451] Step 6: Compound I-01-2-E-6 undergoes a substitution reaction or a coupling reaction to generate compound I-01-2-E-7;
[0452] Preferably, the substitution reaction is a nucleophilic substitution reaction; preferably, the nucleophilic substitution reaction is usually carried out in the presence of a basic reagent (such as potassium carbonate, cesium carbonate, triethylamine, DBU, etc.) at a temperature range of -20°C to 120°C.
[0453] Step 7: Compound I-01-2-E-7 undergoes a reduction reaction to form compound I-01-2-E;
[0454] Preferably, the reduction reaction is carried out under the following conditions: a reducing agent catalyzed system (e.g., LAH, DIBAL-H, borane, etc.), in a solvent (tetrahydrofuran, dichloromethane, diethyl ether, etc., with tetrahydrofuran being the preferred solvent), and at a temperature range of -78°C to 25°C.
[0455] Step 8: Compound I-01-2-E-8 undergoes a substitution or reduction reaction to generate compound I-01-2-E;
[0456] Preferably, the substitution reaction is a nucleophilic substitution reaction; preferably, the nucleophilic substitution reaction is usually carried out in the presence of a basic reagent (such as sodium hydride, potassium carbonate, cesium carbonate, triethylamine, DBU, etc.) at a temperature range of -20°C to 100°C; preferably, the reduction reaction is a reductive amination reaction; preferably, the reductive amination reaction is carried out in a reducing agent catalyzed system (such as sodium borohydride, sodium cyanoborohydride, sodium triacetoxyborohydride) in a solvent (tetrahydrofuran, dichloromethane, methanol, 1,4-dioxane, etc., with methanol being the preferred solvent) at a temperature range of 0°C to 60°C.
[0457] Pharmaceutical compositions and therapeutic uses and methods
[0458] Another aspect of this disclosure provides a pharmaceutical composition comprising a preventive or therapeutically effective amount of the compound described in this disclosure, or a stereoisomer, tautomer, polymorph, solvate, N-oxide, isotopically labeled compound, or a metabolite or prodrug or pharmaceutically acceptable salt or ester thereof, and one or more pharmaceutically acceptable carriers.
[0459] In another embodiment, the pharmaceutical composition may also contain one or more other therapeutic agents.
[0460] In this disclosure, "pharmaceuticalally acceptable carrier" means a diluent, excipient, vehicle, or medium that is administered co-administered with a therapeutic agent and is suitable, to the extent of reasonable medical judgment, for contact with human and / or other animal tissues without excessive toxicity, irritation, allergic reactions, or other problems or complications commensurate with a reasonable benefit / risk ratio.
[0461] Pharmaceutically acceptable carriers that may be used in the pharmaceutical compositions disclosed herein include, but are not limited to, sterile liquids such as water and oils, including those of petroleum, animal, plant, or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil, etc. Water is an exemplary carrier when the pharmaceutical compositions are administered intravenously. Physiological saline and aqueous solutions of glucose and glycerol may also be used as liquid carriers, particularly for injectable solutions. Suitable pharmaceutical excipients include starch, glucose, lactose, sucrose, gelatin, maltose, chalk, silica gel, sodium stearate, glyceryl monostearate, talc, sodium chloride, skim milk powder, glycerol, propylene glycol, water, ethanol, etc. The compositions may also contain small amounts of wetting agents, emulsifiers, or pH buffers as needed. Oral formulations may contain standard carriers such as pharmaceutical-grade mannitol, lactose, starch, magnesium stearate, sodium saccharin, cellulose, magnesium carbonate, etc. Examples of suitable pharmaceutically acceptable carriers are described in Remington's Pharmaceutical Sciences (1990).
[0462] The pharmaceutical compositions disclosed herein can act systemically and / or locally. For this purpose, they can be administered via suitable routes, such as by injection, intravenous, intra-arterial, subcutaneous, intraperitoneal, intramuscular, or transdermal administration; or by oral, sublingual, nasal, transmucosal, topical, ophthalmic formulation, or inhalation administration.
[0463] For these routes of administration, the pharmaceutical compositions disclosed herein can be administered in suitable dosage forms.
[0464] The dosage forms include, but are not limited to, tablets, capsules, lozenges, hard candies, powders, sprays, creams, ointments, suppositories, gels, pastes, lotions, ointments, aqueous suspensions, injectable solutions, elixirs, and syrups.
[0465] The content or amount of the compound disclosed herein in a pharmaceutical composition may be from about 0.01 mg to about 1000 mg.
[0466] Another aspect of this disclosure provides the use of the compounds described herein, or stereoisomers, tautomers, polymorphs, solvates, N-oxides, isotopically labeled compounds, or metabolites or prodrugs or pharmaceutically acceptable salts or esters thereof, or pharmaceutical compositions described herein, in the preparation of medicaments for the prevention and / or treatment of diseases, particularly GPR6 receptor-mediated diseases.
[0467] Another aspect of this disclosure provides the use of the compounds described herein, or stereoisomers, tautomers, polymorphs, solvates, N-oxides, isotopically labeled compounds, or metabolites or prodrugs or pharmaceutically acceptable salts or esters thereof, or pharmaceutical compositions described herein, in the context of medicaments for the prevention and / or treatment of diseases, particularly GPR6 receptor-mediated diseases.
[0468] Another aspect of this disclosure provides methods for preventing and / or treating diseases, particularly GPR6 receptor-mediated diseases, the methods comprising administering to an individual in need an effective amount of the compound described in this disclosure, or a stereoisomer, tautomer, polymorph, solvate, N-oxide, isotopically labeled compound, or a metabolite or prodrug or pharmaceutically acceptable salt or ester thereof, or a pharmaceutical composition described in this disclosure.
[0469] The GPR6 receptor-mediated diseases described in this disclosure are selected from: movement disorders, including Parkinson's disease, levodopa-induced movement disorder, Huntington's disease, drug addiction, eating disorders, cognitive impairment, schizophrenia, bipolar disorder, and depression.
[0470] As used in this article, the term "effective amount" refers to the amount of a compound that, when administered, will alleviate one or more symptoms of the treated condition to some extent.
[0471] The dosing regimen can be adjusted to provide the optimal required response. For example, a single bolus injection can be administered, several fractions can be administered over time, or the dose can be proportionally reduced or increased as indicated by the urgency of the treatment situation. It should be noted that dosage values can vary depending on the type and severity of the condition to be alleviated, and may include single or multiple doses. To further understand, for any given individual, the specific dosing regimen should be adjusted over time based on individual needs and the professional judgment of the person administering the composition or supervising its administration.
[0472] The amount of the disclosed compound administered will depend on the individual being treated, the severity of the condition or illness, the rate of administration, the disposal of the compound, and the judgment of the prescribing physician.
[0473] Unless otherwise stated, as used herein, the term “treating” means reversing, alleviating, or suppressing the progression of one or more symptoms of the condition or illness to which the term applies.
[0474] As used herein, the term "prevention" refers to the prior administration of medication to avoid or prevent the onset of one or more symptoms of a disease or condition. Those skilled in the medical field recognize that the term "prevention" is not an absolute term. In the medical field, it should be understood as the preventive administration of medication to substantially reduce the likelihood or severity of a condition or its symptoms, which is the intended meaning of this disclosure. The Physician's Desk Reference, the standard text in the field, uses the term "prevention" hundreds of times. As used therein, the term "prevention" regarding a condition or disease refers to the avoidance of the cause, effect, symptoms, or progression of a disease or condition before it has fully manifested.
[0475] As used herein, “individual” includes both human and non-human animals. Exemplary human individuals include human individuals suffering from a disease (such as the disease described herein) (referred to as patients) or normal individuals. In this disclosure, “non-human animals” includes all vertebrates, such as non-mammals (e.g., birds, amphibians, reptiles) and mammals, such as non-human primates, livestock, and / or domesticated animals (e.g., sheep, dogs, cats, cows, pigs, etc.).
[0476] Example
[0477] To make the objectives and technical solutions of this disclosure clearer, the embodiments of this disclosure are described in detail below. However, those skilled in the art will understand that the following embodiments are for illustrative purposes only and should not be considered as limiting the scope of this disclosure. Unless otherwise specified, specific conditions in the embodiments are performed under conventional conditions or conditions recommended by the manufacturer. Reagents or instruments whose manufacturers are not specified are all commercially available conventional products.
[0478] The structure of the compound was determined by nuclear magnetic resonance (NMR). 1 The determination was made by 1H NMR or mass spectrometry (MS). The NMR spectrometer was a Bruker AVANCE Ⅲ HD 400MHz. The solvents used were deuterated methanol (CD3OD), deuterated chloroform (CDCl3), or hexadeuterated dimethyl sulfoxide (DMSO-d6), with tetramethylsilane (TMS) as the internal standard. Chemical shifts (δ) were given in parts per million (ppm).
[0479] The instrument used for MS measurements was an Agilent (ESI) mass spectrometer, manufacturer: Agilent, model: Agilent 1260 Infinity / Agilent 6120 Quadrupole.
[0480] The rapid column chromatography method uses the Biotage rapid column chromatograph.
[0481] Preparation method of high performance liquid chromatograph:
[0482] Instrument model: Agilent 1260; Column: Waters SunFire Prep C18 OBD (19mm×150mm×5.0μm); Column temperature: 25℃; Flow rate: 20.0mL / min; Detection wavelength: 214nm; Elution gradient: (0min: 10%A, 90%B; 16.0min: 90%A, 10%B); Mobile phase A: Acetonitrile; Mobile phase B: 0.05% formic acid aqueous solution.
[0483] For thin-layer chromatography (TLC), pre-made silica gel plates (2×5cm) produced by Leyan were used, and the TLC separation and purification used GF 254 (1mm) produced by Yantai.
[0484] The reaction was monitored using thin-layer chromatography (TLC) or LC-MS. The developing solvent systems used included: n-heptane and ethyl acetate, dichloromethane and methanol, and petroleum ether and ethyl acetate. The volume ratio of the solvent was adjusted according to the polarity of the compound or by adding triethylamine, etc.
[0485] Unless otherwise specified in the examples, the reaction temperature is room temperature (20℃~35℃).
[0486] The reagents used in this disclosure were purchased from Acros Organics, Aldrich Chemical Company, TEB Chemicals, and other companies.
[0487] The following experimental examples and embodiments are used to further illustrate, but are not limited to, this disclosure.
[0488] In the conventional synthesis method and in the examples and intermediate synthesis examples, the meanings of the abbreviations are as follows.
[0489] Preparation of Int 1: 2-bromo-3-(4-(2,4-difluorophenoxy)piperidin-1-yl)-5,6,8,9-tetrahydro-7H-pyrazino[2,3-c]nitrogen Synthesis of 7-one
[0490] Step 1: Synthesis of compound Int 1-2
[0491] Compound Int 1-1 (5 g, 9.58 mmol), DMF (50 mL), CsF (6.53 g, 43.0 mmol), DIPEA (6.95 g, 53.57 mmol), and 4-(2,4-difluorophenoxy)piperidine (9.17 g, 43.0 mmol) were mixed and heated to 60 °C with stirring. The reaction was monitored by LC-MS until complete. After returning to room temperature, the reaction mixture was diluted with ethyl acetate and saturated brine. The aqueous layer was extracted with ethyl acetate (50 mL), and the organic layers were combined. The organic layers were washed with brine and dried over anhydrous sodium sulfate. The mixture was concentrated under reduced pressure and purified by column chromatography to obtain compound Int 1-2 (9 g, 28.45 mmol). MS [ESI]: m / z = 317.2 [M+H] + .
[0492] Step 2: Synthesis of compounds Int 1-3
[0493] Compound Int 1-2 (9 g, 28.45 mmol), dichloroethane (100 mL), and NBS (6.08 g, 34.1 mmol) were mixed and reacted at 60 °C. The reaction was confirmed to be complete by LC-MS. The reaction solution was concentrated under reduced pressure and purified by column chromatography to obtain compound Int 1-3 (10 g, 25.3 mmol). MS [ESI]: m / z = 396.2 [M+H] + .
[0494] Step 3: Synthesis of compounds Int 1-4
[0495] Compound Int 1-3 (10 g, 25.3 mmol), (E)-3-(4,4,5,5-tetramethyl-1,3,2-dioxaboran-2-yl)acrylate (8.58 g, 37.95 mmol), DMAC (100 mL), water (10 mL), cesium carbonate (16.49 g, 50.61 mmol), and Pd(dppf)Cl2 (1.85 g, 2.53 mmol) were mixed, purged with nitrogen three times, and then heated to 110 °C with stirring. The reaction was confirmed to be complete by LCMS. After returning to room temperature, the reaction solution was diluted with ethyl acetate (50 mL) and saturated brine (50 mL). The aqueous layer was extracted with ethyl acetate (50 mL), and the organic layers were combined. The organic layers were then washed with brine and dried over anhydrous sodium sulfate. The solution was concentrated under reduced pressure and purified by column chromatography to obtain compound Int 1-4 (6 g, 14.48 mmol). MS [ESI]: m / z = 415.2 [M+H] + .
[0496] Step 4: Synthesis of compounds Int 1-5
[0497] Compound Int 1-4 (6 g, 14.48 mmol), methanol (50 mL), and palladium on carbon (600 mg, 0.1 eq) were mixed, purged three times with hydrogen, and reacted at room temperature. The reaction was confirmed to be complete by LC-MS. The reaction solution was filtered through diatomaceous earth, washed with methanol, concentrated under reduced pressure, and purified by column chromatography to obtain compound Int 1-5 (5.2 g, 12.49 mmol). MS [ESI]: m / z = 417.2 [M+H] + .
[0498] Step 5: Synthesis of compounds Int 1-6
[0499] Compound Int 1-5 (5.2 g, 12.49 mmol), methanol (50 mL), and Raney nickel (500 mg, 0.1 eq) were mixed, purged three times with hydrogen, and reacted at 60 °C. The reaction was monitored by LC-MS until complete. The reaction solution was filtered through diatomaceous earth, washed with methanol, concentrated under reduced pressure, and purified by column chromatography to obtain compound Int 1-6 (3.2 g, 8.55 mmol). MS [ESI]: m / z = 375.2 [M+H] + .
[0500] Step Six: Synthesis of Compound Int 1
[0501] Compound Int 1-6 (3.2 g, 8.55 mmol), dichloroethane (30 mL), and NBS (1.83 g, 10.25 mmol) were mixed and reacted at 60 °C. The reaction was confirmed to be complete by LC-MS. The reaction solution was concentrated under reduced pressure and purified by column chromatography to obtain compound Int 1 (3.5 g, 7.72 mmol). MS [ESI]: m / z = 454.2 [M+H] + .
[0502] Preparation of Int 2: Synthesis of 8-bromo-N-(oxetane-3-yl)-1,3,4,5-tetrahydrobenzo[c]oxetane-7-amine
[0503] Step 1: Synthesis of compound Int 2-3
[0504] Compound Int 2-1 (10 g, 29.3 mmol) was dissolved in 1,4-dioxane / water = 10 / 1 (100 mL). Compound Int 2-2 (7.95 g, 35.1 mmol), Pd(dppf)Cl2 (2.39 g, 2.93 mmol), and potassium carbonate (12.15 g, 87.9 mmol) were added at room temperature. The reaction was carried out at 90 °C for 16 hours under a nitrogen atmosphere. After the reaction was complete, the mixture was allowed to return to room temperature. The mixture was diluted with water, extracted with ethyl acetate, washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The crude product was purified by silica gel column chromatography to obtain compound Int 2-3 (5.5 g, 17.56 mmol).
[0505] 1 H NMR (400MHz, DMSO) δ8.22(d,J=16.0Hz,1H),8.10(d,J=2.0Hz,1H),7.85-7.79(m,1H),7.77- 7.71(m,1H),6.65(d,J=16.0Hz,1H),4.26-4.17(m,2H),3.86(s,3H),1.27(t,J=7.2Hz,3H).
[0506] Step 2: Synthesis of compound Int 2-4
[0507] Compound Int 2-3 (5 g, 16 mmol) and platinum dioxide (0.36 g, 1.6 mmol) were dissolved in ethyl acetate (50 mL). The reaction was carried out at 25 °C for 16 hours under a hydrogen atmosphere. After the reaction was completed, the reaction mixture was filtered through a diatomaceous earth mat, the filtrate was concentrated under reduced pressure, and the crude product was purified by silica gel column chromatography to give compound Int 2-4 (3 g, 9.5 mmol).
[0508] 1 H NMR (400MHz, DMSO) δ7.83-7.72(m,1H),7.63-7.47(m,2H),4.05(q,J=7.2Hz ,2H),3.83(s,3H),3.17-3.11(m,2H),2.63-2.56(m,2H),1.18-1.13(m,3H).
[0509] Step 3: Synthesis of compound Int 2-5
[0510] Compound Int 2-4 (3 g, 9.5 mmol) was dissolved in ultra-dry tetrahydrofuran (30 mL), and a 2.5 M solution of lithium aluminum hydride in tetrahydrofuran (9.5 mL) was slowly added dropwise under an ice bath and nitrogen atmosphere. The mixture was slowly heated to room temperature under a nitrogen atmosphere and reacted for 3 hours. After the reaction was completed, the reaction was quenched with water under an ice bath, filtered through diatomaceous earth, and the filtrate was concentrated under reduced pressure. The crude product was purified by silica gel column chromatography to obtain compound Int 2-5 (2 g), MS m / z (ESI): 244.80 [M+H]. + .
[0511] Step 4: Synthesis of compound Int 2-6
[0512] Compound Int 2-5 (1.9 g, 7.8 mmol) was dissolved in 1-butylsulfonic acid-3-methylimidazolium trifluoromethanesulfonate (2.87 g, 7.8 mmol), and the reaction mixture was stirred at 120 °C for 2 hours. After the reaction was complete, the mixture was cooled to room temperature, diluted with ethyl acetate, and the organic phase was washed with water and saturated brine and dried over anhydrous sodium sulfate. The mixture was filtered, the filtrate was concentrated under reduced pressure, and the crude product was purified by silica gel column chromatography to give compound Int 2-6 (0.8 g, 3.5 mmol).
[0513] 1 H NMR(400MHz,DMSO)δ7.43(d,J=2.0Hz,1H),7.34-7.28(m,1H),7.15(d,J=8.0H z,1H),4.56(s,2H),3.95-3.87(m,2H),3.00-2.92(m,2H),1.75-1.64(m,2H).
[0514] Step 5: Synthesis of compound Int 2-8
[0515] Compound Int 2-6 (600 mg, 2.64 mmol) was dissolved in 1,4-dioxane (10 mL), followed by the addition of compound Int 2-7 (290 mg, 3.96 mmol), XPhos Pd G3 (223 mg, 0.26 mmol), and cesium carbonate (2585 mg, 7.92 mmol) at room temperature. The reaction was carried out at 90 °C for 4 hours under a nitrogen atmosphere. After the reaction was complete, the temperature was allowed to return to room temperature. The reaction solution was filtered through diatomaceous earth, the filtrate was concentrated under reduced pressure, and the crude product was purified by silica gel column chromatography to obtain compound Int 2-8 (460 mg, 2.09 mmol), MS m / z (ESI): 220.10 [M+H]. + .
[0516] Step Six: Synthesis of Compound Int 2
[0517] Compound Int 2-8 (460 mg, 2.09 mmol) was dissolved in dichloromethane (10 mL), and N-bromosuccinimide (373 mg, 2.09 mmol) was added under ice bath conditions. The reaction was carried out at 0 °C for 1 hour under a nitrogen atmosphere. After the reaction was completed, the mixture was quenched with saturated sodium bicarbonate solution, extracted with dichloromethane, washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The crude product was purified by silica gel column chromatography to obtain compound Int2 (280 mg, 0.94 mmol), MS m / z (ESI): 299.90 [M+H]. + .
[0518] Referring to steps three, four, and six in Int 2, replacing Int 2-4 with the following reactant Int 15 will yield the following compounds:
[0519] Preparation of Int 3: Synthesis of 8-bromo-N-(oxetane-3-yl)-1,2,4,5-tetrahydrobenzo[d]oxetane-7-amine
[0520] Step 1: Synthesis of compound Int 3-2
[0521] Compound Int 3-1 (10 g, 51.5 mmol) was dissolved in ultradry tetrahydrofuran (300 mL), and a 2.5 M lithium aluminum hydride tetrahydrofuran solution (82.7 mL) was slowly added dropwise under an ice bath and nitrogen atmosphere. The mixture was slowly heated to room temperature and reacted for 3 hours under nitrogen atmosphere. After the reaction was complete, water was added to quench the reaction in an ice bath, the mixture was filtered through diatomaceous earth, concentrated under reduced pressure, and the crude product was purified by silica gel column chromatography to obtain compound Int 3-2 (6 g, 36.1 mmol), MS m / z (ESI): 184.05 [M + H₂O]. + .
[0522] Step 2: Synthesis of compound Int 3-3
[0523] Compound Int 3-2 (4 g, 24.06 mmol) was dissolved in 1-butylsulfonic acid-3-methylimidazolium trifluoromethane sulfonate (4.4 g, 12.03 mmol) and reacted at 120 °C for 16 hours. After the reaction was complete, the mixture was cooled to room temperature, diluted with ethyl acetate, and the organic phase was washed with water and saturated brine. The mixture was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The crude product was purified by silica gel column chromatography to give compound Int 3-3 (2 g, 13.5 mmol).
[0524] 1H NMR (400MHz, CDCl3) δ7.17–7.01(m,4H),3.85–3.71(m,4H),3.04-2.93(m,4H).
[0525] Step 3: Synthesis of compound Int 3-4
[0526] Compound Int 3-3 (1.6 g, 10.8 mmol) and aluminum trichloride (2.88 g, 21.6 mmol) were dissolved in ultradry dichloroethane (20 mL), and liquid bromine (1.9 g, 1.88 mmol) was slowly added dropwise under an ice bath. The mixture was stirred at 0 °C for 15 minutes under a nitrogen atmosphere. After the reaction was complete, the mixture was quenched with saturated sodium thiosulfate solution and extracted with ethyl acetate. The mixture was washed with saturated brine and dried over anhydrous sodium sulfate. The mixture was filtered, and the filtrate was concentrated under reduced pressure. The crude product was purified by rapid silica gel column chromatography to give compound Int 3-4 (500 mg, 2.2 mmol).
[0527] 1 H NMR (400MHz, DMSO) δ7.36 (d, J = 2.4Hz, 1H), 7.29 (dd, J = 8.0, 2.4Hz, 1H), 7.10 (d, J = 8.0Hz, 1H), 3.65-3.61 (m, 4H), 2.93-2.88 (m, 4H).
[0528] Step 4: Synthesis of compound Int 3-5
[0529] Compound Int 3-4 (500 mg, 2.2 mmol) was dissolved in 1,4-dioxane (10 mL). Compound Int 2-7 (241 mg, 3.3 mmol), XPhos Pd G3 (186 mg, 0.22 mmol), and cesium carbonate (2.15 g, 6.6 mmol) were added at room temperature. The reaction was carried out at 120 °C for 2 hours under a nitrogen atmosphere. After the reaction was complete, the mixture was allowed to return to room temperature. The mixture was filtered through diatomaceous earth, concentrated under reduced pressure, and the crude product was purified by silica gel column chromatography to give compound Int 3-5 (350 mg, 1.6 mmol), MS m / z (ESI): 220.05 [M+H]. + .
[0530] Step 5: Synthesis of compound Int 3
[0531] Compound Int 3-5 (350 mg, 1.6 mmol) was dissolved in dichloromethane (10 mL), and N-bromosuccinimide (256 mg, 1.4 mmol) was added under ice bath conditions. The reaction was carried out at 0 °C for 15 minutes under a nitrogen atmosphere. After the reaction was completed, the mixture was quenched with saturated sodium bicarbonate solution and extracted with ethyl acetate. The mixture was washed with saturated brine and dried over anhydrous sodium sulfate. The mixture was filtered, concentrated under reduced pressure, and the crude product was purified by silica gel column chromatography to give compound Int 3 (280 mg, 0.9 mmol), MS m / z (ESI): 299.5 [M+H]. + .
[0532] 1 H NMR (400MHz, DMSO) δ7.22 (s, 1H), 6.20 (s, 1H), 5.49 (d, J = 5.2Hz, 1H), 4.86-4 .79(m,2H),4.56–4.48(m,3H),3.64-3.56(m,2.9Hz,4H),2.84–2.74(m,4H).
[0533] Preparation of Int 4: 4-((2,4-difluorophenyl)fluoromethylene)piperidine
[0534] Step 1: Synthesis of compound Int 4-2
[0535] Under ice bath conditions, Dess-Martin reagent (5.06 g, 11.92 mmol) was slowly added to a dichloromethane (50 mL) solution of compound Int 4-1 (2 g, 9.94 mmol). The reaction was heated to room temperature, and the reaction was monitored by LC-MS until complete. The reaction solution was filtered through diatomaceous earth, washed with dichloromethane, dried, concentrated, and purified by column chromatography to obtain compound Int 4-2 (1.2 g, 6.02 mmol). MS [ESI]: m / z = 144.2 [M+H-56] + .
[0536] Step 2: Synthesis of compound Int 4-3
[0537] Compound Int 4-2 (1.2 g, 6.02 mmol), anhydrous tetrahydrofuran (20 mL), and triphenylphosphine (1.9 g, 7.23 mmol) were mixed under nitrogen protection. Diethylzinc (0.89 g, 7.23 mmol) was slowly added dropwise. The reaction was carried out at room temperature, and the reaction was monitored by LC-MS until complete. The reaction was quenched with methanol and continued for 0.5 hours. The mixture was then concentrated under reduced pressure and purified by column chromatography to give compound Int 4-3 (1 g, 3.4 mmol). MS [ESI]: m / z = 239.9 [M+H-56] + .
[0538] Step 3: Synthesis of compound Int 4-5
[0539] Compound Int 4-3 (1 g, 3.4 mmol), compound Int 4-4 (0.64 g, 4.08 mmol), Pd(dppf)Cl2 (0.84 g, 1.16 mmol), cesium carbonate (2.22 g, 6.8 mmol), 1,4-dioxane (10 mL), and water (1 mL) were mixed, purged with nitrogen, heated to 90 °C, stirred, and the reaction was monitored to complete by LC-MS. The mixture was then cooled to room temperature, extracted with ethyl acetate, washed with saturated brine, dried over anhydrous sodium sulfate, concentrated under reduced pressure, and purified by column chromatography to obtain compound Int 4-5 (0.8 g, 2.4 mmol). MS [ESI]: m / z = 272.2 [M+H-56] + .
[0540] Step 4: Synthesis of compound Int 4
[0541] Compound Int 4-5 (0.8 g, 2.4 mmol) was mixed with dichloromethane (10 mL). Under ice bath conditions, hydrochloric acid / 1,4-dioxane solution (2 mL, 4 M) was slowly added dropwise. The reaction was carried out at room temperature, and LC-MS was used to determine the completeness of the reaction. The pH was adjusted to 7-8 with sodium bicarbonate, and the mixture was extracted with ethyl acetate, washed with saturated brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure to give crude compound Int 4 (0.5 g, 2.20 mmol). MS [ESI]: m / z = 228.1 [M+H] + .
[0542] Preparation of Int 5: 4-((2,4-difluorophenyl)fluoromethyl-d)piperidine
[0543] Step 1: Synthesis of compound Int 5-2
[0544] Compound Int 5-1 (1 g, 3.07 mmol) was dissolved in MeOH (10 mL) at room temperature, followed by the addition of NaBD4 (255.82 mg, 6.7 mmol). The reaction was allowed to proceed for 1 hour at room temperature. The reaction was confirmed to be complete by LC-MS. The solution was diluted with water, extracted with ethyl acetate, washed with saturated brine, dried over anhydrous sodium sulfate, filtered, concentrated under reduced pressure, and the crude product was purified by silica gel column chromatography to give compound Int 5-2 (0.9 g, 2.75 mmol). MS [ESI]: m / z = 255.1
[0545] [M+H-56-18] + .
[0546] Step 2: Synthesis of compound Int 5-3
[0547] Compound Int 5-2 (0.9 g, 2.75 mmol) was dissolved in DCM (10 mL) under ice bath conditions, and DAST (1.22 g, 5.50 mmol) was added. The reaction was carried out at room temperature for 1 hour under nitrogen protection. The reaction was confirmed to be complete by LC-MS. The pH was adjusted to neutral with saturated sodium bicarbonate solution, diluted with water, extracted with ethyl acetate, washed with saturated brine, dried over anhydrous sodium sulfate, filtered, concentrated under reduced pressure, and the crude product was purified by silica gel column chromatography to give compound Int 5-3 (850 mg, 2.58 mmol). MS [ESI]: m / z = 255.1 [M+H-56-20] + .
[0548] Step 3: Synthesis of compound Int 5
[0549] Compound Int 5-3 (850 mg, 2.58 mmol) was dissolved in DCM (9 mL) under ice bath conditions, followed by the addition of TFA (3 mL). The reaction was allowed to proceed for 1 hour at room temperature. The reaction was confirmed to be complete by LC-MS. The pH was adjusted to alkaline with saturated sodium bicarbonate solution, diluted with water, extracted with ethyl acetate, washed with saturated brine, dried over anhydrous sodium sulfate, filtered, concentrated under reduced pressure, and the crude product was purified by silica gel column chromatography to give compound Int 5 (450 mg, 1.95 mmol). MS (ESI): m / z = 231.1 [M+H] + .
[0550] Preparation of Int 6: 4-(2,4-difluorobenzyl)piperidine
[0551] Step 1: Synthesis of compound Int 6-2
[0552] Compound Int 6-1 (2 g, 9.66 mmol, 1.24 mL) and triphenylphosphine (3.80 g, 14.49 mmol) were dissolved in toluene (20 mL) under a nitrogen atmosphere and reacted at 100 °C. The reaction was monitored by LC-MS until complete. The mixture was diluted with water, extracted with ethyl acetate, washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to give compound Int 6-2 (4 g, 8.52 mmol). MS (ESI): m / z = 389.0 [M-80] + .
[0553] Step 2: Synthesis of compound Int 6-3
[0554] Compound Int 6-2 (2.5 g, 5.33 mmol) was dissolved in THF (2.87 mL) under a nitrogen atmosphere, and n-butyllithium (2.5 M, 5.33 mmol, 2.13 mL) was added. The reaction was carried out at room temperature, followed by the addition of compound Int 4-2 (1.06 g, 5.33 mmol). The reaction was heated to 60 °C and monitored by LC-MS until complete. The reaction was quenched with saturated ammonium chloride solution, diluted with water, extracted with ethyl acetate, washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The crude product was purified by column chromatography to give compound Int 6-3 (1.5 g, 4.85 mmol). MS (ESI): m / z = 254.0 [M-56+H] + .
[0555] Step 3: Synthesis of compound Int 6
[0556] Compound Int 6-3 (1.5 g, 4.85 mmol) was dissolved in DCM (10 mL) at room temperature. Hydrochloric acid / 1,4-dioxane (176.79 mg, 4.85 mmol) was added, and the reaction was allowed to proceed at room temperature. The reaction was monitored by LC-MS until complete. The solution was diluted with water, extracted with ethyl acetate, washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to give compound Int 6 (870 mg). MS (ESI): m / z = 210.0 [M+H] + .
[0557] Preparation of Int 7: 8-(4-(2,4-difluorophenoxy)piperidin-1-yl)-N-(oxetane-3-yl)-2,3,4,5-tetrahydropyridino[3,2-f][1,4]oxa 7-amine
[0558] Step 1: Synthesis of compound Int 7-2
[0559] Under ice bath conditions, N-benzylethanolamine (5.15 g, 34.09 mmol) was added to a 50 mL solution of compound Int 7-1 (5 g, 28.41 mmol) in dichloromethane, followed by sodium triacetoxyborohydride (9.03 g, 42.61 mmol). The reaction was allowed to proceed for 12 hours at room temperature. The reaction was confirmed to be complete by LC-MS. The solution was diluted with water, extracted with ethyl acetate, washed with saturated brine, dried over anhydrous sodium sulfate, filtered, concentrated under reduced pressure, and the crude product was purified by column chromatography to give compound Int 7-2 (7.2 g, 23.14 mmol). MS [ESI]: m / z = 312.1 [M+H] + .
[0560] Step 2: Synthesis of compound Int 7-3
[0561] Under ice bath conditions, sodium hydride (1.11 g, 46.27 mmol) was added to a 50 mL solution of compound Int 7-2 (7.2 g, 23.14 mmol) in tetrahydrofuran. The mixture was heated to 60 °C and reacted for 4 hours. The reaction was confirmed to be complete by LC-MS. The solution was cooled to room temperature, diluted with water, extracted with ethyl acetate, washed with saturated brine, dried over anhydrous sodium sulfate, filtered, concentrated under reduced pressure, and the crude product was purified by column chromatography to give compound Int 7-3 (6 g, 21.84 mmol). MS [ESI]: m / z = 275.1 [M+H] + .
[0562] Step 3: Synthesis of compound Int 7-4
[0563] Under nitrogen protection, compound Int 7-3 (1 g, 3.64 mmol), RuphosPdG3 (0.3 g, 0.36 mmol), cesium carbonate (2.3 g, 7.28 mmol), and 4-(2,4-difluorophenoxy)piperidine (0.93 g, 4.37 mmol) were dissolved in toluene (10 mL), and the mixture was heated to 120 °C and reacted for 12 hours. The reaction was confirmed to be complete by LC-MS. The solution was concentrated and evaporated to dryness. The crude product was purified by column chromatography to give compound Int 7-4 (1 g, 2.21 mmol). MS [ESI]: m / z = 452.2 [M+H] + .
[0564] Step 4: Synthesis of compound Int 7-5
[0565] At room temperature, NBS (0.47 g, 2.66 mmol) was slowly added to a 10 mL solution of compound Int 7-4 (1 g, 2.21 mmol) in dichloroethane, and the mixture was heated to 60 °C and reacted for 4 hours. The reaction was confirmed to be complete by LC-MS. The solution was concentrated and evaporated to dryness. The crude product was purified by column chromatography to give compound Int 7-5 (0.8 g, 1.51 mmol). MS [ESI]: m / z = 530.9 [M+H] + .
[0566] Step 5: Synthesis of compound Int 7-6
[0567] Under nitrogen protection, compound Int 7-5 (0.8 g, 1.51 mmol), Pd-PEPPSI-IPentCl (0.12 g, 0.15 mmol), cesium carbonate (0.98 g, 3.02 mmol), and compound Int 2-7 (0.16 g, 2.26 mmol) were dissolved in toluene (10 mL), and the mixture was heated to 120 °C and reacted for 12 hours. The reaction was confirmed to be complete by LC-MS. The solution was concentrated and evaporated to dryness. The crude product was purified by column chromatography to give compound Int 7-6 (0.3 g, 0.57 mmol). MS [ESI]: m / z = 523.2 [M+H] + .
[0568] Step Six: Synthesis of Compound Int 7
[0569] At room temperature, Pd(OH)₂ / C (30 mg) was added to a methanol solution (5 mL) of compound Int 7-6 (0.3 g, 0.57 mmol), purged with hydrogen, and the mixture was heated to 60 °C for 12 hours. The reaction was confirmed to be complete by LC-MS. The mixture was filtered through diatomaceous earth, the filter cake was washed with methanol, and the filtrate was concentrated to obtain compound Int7 (0.2 g, 0.46 mmol). MS [ESI]: m / z = 433.2 [M+H] + .
[0570] Following the synthetic method of Int 7, by replacing the reactants, the following compounds can be prepared:
[0571] Preparation of Int 8: 8-bromo-N-(oxetane-3-yl)-2,3-dihydro-5H-benzo[e][1,4]dioxane 7-amine
[0572] Step 1: Synthesis of compound Int 8-2
[0573] Compound Int 8-1 (15 g, 74.6 mmol) was dissolved in methanol (200 mL), and NaBH4 (5.6 g, 149.2 mmol) was added dropwise under ice bath. The reaction was allowed to proceed for 2 h. The reaction was monitored by LC-MS until complete. The solution was quenched with 20% NH4Cl, concentrated under reduced pressure, extracted with ethyl acetate, and concentrated again under reduced pressure to give compound Int 8-2 (14.5 g, 71.42 mmol). MS [ESI]: m / z = 203.0 [M+H] + .
[0574] Step 2: Synthesis of compound Int 8-3
[0575] Compound Int 8-2 (14.5 g, 72.2 mmol) and TsOH·H2O (17.2 g, 90.3 mmol) were dissolved in ethylene glycol (70 mL), purged with nitrogen, and reacted at 80 °C for 3 h. The reaction was monitored by LC-MS until complete. The mixture was cooled to room temperature, extracted with ethyl acetate, washed with saturated brine, dried over anhydrous sodium sulfate, filtered, concentrated under reduced pressure, and the crude product was purified by per-HPLC to obtain compound Int 8-3 (8.9 g, 36.0 mmol). MS [ESI]: m / z = 264.0 [M+H] + .
[0576] Step 3: Synthesis of compound Int 8-4
[0577] Compound Int 8-3 (8.4 g, 34.3 mmol) was dissolved in DCM (150 mL), purged with nitrogen, and cooled to -10 °C. DIAD (9.0 g, 44.6 mmol) and tributylphosphine (9.0 g, 44.6 mmol) were slowly added dropwise, and the reaction was carried out at -10 °C for 2 h. The reaction was monitored by LCMS until complete. The reaction was quenched with water, extracted with dichloromethane, washed with saturated brine, dried over anhydrous sodium sulfate, filtered, concentrated under reduced pressure, and the crude product was purified by column chromatography to obtain compound Int 8-4 (7.0 g, 30.5 mmol). MS [ESI]: m / z = 205.0 [M+H] + .
[0578] Step 4: Synthesis of compound Int 8-5
[0579] Compound Int 8-5 can be obtained by referring to the synthesis steps of compound Int7-6 in the preparation of Int 7.
[0580] Step 5: Synthesis of compound Int 8
[0581] Compound Int 8-5 (250 mg, 1.1 mmol) was dissolved in DCM (20 mL) under nitrogen protection. NBS (181 mg, 1.0 mmol) was added dropwise in an ice bath, and the reaction was allowed to proceed at room temperature for 2 h. The reaction was monitored by LC-MS until complete. The reaction was quenched with water, extracted with dichloromethane, and concentrated under reduced pressure to give compound Int 8 (250 mg, 0.83 mmol). MS [ESI]: m / z = 300.1 [M+H] + .
[0582] Referring to steps four and five in Int 8, replacing Int 2-7 with the following reactants will yield the following compounds:
[0583] Referring to steps four and five in Int 8, replacing Int 8-4 with the following reactants will yield the following compounds:
[0584] Preparation of Int 10: 8-(4-(2,4-difluorophenoxy)piperidin-1-yl)-N-(oxecyclobutane-3-yl)-2,3,4,5-tetrahydrobenzo[f][1,4]oxa 7-amine
[0585] Step 1: Synthesis of compound Int 10-1
[0586] Compound Int 10-1 can be obtained by referring to the synthesis steps of compound Int7-2 in the preparation of Int 7.
[0587] Step 2: Synthesis of compound Int 10⁻²
[0588] Triphenylphosphine (8.43 g, 32.12 mmol) was added to a tetrahydrofuran solution (50 mL) of compound Int 10⁻¹ (7.2 g, 21.41 mmol) under ice bath conditions, followed by DIAD (6.5 g, 32.12 mmol). The reaction was carried out at room temperature for 4 hours. The solution was diluted with water, extracted with ethyl acetate, washed with saturated brine, dried over anhydrous sodium sulfate, filtered, concentrated under reduced pressure, and the crude product was purified by column chromatography to give compound Int 10⁻² (4.2 g, 13.2 mmol). MS [ESI]: m / z = 318.9 [M+H] + .
[0589] Step 3: Synthesis of compound Int 10⁻³
[0590] Under nitrogen protection, compound Int 10⁻² (1 g, 3.14 mmol), RuphosPdG₃ (0.26 g, 0.31 mmol), cesium carbonate (2.0 g, 6.29 mmol), and compound Int 2⁻⁷ (0.8 g, 3.77 mmol) were dissolved in toluene (10 mL), and the mixture was heated to 120 °C and reacted for 12 hours. The solution was concentrated and evaporated to dryness. The crude product was purified by column chromatography to give compound Int 10⁻³ (0.5 g, 1.61 mmol), MS [ESI]: m / z = 311.2 [M + H⁺]. + .
[0591] Step 4: Synthesis of compound Int 10⁻⁴
[0592] Compound Int 10-4 can be obtained by referring to the synthesis steps of compound Int-7-5 in the preparation of Int 7.
[0593] Step 5: Synthesis of compound Int 10⁻⁵
[0594] Under nitrogen protection, compound Int 10⁻⁴ (0.45 g, 1.15 mmol), Pd-PEPSI-IPent (0.09 g, 0.11 mmol), cesium carbonate (0.75 g, 2.31 mmol), and 4-(2,4-difluorophenoxy)piperidine (0.29 g, 1.39 mmol) were dissolved in toluene (10 mL), and the mixture was heated to 120 °C and reacted for 12 hours. The solution was concentrated and evaporated to dryness. The crude product was purified by column chromatography to give compound Int 10⁻⁵ (0.3 g, 0.57 mmol), MS [ESI]: m / z = 522.2 [M+H]. + .
[0595] Step Six: Synthesis of Compound Int 10
[0596] At room temperature, Pd(OH)₂ / C (30 mg) was added to a methanol solution (5 mL) of compound Int 10⁻⁵ (0.3 g, 0.57 mmol), followed by hydrogen purging. The mixture was then heated to 60 °C and reacted for 12 hours. The solution was filtered through diatomaceous earth, the filter cake was washed with methanol, and the filtrate was concentrated to obtain compound Int 10 (0.2 g, 0.46 mmol). MS [ESI]: m / z = 432.2 [M + H] + .
[0597] Preparation of Int 11: 7-bromo-8-(4-(2,4-difluorophenoxy)piperidin-1-yl)-2,3-dihydro-5H-[1,4]dioxahepteno[5,6-b]pyridine
[0598] Step 1: Synthesis of compound Int 11-1
[0599] Int 11-1 can be prepared by referring to the synthesis steps of compound Int 8-2 in the preparation of Int 8.
[0600] Step 2: Synthesis of compound Int 11-2
[0601] Compound Int 11-1 (4.5 g, 25.3 mmol) was dissolved in THF (50 mL), and triethylamine (7.6 g, 75.8 mmol) and TsCl (6.0 g, 31.6 mmol) were added. The reaction was carried out at room temperature for 2 h. The reaction was quenched with water, extracted with ethyl acetate, washed with saturated brine, dried over anhydrous sodium sulfate, filtered, concentrated under reduced pressure, and the crude product was purified by column chromatography to give compound Int 11-2 (4.9 g, 14.7 mmol). MS [ESI]: m / z = 332.0 [M+H] + .
[0602] Step 3: Synthesis of compound Int 11-3
[0603] Under ice bath conditions, NaH (1.3 g, 56.0 mmol) was added to ethylene glycol (7 mL), and the reaction was allowed to proceed for 0.5 h. The reaction mixture was then added dropwise to compound Int 11-2 (4.9 g, 14.8 mmol) at 0 °C, and the reaction was allowed to proceed overnight at 60 °C. The mixture was cooled to room temperature, quenched with water, extracted with ethyl acetate, washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to give compound Int 11-3 (3.0 g, 14.8 mmol). MS [ESI]: m / z = 222.0 [M+H] + .
[0604] Step 4: Synthesis of compound Int 11-4
[0605] Int 11-4 can be prepared by referring to the synthesis steps of compound Int7-3 in the preparation of Int 7.
[0606] Step 5: Synthesis of compound Int 11-5
[0607] Int 11-5 can be prepared by referring to the synthesis steps of compound Int7-4 in the preparation of Int 7.
[0608] Step Six: Synthesis of Compound Int 11
[0609] Compound Int 11-5 (140 mg, 0.4 mmol) was dissolved in DCM (10 mL). NBS (62 mg, 0.3 mmol) was slowly added under nitrogen protection in an ice bath, and the reaction was carried out at room temperature for 2 h. The reaction was quenched with water, extracted with dichloromethane, and concentrated under reduced pressure to give compound Int 11 (160 mg, 0.3 mmol). MS [ESI]: m / z = 441.1 [M+H] + .
[0610] Referring to steps five and six in Int 11, By replacing the reactants with the following, the following compounds can be prepared:
[0611] Preparation of Int 12: 8-bromo-7-(4-(2,4-difluorophenoxy)piperidin-1-yl)-2,3-dihydro-5H-[1,4]dioxahepteno[6,5-b]pyridine
[0612] Step 1: Synthesis of compound Int 12-2
[0613] Int 12-2 can be prepared by referring to the synthesis steps of compound Int 8-2 in the preparation of Int 8.
[0614] Step 2: Synthesis of compound Int 12-3
[0615] Int 12-3 can be prepared by referring to the synthesis steps of compound Int 11-2 in the preparation of Int 11.
[0616] Step 3: Synthesis of compound Int 12-4
[0617] Int 12-4 can be prepared by referring to the synthesis steps of compound Int 11-3 in the preparation of Int 11.
[0618] Step 4: Synthesis of compound Int 12-5
[0619] Compound Int 12-4 (5.0 g, 13.9 mmol) was dissolved in DMF (10 mL), and potassium tert-butoxide (2.3 g, 20.9 mmol) was added. The mixture was purged with nitrogen and reacted overnight at room temperature. The reaction was quenched with water, and a solid precipitated. The solid was filtered, the filter cake was washed with water, and dried to give compound Int 12-5 (1.3 g, 5.7 mmol). MS [ESI]: m / z = 230.0 [M+H] + .
[0620] Step 5: Synthesis of compound Int 12-6
[0621] Int 12-6 can be prepared by referring to the synthesis steps of compound Int11-5 in the preparation of Int 11.
[0622] Step Six: Synthesis of Compound Int 12
[0623] Compound Int 12-6 (140 mg, 0.4 mmol) was dissolved in DCM (10 mL). Under nitrogen protection in an ice bath, NBS (66 mg, 0.3 mmol) was slowly added, and the reaction was carried out at room temperature for 2 h. The reaction was then quenched with water, extracted with dichloromethane, and concentrated under reduced pressure to give compound Int 12 (150 g, 0.3 mmol). MS [ESI]: m / z = 441.1 [M+H] + .
[0624] Referring to steps five and six in Int 12, By replacing the reactants with the following reactants, the following compounds can be prepared:
[0625] Preparation of Int 15: (R)-2-(3-ethoxy-3-oxopropyl)-6-((tetrahydrofuran-3-yl)amino)nicotinic acid ethyl ester
[0626] Step 1: Synthesis of compound Int 15-2
[0627] Int 15-1 (9 g, 41.0 mmol) was dissolved in DMF (100 mL), and (R)-tetrahydrofuran-3-amine (5.0 g, 41.0 mmol) and DIPEA (13.3 g, 102.5 mmol) were added. The reaction was carried out under nitrogen atmosphere at 60 °C for 16 h. After the reaction was completed, the mixture was cooled to room temperature, quenched with water, extracted with ethyl acetate, washed with saturated brine, dried over anhydrous sodium sulfate, filtered, concentrated under reduced pressure, and the crude product was purified by column chromatography to obtain compound Int 15-2 (3.1 g, 11.4 mmol), MS [ESI]: m / z = 271.1 [M+H]. + .
[0628] Step 2: Synthesis of compound Int 15-3
[0629] Compound Int 15-2 (3.1 g, 11.4 mmol) was dissolved in DMAC (30 mL), and compound Int 2-2 (2.8 g, 12.5 mmol), cataCXium A Pd-G3 (829 mg, 1.1 mmol), and anhydrous potassium carbonate (4.7 g, 34.2 mmol) were added. The reaction was carried out at 120 °C for 3 h under a nitrogen atmosphere. After the reaction was completed, the mixture was cooled to room temperature, quenched with water, extracted with ethyl acetate, washed with saturated brine, dried over anhydrous sodium sulfate, filtered, concentrated under reduced pressure, and the crude product was purified by column chromatography to obtain compound Int 15-3 (3.7 g, 11.0 mmol). MS [ESI]: m / z = 335.1 [M+H] + .
[0630] Step 3: Synthesis of compound Int 15
[0631] Compound Int 15-3 (3.7 g, 11.0 mmol) was dissolved in 1,4-dioxane / water (30 mL, 10:1), and Ts-NHNH2 (6.1 g, 33.0 mmol) and sodium acetate (4.5 g, 55.0 mmol) were added. The reaction was carried out under a nitrogen atmosphere at 90 °C for 16 h. After the reaction was completed, the mixture was cooled to room temperature, quenched with water, extracted with ethyl acetate, washed with saturated brine, dried over anhydrous sodium sulfate, filtered, concentrated under reduced pressure, and the crude product was purified by column chromatography to obtain compound Int 15 (2.6 g, 7.7 mmol), MS [ESI]: m / z = 337.1 [M+H]. + .
[0632] Preparation of Int 17: 3-((1R,5S)-3-azabicyclo[3.1.0]hexane-6-yl)-N-((R)-tetrahydrofuran-3-yl)pyrido[3,4-b]pyrazine-2-amine
[0633] Step 1: Synthesis of compound Int 17-2
[0634] Compound Int 17-2 can be obtained by referring to the synthesis steps of compound Int 15-2 in the preparation of Int 15.
[0635] Step 2: Synthesis of compound Int 17-4
[0636] Compound Int 17-4 can be obtained by referring to the synthesis steps of compound Int 15-3 in the preparation of Int 15.
[0637] Step 3: Synthesis of compound Int 17
[0638] Compound Int 17-4 (340 mg, 855.41 μmol) was dissolved in DCM (3 mL) at room temperature, and TFA (1.48 g, 12.98 mmol, 1 mL) was added. The reaction was carried out at room temperature for 2 h, and the product was monitored by LC-MS. The product was diluted with water, extracted with ethyl acetate, washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to give compound Int 17 (210 mg, 706.23 μmol). MS [ESI]: m / z = 298.1 [M+H] +
[0639] Preparation of Int 18: 8-(4-(2,4-difluorophenoxy)piperidin-1-yl)-N-(oxecyclobutane-3-yl)-2,3,4,5-tetrahydro-1H-benzo[d]aza 7-amine
[0640] Step 1: Synthesis of compound Int 18-2
[0641] Compound Int 18-1 (3.2 g, 10.94 mmol) was dissolved in methanol (30 mL), and palladium on carbon (0.3 g) was added. The mixture was then purged with hydrogen and reacted at room temperature for 12 h. The reaction was monitored for completeness by LC-MS. The mixture was filtered through diatomaceous earth, the filter cake was washed with methanol, concentrated under reduced pressure, and the crude product was purified by rapid chromatography to give compound Int 18-2 (2.7 g, 10.29 mmol). MS [ESI]: m / z = 207.1 [M-56+H] + .
[0642] Step 2: Synthesis of compound Int 18-3
[0643] Compound Int 18-2 (2.7 g, 10.29 mmol), 3-oxetane (0.74 g, 10.29 mmol), and trifluoroethanol (30 mL) were added, followed by glacial acetic acid (2 mL). The reaction was carried out under nitrogen protection for 12 h. Palladium on carbon (0.27 g) was then added, and the mixture was purged with hydrogen and reacted at room temperature for 12 h. The reaction was monitored for completeness by LC-MS. The mixture was filtered through diatomaceous earth, the filter cake was washed with methanol, concentrated under reduced pressure, and the crude product was purified by chromatography to obtain compound Int 18-3 (2.6 g, 8.2 mmol). MS [ESI]: m / z = 263.1 [M-56+H] + .
[0644] Step 3: Synthesis of compound Int 18-4
[0645] Compound Int 18-4 can be obtained by referring to the synthesis steps of compound Int7-5 in the preparation of Int 7.
[0646] Step 4: Synthesis of compound Int 18-5
[0647] Compound Int 18-5 can be obtained by referring to the synthesis steps of compound Int 10-5 in the preparation of Int 10.
[0648] Step 5: Synthesis of compound Int 18
[0649] Compound Int 18-5 (430 mg, 0.81 mmol), dichloromethane (10 mL), and trifluoroacetic acid (2 mL) were added. The mixture was stirred at room temperature for 12 h. The product was monitored by LCMS. The product was diluted with water, concentrated under reduced pressure, and the crude product was purified by pre-HPLC to obtain compound Int 18 (320 mg). MS [ESI]: m / z = 430.1 [M+H] + .
[0650] Preparation of Int 19: 7-bromo-1,2,4,5-tetrahydrobenzo[d]thiazo
[0651] Step 1: Synthesis of compound Int 19-2
[0652] Compound Int 19-1 (25 g, 94.8 mmol) and mercaptoacetic acid (13.1 g, 142.0 mmol) were added and dissolved in MeOH (250 mL). A 1 N sodium hydroxide solution was added dropwise, and the mixture was stirred at room temperature for 1 h. The reaction was monitored by TLC until complete. The solution was concentrated under reduced pressure, extracted with dichloromethane, and the aqueous phase was adjusted to acidic pH with 1 N hydrochloric acid, then extracted with ethyl acetate, washed with saturated sodium chloride solution, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to give compound Int 19-2 (23.4 g, 85.4 mmol). MS [ESI]: m / z = 275.0 [M+H] + .
[0653] Step 2: Synthesis of compound Int 19-3
[0654] Compound Int 19-2 (23.4 g, 85.4 mmol), DCM (200 mL), and thionyl chloride (20.1 g, 170.7 mmol) were added, and the reaction was carried out at 40 °C for 2 h under nitrogen protection. The reaction was monitored by LC-MS until completion, then cooled to room temperature and concentrated under reduced pressure to give compound Int 19-3 (24 g, 85.1 mmol). MS [ESI]: m / z = 291.9 [M+H] + .
[0655] Step 3: Synthesis of compound Int 19-4
[0656] Compound Int 19-3 (24 g, 85.1 mmol) was dissolved in ultradry DCM (100 mL), and AlCl3 (22.6 g, 170.2 mmol) was added at 0 °C. The reaction was carried out at 0 °C for 30 min with N2 displacement. The reaction was monitored by TLC until complete, quenched with ice water, extracted with dichloromethane, dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The crude product was purified by column chromatography to obtain compound Int 19-4 (2.4 g, 9.3 mmol). MS [ESI]: m / z = 257.0 [M+H] + .
[0657] Step 4: Synthesis of compound Int 19
[0658] Compound Int 19-4 (643 mg, 2.5 mmol), triethylsilane (4.0 mL, 25 mmol), and trifluoroacetic acid (6 mL) were added. The reaction was carried out at 80 °C for 4 h under nitrogen purging. The reaction was monitored by LC-MS until completion. The mixture was then quenched with water, extracted with ethyl acetate, washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain compound Int 19 (500 mg, 2.0 mmol). MS [ESI]: m / z = 243.0 [M+H] + .
[0659] Example 1: Synthesis of compounds 1-A and 1-B
[0660] Step 1: Synthesis of Compounds 1-2
[0661] Compound Int 1 (520 mg, 1.15 mmol), compound 1-1 (550.89 mg, 2.29 mmol), cesium carbonate (1.12 g, 3.44 mmol), and Pd(dppf)Cl2 (167.88 mg, 229.44 μmol) were dissolved in 1,4-dioxane (5 mL) and H2O (0.5 mL) under a nitrogen atmosphere. The atmosphere was purged with nitrogen, and the mixture was heated to 95 °C. The reaction was monitored by LC-MS until complete. The reaction mixture was diluted with H2O (50 mL) and extracted with ethyl acetate. The combined organic layers were washed with brine, dried over Na2SO4, filtered, and concentrated under reduced pressure to give the crude product. Compound 1-2 (500 mg, 1.03 mmol) was purified by column chromatography. MS (ESI): m / z = 487.2 [M+H] + .
[0662] Step 2: Synthesis of compounds 1-A and 1-B
[0663] Compounds 1-2 (150 mg, 308.32 μmol) were dissolved in 5 mL of THF under a nitrogen atmosphere. The mixture was cooled to 0 °C, and lithium aluminum hydride (2.5 M, 924.96 μmol, 369.98 μL) was slowly added dropwise. The reaction was carried out in an ice bath. LC-MS analysis showed the reaction was complete. The reaction solution was diluted with 10 mL of THF, and the reaction was quenched dropwise with 5 mL of 20% NaOH. The mixture was then extracted with ethyl acetate. The combined organic layers were washed with brine, dried over Na₂SO₄, filtered, and concentrated under reduced pressure to obtain the crude product. The reaction mixture was purified by Prep-HPLC to obtain compound 1-A (4.7 mg, 10.92 μmol). MS (ESI): m / z = 431.2 [M+H] + , 1 H NMR (400MHz, DMSO-d6) δ7.35–7.25(m,2H),7.05–6.98(m,1H),4.63(s,1H),4.57–4.48(m,1H),3.83(s,2H),3.62–3.47(m,5H),3.13–2.93(m ,4H),2.92–2.82(m,2H),2.13–1.99(m,3H),1.87–1.72(m,2H),1.69– 1.58(m,2H),1.58–1.48(m,1H),1.18–1.09(m,1H),0.94–0.85(m,1H).
[0664] Compound 1-B (4.6 mg, 10.69 μmol), MS (ESI): m / z = 431.2 [M+H] + , 1 H NMR(400MHz,DMSO-d6)δ7.37–7.23(m,2H),7.08–6.96(m,1H),4.61–4.46(m,1H) ,4.34(s,1H),3.93–3.77(m,3H),3.62–3.52(m,2H),3.30–3.15(m,3H),3.06–2.9 9(m,2H),2.97–2.85(m,3H),2.30–2.21(m,1H),2.15–2.05(m,1H),2.04–1.94(m, 1H),1.94–1.82(m,1H),1.71–1.55(m,4H),1.35–1.27(m,1H),1.01–0.91(m,1H).
[0665] Example 2: Synthesis of compound 3-A
[0666] Step 1: Synthesis of Compound 3-2
[0667] (R)-Tetrahydrofuran-3-amine (2.53 g, 28.98 mmol), compound 3-1 (5 g, 24.15 mmol), DMF (50 mL) and triethylamine (3.67 g, 36.23 mmol) were mixed. The reaction was monitored to completion by TLC. The mixture was extracted with ethyl acetate and saturated brine. The organic layers were combined, washed with brine, dried over Na2SO4, filtered, and concentrated under reduced pressure to obtain the residue. Compound 3-2 (4 g, 15.52 mmol) was purified by column chromatography. MS [ESI]: m / z = 258.2 [M+H] + .
[0668] Step 2: Synthesis of Compound 3-3
[0669] Compound 3-2 (4 g, 15.52 mmol), (E)-3-(4,4,5,5-tetramethyl-1,3,2-dioxaboran-2-yl)acrylate (5.26 g, 23.29 mmol), DMAC (40 mL), water (4 mL), cesium carbonate (10.12 g, 31.05 mmol), and Pd(dppf)Cl2 (1.14 g, 1.55 mmol) were mixed, purged with nitrogen, and heated to 120 °C. The reaction was confirmed to be complete by LC-MS. After returning to room temperature, the reaction mixture was diluted with ethyl acetate and saturated brine. The aqueous layer was extracted with ethyl acetate (50 mL), and the organic layers were combined. The organic layers were washed with brine and dried over anhydrous sodium sulfate. The mixture was concentrated under reduced pressure and purified by column chromatography to obtain compound 3-3 (3.2 g, 9.96 mmol). MS [ESI]: m / z = 322.2 [M+H] + .
[0670] Step 3: Synthesis of compounds 3-4
[0671] Compound 3-3 (3.2 g, 9.96 mmol) was mixed with methanol (30 mL) and palladium on carbon (320 mg, 10% w / w), purged with hydrogen, and reacted at room temperature. The reaction was confirmed to be complete by LC-MS. The reaction solution was filtered through diatomaceous earth, washed with methanol, concentrated under reduced pressure, and purified by column chromatography to obtain compound 3-4 (2.8 g, 8.66 mmol). MS [ESI]: m / z = 324.2 [M+H] + .
[0672] Step 4: Synthesis of compounds 3-5
[0673] Compounds 3-4 (2.8 g, 8.66 mmol) were mixed with anhydrous tetrahydrofuran (30 mL), and after nitrogen purging, LAH (43.30 mmol) was slowly added at -78 °C. The reaction was allowed to proceed for 4 hours, followed by a slow increase to room temperature. LC-MS analysis confirmed the reaction was complete. Under ice bath conditions, 3 mL of water, 3 mL of 15% sodium hydroxide solution, 9 mL of water, and anhydrous magnesium sulfate were added to the reaction mixture. The reaction was allowed to proceed for 15 minutes, followed by filtration, concentration under reduced pressure, and purification by column chromatography to obtain compound 3-5 (1.8 g, 7.11 mmol). MS [ESI]: m / z = 254.2 [M+H] + .
[0674] Step 5: Synthesis of compounds 3-6
[0675] Compounds 3-5 (1.8 g, 7.11 mmol) were mixed with DMSO (20 mL), and TFA (2 mL) was added at room temperature. The mixture was heated to 90 °C, and the reaction was monitored by LC-MS until complete. The reaction mixture was adjusted to neutral pH with NaHCO3 solution, diluted with H2O, and extracted with ethyl acetate. The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, concentrated under reduced pressure, and purified by column chromatography to give compounds 3-6 (1.2 g, 5.10 mmol). MS [ESI]: m / z = 236.2 [M+H] + .
[0676] Step Six: Synthesis of Compounds 3-7
[0677] Compounds 3-6 (1.2 g, 5.10 mmol), dichloromethane (10 mL), and NBS (0.9 g, 5.10 mmol) were mixed and reacted at room temperature. The reaction was confirmed to be complete by LC-MS. The reaction solution was concentrated under reduced pressure and purified by column chromatography to obtain compounds 3-7 (1.3 g, 4.14 mmol). MS [ESI]: m / z = 315.2 [M+H] + .
[0678] Step 7: Synthesis of Compound 3-A
[0679] Under a nitrogen atmosphere, compounds 3-6 (0.1 g, 0.31 mmol), 4-(2,4-difluorophenoxy)piperidine (81.44 mg, 0.38 mmol), cesium carbonate (207.41 mg, 636.57 μmol), Ruphos Pd G3 (26.65 mg, 31.83 μmol), and Ruphos (14.85 mg, 31.83 μmol) were dissolved in 1,4-dioxane (2 mL). The mixture was purged with nitrogen, and the temperature was raised to 95 °C. The reaction was confirmed to be complete by LC-MS. The reaction mixture was purified by Prep-HPLC to give compound 3-A (75 mg, 167.9 μmol). MS [ESI]: m / z = 447.2 [M+H] + . 1H NMR (400MHz, DMSO-d6) δ7.36–7.26(m,2H),7.11–6.95(m,1H),5.84(d,J=6.0 Hz,1H),4.50(d,J=9.2Hz,3H),4.44–4.35(m,1H),3.96–3.82(m,4H),3.75–3. 65(m,1H),3.55(dd,J=8.8,4.8Hz,1H),3.33–3.20(m,2H),2.94–2.78(m,4H) ,2.25–2.14(m,1H),2.11–2.00(m,2H),2.00–1.81(m,3H),1.80–1.70(m,2H).
[0680] Referring to the synthesis method of Example 2, by replacing the corresponding parts in Example 2 with the following reactants, the following compounds can be prepared:
[0681] Example 3: Synthesis of Compound 4-A
[0682] Step 1: Synthesis of Compound 4-2
[0683] Under a nitrogen atmosphere, compound 4-1 (10 g, 42.04 mmol), 4-(2,4-difluorophenoxy)piperidine (8.96 g, 42.04 mmol), cesium carbonate (27.39 g, 84.08 mmol), Ruphos Pd G3 (3.52 g, 4.2 mmol), and Ruphos (1.96 g, 4.20 mmol) were dissolved in 1,4-dioxane (100 mL). The mixture was purged with nitrogen and heated to 95 °C. The reaction was confirmed to be complete by LC-MS. The reaction mixture was purified by column chromatography to give compound 4-2 (6.2 g, 16.75 mmol). MS [ESI]: m / z = 371.2 [M+H] + .
[0684] Step 2: Synthesis of Compound 4-3
[0685] Compound 4-2 (6.2 g, 16.75 mmol), dichloroethane (50 mL), and NBS (3.75 g, 21.07 mmol) were mixed and heated to 60 °C. The reaction was confirmed to be complete by LC-MS. The reaction solution was concentrated under reduced pressure and purified by column chromatography to obtain compound 4-3 (5.2 g, 11.58 mmol). MS [ESI]: m / z = 449.9 [M+H] + .
[0686] Step 3: Synthesis of Compound 4-4
[0687] Compound 4-3 (5.2 g, 11.58 mmol), potassium 2-(tetrahydro-2H-pyran-2-oxy)ethyltrifluoroborate (6.83 g, 28.95 mmol), cataCXium A Pd-G3 (0.84 g, 1.16 mmol), cesium carbonate (11.3 g, 34.74 mmol), DMAC (40 mL), and water (4 mL) were mixed. After nitrogen purging, the mixture was heated to 120 °C. The reaction was monitored by LC-MS until complete. The mixture was then cooled to room temperature, and ethyl acetate and saturated brine were added to dilute the reaction solution. The aqueous layer was extracted with ethyl acetate, and the organic layers were combined. The organic layers were then washed with brine and dried over anhydrous sodium sulfate. The mixture was concentrated under reduced pressure and purified by column chromatography to obtain compound 4-4 (2.2 g, 4.02 mmol). MS [ESI]: m / z = 548.3 [M+H] + .
[0688] Step 4: Synthesis of compounds 4-5
[0689] Compound 4-4 (2.2 g, 4.02 mmol) was mixed with methanol (20 mL). Under ice bath conditions, HCl (12 N, 2 mL) was added dropwise. The reaction was carried out at room temperature, and LC-MS was used to determine the completeness of the reaction. Sodium bicarbonate was added to adjust the pH to 7-8. The reaction mixture was diluted with ethyl acetate and saturated brine. The aqueous layer was extracted with ethyl acetate, and the organic layers were combined. The organic layers were then washed with brine and dried over anhydrous sodium sulfate. The solution was concentrated under reduced pressure to obtain crude compound 4-5 (1.2 g, 3.16 mmol). MS [ESI]: m / z = 380.1 [M+H] + .
[0690] Step 5: Synthesis of compounds 4-6
[0691] Compounds 4-5 (0.3 g, 0.79 mmol), toluene (3 mL), and CMBP (0.57 g, 2.37 mmol) were mixed, heated to 120 °C, stirred, and the reaction was monitored by LC-MS until complete. After returning to room temperature, compounds 4-6 (80 mg, 0.22 mmol) were purified by column chromatography. MS [ESI]: m / z = 362.2 [M+H] + .
[0692] Step Six: Synthesis of Compounds 4-7
[0693] Compounds 4-6 (80 mg, 0.22 mmol), dichloroethane (1 mL), and NBS (47.28 mg, 0.26 mmol) were mixed and heated to 60 °C. The reaction was monitored by LC-MS until complete. The reaction solution was concentrated under reduced pressure and purified by column chromatography to obtain compound 4-7 (60 mg, 0.13 mmol). MS [ESI]: m / z = 440.0 [M+H] + .
[0694] Step 7: Synthesis of Compound 4-A
[0695] Compounds 4-7 (60 mg, 0.13 mmol), 1,4-dioxane (1 mL), cesium carbonate (88 mg, 0.27 mmol), Pd-PEPPSI-IPentCl (13 mg, 0.01 mmol), and (R)-3-aminotetrahydrofuran (18 mg, 0.18 mmol) were mixed, purged with nitrogen, and heated to 90 °C. The reaction was monitored by LCMS until complete. After returning to room temperature, the mixture was filtered through diatomaceous earth, washed with dichloromethane, concentrated under reduced pressure, and purified by Prep-HPLC to obtain compound 4-A (5 mg, 0.01 mmol). MS [ESI]: m / z = 447.2 [M+H] + .
[0696] 1 H NMR(400MHz, DMSO-d6)δ7.36–7.25(m,2H),7.06–6.96(m,1H),5.71(d,J=6.0Hz,1H),4.57–4.45(m,1H),4.45–4.34(m,1H),3.94–3.80(m,2H), 3.74–3.63(m,5H),3.54(dd,J=8.8,4.8Hz,1H),3.32–3.19(m,2H),2.99 –2.79(m,6H),2.23–2.13(m,1H),2.12–2.02(m,2H),1.99–1.77(m,3H).
[0697] Example 4: Synthesis of Compound 7-A and Compound 7-B
[0698] Compounds 3-7 (120 mg, 0.38 mmol), 4-((2,4-difluorophenyl)fluoromethyl)piperidine (105 mg, 0.45 mmol), Pd-PEPPSI-IPentCl (37 mg, 0.04 mmol), and cesium carbonate (373 mg, 1.14 mmol) were dissolved in 1,4-dioxane (2 mL). The reaction mixture was stirred at 110 °C under a nitrogen atmosphere. After the reaction was complete, the reaction solution was filtered, and the filtrate was concentrated under reduced pressure. The crude product was purified by rapid silica gel column chromatography to obtain compound 7. Compound 7 was then separated by SFC (column: DAICEL OJ-H 4.6 mm * 250 mm 5 μm, mobile phase: CO2 / MeOH [0.1% NH3 (7M methanol solution)] = 80 / 20) to obtain compound 7-fraction 1 (compound 7-A or 7-B) and compound 7-fraction 2 (compound 7-B or 7-A).
[0699] Compound 7 - Component 1: 10.77 mg, retention time: 2.974 min. MS [ESI]: m / z = 463.35 [M+H] + , 1 H NMR (400MHz, DMSO-d6) δ7.67-7.46(m,1H),7.38-7.23(m,1H),7.26-7.14(m,1H),5.69(d,J=6.4Hz,1 H),5.61-5.43(m,1H),4.49(s,2H),4.45-4.36(m,1H),3.96-3.80(m,4H),3.74-3.66(m,1H),3.56-3. 50(m,1H),3.40-3.35(m,1H),3.31-3.18(m,2H),2.96-2.82(m,2H),2.68-2.58(m,1H),2.22-2.13(m ,1H),2.11-1.99(m,1H),1.96-1.86(m,2H),1.77-1.69(m,2H),1.67-1.48(m,2H),1.35-1.25(m,1H).
[0700] Compound 7 - Component 2: 11.32 mg, retention time: 3.263 min. MS [ESI]: m / z = 463.0 [M+H] + , 1 H NMR (400MHz, DMSO-d6) δ7.67-7.46(m,1H),7.38-7.23(m,1H),7.26-7.14(m,1H),5.69(d,J=6.4Hz,1 H),5.61-5.43(m,1H),4.49(s,2H),4.45-4.36(m,1H),3.96-3.80(m,4H),3.74-3.66(m,1H),3.56-3. 50(m,1H),3.40-3.35(m,1H),3.31-3.18(m,2H),2.96-2.82(m,2H),2.68-2.58(m,1H),2.22-2.13(m ,1H),2.11-1.99(m,1H),1.96-1.86(m,2H),1.77-1.69(m,2H),1.67-1.48(m,2H),1.35-1.25(m,1H).
[0701] Example 5: Synthesis of Compound 8-A
[0702] Step 1: Synthesis of Compound 8-1
[0703] Compound 3-1 (10 g, 48.31 mmol) was added to a flask under ice-water bath conditions, followed by DMF (100 mL), triethylamine (5.87 g, 57.97 mmol), and 4-(2,4-difluorophenoxy)piperidine (12.36 g, 57.97 mmol). The reaction was carried out overnight at room temperature under nitrogen purging protection. After the reaction was complete, purified water was added to precipitate the solid. The solid was filtered, washed, and slurried with n-heptane to give compound 8-1 (12.1 g, 31.53 mmol). MS [ESI]: m / z = 384.2 [M+H] + .
[0704] Step 2: Synthesis of Compound 8-2
[0705] Compound 8-1 (12.1 g, 31.53 mmol), potassium 2-(tetrahydro-2H-pyran-2-oxy)ethyltrifluoroborate (8.55 g, 37.83 mmol), Cs₂CO₃ (30.82 g, 94.59 mmol), DMF (150 mL), and water (15 mL) were mixed, and then Pd(dppf)Cl₂ (2.31 g, 3.15 mmol) was added. The mixture was purged with nitrogen, stirred, and heated to 115 °C. After the reaction was complete, purified water and EA were added for extraction and washing. The mixture was concentrated to dryness and purified by column chromatography to obtain compound 8-2 (9.3 g, 20.78 mmol). MS [ESI]: m / z = 448.1 [M+H] + .
[0706] Step 3: Synthesis of Compound 8-3
[0707] Compound 8-2 (5 g, 11.17 mmol), methanol (50 mL), and palladium on carbon (500 mg, 10% w / w) were mixed, purged with hydrogen, and reacted at room temperature. The reaction was confirmed to be complete by LC-MS. The reaction solution was filtered through diatomaceous earth, washed with methanol, concentrated under reduced pressure, and purified by column chromatography to obtain compound 8-3 (3.3 g, 7.34 mmol). MS [ESI]: m / z = 450.2 [M+H] + .
[0708] Step 4: Synthesis of Compound 8-4
[0709] Compound 8-3 (3.3 g, 7.34 mmol) was mixed with THF (30 mL), purged with nitrogen, and a THF solution containing LAH (14.68 mmol) was added dropwise at 0–5 °C. The reaction was allowed to proceed, and LC-MS analysis confirmed the reaction was complete. H₂O was added dropwise to the reaction mixture, and the reaction was quenched with 15% NaOH. The mixture was then extracted with DCM and water, and the organic phases were combined, concentrated under reduced pressure, and purified by column chromatography to obtain compound 8-4 (2 g, 5.27 mmol). MS [ESI]: m / z = 380.2 [M+H]⁺.
[0710] Step 5: Synthesis of Compound 8-5
[0711] Compound 8-4 (2 g, 5.27 mmol), DMSO (20 mL), and TFA (2 mL) were mixed and stirred at 90 °C under nitrogen purging protection. The reaction was confirmed to be complete by LC-MS. H₂O was added, the pH was adjusted to 7 in an ice-water bath, and the mixture was extracted with EA. The organic phases were combined, concentrated under reduced pressure, and purified by column chromatography to obtain compound 8-5 (1.6 g, 4.43 mmol). MS [ESI]: m / z = 362.2 [M+H]⁺.
[0712] Step Six: Synthesis of Compounds 8-6
[0713] Compound 8-5 (1.6 g, 4.43 mmol), DCE (20 mL), and NBS (0.94 g) were mixed and reacted at 55 °C under nitrogen protection. The reaction was confirmed to be complete by LCMS. The mixture was concentrated under reduced pressure and purified by column chromatography to obtain compound 8-6 (1.4 g, 3.18 mmol). MS [ESI]: m / z = 441.2 [M+H]+.
[0714] Step 7: Synthesis of Compound 8-A
[0715] Compound 8-6 (100 mg, 0.22 mmol), 1,4-dioxane (5 mL), cesium carbonate (148 mg, 0.45 mmol), Pd-PEPPSI-IPentCl (22 mg, 0.02 mmol), and (R)-3-aminotetrahydrofuran (29 mg, 0.34 mmol) were mixed. After nitrogen purging, the mixture was heated to 90 °C and stirred. The reaction was monitored by LCMS until complete. The mixture was then allowed to return to room temperature, filtered through diatomaceous earth, washed with dichloromethane, concentrated under reduced pressure, and purified by Prep-HPLC to obtain compound 8-A (45 mg, 0.1 mmol). MS [ESI]: m / z = 447.2 [M+H] + .
[0716] 1H NMR (400MHz, CD3OD) δ7.21–7.13(m,1H),7.02–6.94(m,1H),6.91–6.84(m,1H),4.62(m,4H),4.54–4.40(m,2H),4.03–3.93(m,4H),3.87–3.79 (m,1H),3.70–3.64(m,1H),3.42–3.34(m,1H),3.05–2.89(m,4H),2.36 –2.25(m,1H),2.16–2.06(m,2H),1.99–1.89(m,3H),1.89–1.79(m,2H).
[0717] Referring to the synthesis method of Example 5, by replacing the (R)-3-aminotetrahydrofuran in Example 5 with the following reactants, the following compounds can be prepared:
[0718] Example 8: Synthesis of Compound 11-A
[0719] Step 1: Synthesis of Compound 11-2
[0720] Compound 11-1 (500 mg, 2.51 mmol), (R)-3-aminotetrahydrofuran (465.65 mg, 3.77 mmol), cesium carbonate (4.09 g, 12.56 mmol), and Pd-PEPPSI-IPentCl (244.36 mg, 251.20 μmol) were dissolved in toluene (2 mL) under a nitrogen atmosphere, purged with nitrogen, and heated to 120 °C. The product was monitored by LC-MS. The reaction mixture was diluted with H₂O and extracted with EA. The combined organic layers were washed with brine, dried over Na₂SO₄, filtered, and concentrated under reduced pressure to give a crude product. Compound 11-2 (260 mg, 1.27 mmol) was purified by column chromatography. MS (ESI): m / z = 206.1 [M+H] +
[0721] Step 2: Synthesis of Compound 11-3
[0722] Compound 11-2 (190 mg, 925.69 μmol) was dissolved in DCM (2 mL) at room temperature, followed by the addition of NBS (247.14 mg, 1.39 mmol). The reaction was carried out at room temperature, and the product was monitored by LC-MS. The crude product was concentrated under reduced pressure and purified by silica gel column chromatography to obtain compound 11-3 (40 mg, 140.77 μmol). MS (ESI): m / z = 284.0 [M+H] +
[0723] Step 3: Synthesis of Compound 11-A
[0724] Compound 11-3 (40 mg, 140.77 μmol), 4-(2,4-difluorophenoxy)piperidine (45.02 mg, 211.16 μmol), cesium carbonate (137.60 mg, 422.31 μmol), and Pd-PEPPSI-IPentCl (13.69 mg, 14.08 μmol) were dissolved in 1,4-dioxane (2 mL) under a nitrogen atmosphere, purged with nitrogen, and heated to 120 °C. The product was monitored by LC-MS. The reaction mixture was concentrated under reduced pressure to obtain a crude product, which was purified by column chromatography followed by prep-HPLC to obtain compound 11-A (20.6 mg, 49.32 μmol). MS (ESI): m / z = 417.2 [M+H] + .
[0725] 1 H NMR (400MHz, DMSO-d6) δ7.34–7.25(m,2H),7.05–6.98(m,1H),6.55(s,1H),6.49(s,1H),4.49–4.34(m,4H),4.01–3.92(m,1H),3.91–3.78(m,2H) ,3.76–3.67(m,1H),3.56–3.50(m,1H),3.07(t,J=8.5Hz,2H),3.00–2.8 7(m,2H),2.71–2.56(m,2H),2.23–2.12(m,1H),2.09–1.99(m,2H),1.86–
[0726] 1.70 (m, 3H).
[0727] Example 9: Synthesis of Compound 12-A
[0728] Step 1: Synthesis of Compound 12-2
[0729] Compound 12-1 (400 mg, 1.88 mmol), 4-(2,4-difluorophenoxy)piperidine (600.43 mg, 2.82 mmol), cesium carbonate (1.83 g, 5.63 mmol), and Pd-PEPPSI-IPentCl (182.62 mg, 187.73 μmol) were dissolved in 1,4-dioxane (10 mL) under a nitrogen atmosphere and the mixture was heated to 120 °C. The reaction was monitored by LC-MS until complete. The reaction mixture was diluted with H₂O and extracted with EA. The combined organic layers were washed with brine, dried over Na₂SO₄, filtered, and concentrated under reduced pressure to give a crude product. The crude product was purified by column chromatography to give compound 12-2 (600 mg, 1.74 mmol). MS (ESI): m / z = 346.2 [M+H] + .
[0730] Step 2: Synthesis of Compound 12-3
[0731] Compound 12-2 (500 mg, 1.45 mmol) and NBS (244.78 mg, 1.38 mmol) were dissolved in DCE (10 mL) at room temperature. The mixture was heated to 60 °C and the reaction was monitored by LC-MS until complete. The reaction mixture was diluted with H2O and extracted with EA. The combined organic layers were washed with brine, dried over Na2SO4, filtered, and concentrated under reduced pressure to obtain the crude product. The crude product was purified by normal-phase column chromatography to obtain compound 12-3 (120 mg, 282.83 μmol), MS (ESI): m / z = 424.9 [M+H]. + .
[0732] Step 3: Synthesis of Compound 12-A
[0733] Compound 12-3 (60 mg, 141.42 μmol), (R)-3-aminotetrahydrofuran (24.64 mg, 282.83 μmol), cesium carbonate (138.23 mg, 424.25 μmol), and Pd-PEPPSI-IPentCl (13.76 mg, 14.14 μmol) were dissolved in toluene (2 mL) under a nitrogen atmosphere. The atmosphere was purged with nitrogen, and the mixture was heated to 120 °C. The reaction was monitored by LC-MS until complete. The reaction mixture was diluted with H₂O and extracted with EA. The combined organic layers were washed with brine, dried over Na₂SO₄, filtered, and concentrated under reduced pressure to obtain the crude product. The crude product was purified by prep-HPLC to obtain compound 12-A (59.1 mg, 137.29 μmol). MS (ESI): m / z = 431.1 [M+H] +
[0734] 1H NMR (400MHz, DMSO-d6) δ7.34–7.25(m,2H),7.05–6.98(m,1H),6.63(s,1H),6.33( s,1H),4.72(d,J=6.8Hz,1H),4.54(s,2H),4.46(s,1H),4.05–3.96(m,1H),3.91–3 .85(m,1H),3.86–3.77(m,3H),3.76–3.69(m,1H),3.58–3.52(m,1H),2.99–2.88(m ,2H),2.73–2.58(m,4H),2.26–2.15(m,1H),2.09–1.99(m,2H),1.89–1.71(m,3H).
[0735] Example 10: Synthesis of Compound 13-A
[0736] Step 1: Synthesis of Compound 13-2
[0737] Compound 13-1 (3 g, 17.24 mmol) was added to DMF (30 mL) under ice bath conditions, followed by DIPEA (3.57 g, 27.59 mmol, 4.81 mL) and 4-(2,4-difluorophenoxy)piperidine (4.41 g, 20.69 mmol). The reaction was carried out, and TLC monitoring showed that the reaction was complete. The reaction mixture was diluted with ethyl acetate and saturated brine. The aqueous layer was extracted with ethyl acetate, and the organic layers were combined. The organic layers were washed with brine and dried over anhydrous sodium sulfate. The solution was concentrated under reduced pressure to obtain crude compound 13-2 (6 g, 17.1 mmol). MS (ESI): m / z = 351.1 [M+H] + .
[0738] Step 2: Synthesis of Compound 13-3
[0739] Compound 13-2 (3 g, 8.50 mmol), potassium 2-(tetrahydro-2H-pyran-2-oxy)ethyltrifluoroborate (2.31 g, 10.21 mmol), potassium carbonate (2.35 g, 17.01 mmol), and Pd(dppf)Cl2 (1.24 g, 1.70 mmol) were mixed under a nitrogen atmosphere, purged with nitrogen, and then 1,4-dioxane (30 mL) and H2O (3 mL) were added and heated to 80 °C. The reaction was carried out. TLC monitoring showed that the reaction was complete. The mixture was concentrated under reduced pressure and purified by column chromatography to give compound 13-3 (3.1 g, 7.4 mmol).
[0740] Step 3: Synthesis of Compound 13-4
[0741] Compound 13-3 (3.1 g, 7.4 mmol) was added to ethanol (50 mL), followed by the addition of 10% palladium on carbon (0.3 g). The mixture was then purged with hydrogen and reacted at room temperature. The reaction was monitored by LC-MS until complete. The mixture was filtered through diatomaceous earth, washed with methanol, concentrated, and evaporated to dryness to obtain the crude product. The crude product was then purified by column chromatography to obtain compound 13-4 (2.8 g, 6.74 mmol), MS (ESI): m / z = 417.1 [M+H]. + .
[0742] Step 4: Synthesis of Compound 13-5
[0743] Compound 13-4 (2.8 g, 6.74 mmol), methanol (20 mL), and Raney nickel (280 mg) were mixed, purged with hydrogen, and reacted at 60 °C. The reaction was confirmed to be complete by LC-MS. The reaction solution was filtered through diatomaceous earth, washed with methanol, concentrated under reduced pressure, and purified by column chromatography to obtain compound 13-5 (1.2 g, 3.21 mmol). MS [ESI]: m / z = 375.2 [M+H] + .
[0744] Step 5: Synthesis of Compounds 13-6
[0745] Compound 13-5 (1.2 g, 3.21 mmol), dichloroethane (10 mL), and NBS (0.68 g, 3.85 mmol) were mixed and heated to 60 °C. The reaction was monitored by LC-MS until complete. The reaction solution was concentrated under reduced pressure and purified by column chromatography to obtain compound 13-6 (1 g, 2.21 mmol). MS [ESI]: m / z = 453.0 [M+H] + .
[0746] Step Six: Synthesis of Compounds 13-7
[0747] Compound 13-6 (500 mg, 0.1 mmol), (R)-3-aminotetrahydrofuran (96.1 mg, 0.1 mmol), Pd-PEPPSI-IPentCl (107.3 mg, 110.3 μmol), and cesium carbonate (1.07 g, 3.3 mmol) were dissolved in toluene (10 mL) under a nitrogen atmosphere. The atmosphere was purged with nitrogen, and the mixture was heated to 120 °C. The reaction was monitored by LC-MS until complete. The reaction mixture was diluted and extracted with EA. The combined organic layers were washed with brine, dried over Na2SO4, filtered, and concentrated under reduced pressure to obtain a crude product. Compound 13-7 (57 mg, 122.7 μmol) was purified by prep-HPLC. MS (ESI): m / z = 460.2 [M+H] + .
[0748] Step 7: Synthesis of Compounds 13-8
[0749] Compound 13-7 (16 mg, 34.82 μmol) was dissolved in THF (1 mL) under a nitrogen atmosphere, cooled to 0 °C, and then LAH (2.5 M, 34.82 μmol, 13.93 μL) was slowly added dropwise. The reaction was carried out in an ice bath, and the reaction was monitored by LCMS until complete. The reaction was quenched by adding 10% NaOH. The reaction mixture was diluted with H2O and extracted with EA. The combined organic layers were washed with brine, dried over Na2SO4, filtered, and concentrated under reduced pressure to give compound 13-8 (12 mg, crude product). MS (ESI): m / z = 446.1 [M+H] + .
[0750] Step 8: Synthesis of Compound 13-A
[0751] Compound 13-8 (12 mg) and acetic anhydride (4.6 mg, 40 μmol) were dissolved in THF (1 mL) at room temperature. DIPEA (5 mg, 40 μmol) was added, and the reaction was carried out at room temperature. The reaction was monitored by LC-MS until complete. The reaction mixture was concentrated under reduced pressure and purified by prep-HPLC to obtain compound 13-A (6 mg, 12.3 μmol). MS (ESI): m / z = 488.1 [M+H] + .
[0752] 1 H NMR(400MHz, DMSO-d6)δ7.37–7.23(m,2H),7.01(t,J=8.0Hz,1H),5.85–5.67(m,1H),4. 58–4.45(m,3H),4.44–4.31(m,1H),3.97–3.89(m,1H),3.88–3.80(m,1H),3.77–3.68(m, 2H),3.67–3.61(m,1H),3.58–3.48(m,1H),3.30–3.20(m,2H),2.98–2.78(m,4H),2.27–2 .13(m,1H),2.10–2.01(m,4H),2.01–1.99(m,1H),1.98–1.81(m,4H),1.70–1.61(m,1H).
[0753] Example 11: Synthesis of Compound 14
[0754] Step 1: Synthesis of Compound 14-2
[0755] Compound 14-1 (5 g, 23.57 mmol) was dissolved in DCM (50 mL) under ice bath conditions. Triethylamine (3.58 g, 35.36 mmol) was added, and the mixture was stirred for half an hour. Acetyl chloride (2.22 g, 28.29 mmol) was then added, and the reaction was allowed to proceed at room temperature. The reaction was confirmed to be complete by LC-MS. The reaction mixture was purified by column chromatography to give compound 14-2 (5.2 g, 20.46 mmol). MS [ESI]: m / z = 255.1 [M+H] + .
[0756] Step 2: Synthesis of Compound 14-3
[0757] Compound 14-2 (1 g, 3.94 mmol) was dissolved in concentrated sulfuric acid (10 mL) under ice bath conditions, and concentrated nitric acid (0.37 g, 5.9 mmol) was added dropwise. The reaction was monitored by LC-MS until complete. Ice water was slowly added until a solid precipitated, which was then filtered and dried to give crude compound 14-3 (1.0 g, 3.34 mmol). MS [ESI]: m / z = 299.0 [M+H] + .
[0758] Step 3: Synthesis of Compound 14-4
[0759] Under a nitrogen atmosphere, compound 14-3 (1.0 g, 3.34 mmol), 4-(2,4-difluorophenoxy)piperidine (1.07 g, 5.01 mmol), cesium carbonate (3.27 g, 10.03 mmol), Ruphos Pd G3 (279.6 mg, 334.3 μmol), and Ruphos (156.0 mg, 334.3 μmol) were dissolved in 1,4-dioxane (2 mL), purged with nitrogen, and reacted at 90 °C in the reaction apparatus. The reaction was confirmed to be complete by LC-MS, and the reaction mixture was purified by column chromatography to give compound 14-4 (1.1 g, 1.62 mmol). MS [ESI]: m / z = 432.2 [M+H] + .
[0760] Step 4: Synthesis of Compounds 14-5
[0761] Compound 14-4 (0.9 g, 2.09 mmol) was mixed with methanol (10 mL) and palladium on carbon (90 mg, 10% w / w), and the mixture was purged with hydrogen at room temperature. The reaction was confirmed to be complete by LC-MS. The reaction solution was filtered through diatomaceous earth, washed with methanol, concentrated under reduced pressure, and purified by column chromatography to obtain compound 14-5 (0.25 g, 0.62 mmol). MS [ESI]: m / z = 402.2 [M+H] + .
[0762] Step 5: Synthesis of Compound 14
[0763] Under nitrogen protection, compound 14-5 (0.1 g, 0.24 mmol), dichloromethane (2 mL), tetrahydrofuran-3-one (32.17 mg, 0.37 mmol), and tetraisopropyl titanate (70.80 mg, 0.24 mmol) were mixed and reacted at room temperature. Sodium triacetoxyborohydride (158.38 mg, 0.74 mmol) was added, and the reaction continued. The reaction was monitored by LCMS until complete. The reaction mixture was diluted with 10 mL of H₂O and extracted with ethyl acetate. The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, concentrated under reduced pressure, and subjected to Prep-HPLC to give compound 14 (0.11 g, 0.23 mmol). MS [ESI]: m / z = 472.3 [M+H] + . 1 H NMR(400MHz,DMSO-d6)δ7.37–7.22(m,2H),7.08–6.97(m,1H),6.76(s,1H), 6.39(s,1H),4.73(t,J=6.8Hz,1H),4.54–4.38(m,3H),4.06–3.96(m,1H),3 .94–3.78(m,2H),3.78–3.69(m,1H),3.65–3.50(m,3H),3.01–2.89(m,2H), 2.76–2.58(m,4H),2.28–2.18(m,1H),2.10–2.00(m,5H),1.90–1.72(m,3H).
[0764] Referring to the synthesis method of Example 11, by replacing the corresponding parts in Example 11 with the following reactants, the following compounds can be prepared:
[0765] Example 12: Synthesis of Compound 15-A
[0766] Step 1: Synthesis of Compound 15-2
[0767] Under a nitrogen atmosphere, compound 15-1 (10 g, 42.04 mmol), 4-(2,4-difluorophenoxy)piperidine (8.96 g, 42.04 mmol), cesium carbonate (27.39 g, 84.08 mmol), Ruphos Pd G3 (3.52 g, 4.2 mmol), and Ruphos (1.96 g, 4.20 mmol) were dissolved in 1,4-dioxane (100 mL), purged with nitrogen, and reacted at 95 °C in the reaction apparatus. The reaction was confirmed to be complete by LC-MS. The reaction mixture was purified by column chromatography to give compound 15-2 (6.2 g, 16.75 mmol), MS [ESI]: m / z = 371.2 [M+H]. + .
[0768] Step 2: Synthesis of compound 15-3
[0769] Compound 15-2 (6.2 g, 16.75 mmol), dichloroethane (50 mL), and NBS (3.75 g, 21.07 mmol) were reacted at 60 °C. The reaction was monitored to be complete by LC-MS. The reaction solution was concentrated under reduced pressure and purified by column chromatography to obtain compound 15-3 (5.2 g, 11.58 mmol). MS [ESI]: m / z = 449.9 [M+H] + .
[0770] Step 3: Synthesis of Compound 15-4
[0771] Compound 15-3 (5.2 g, 11.58 mmol), potassium 2-(tetrahydro-2H-pyran-2-oxy)ethyltrifluoroborate (6.83 g, 28.95 mmol), cataCXium A Pd-G3 (0.84 g, 1.16 mmol), cesium carbonate (11.3 g, 34.74 mmol), DMAC (40 mL), and water (4 mL) were mixed. After purging with nitrogen, the mixture was heated to 120 °C and stirred. The reaction was confirmed to be complete by LC-MS. After returning to room temperature, the reaction mixture was diluted with ethyl acetate and saturated brine. The aqueous layer was extracted with ethyl acetate, and the organic layers were combined. The organic layers were then washed with brine and dried over anhydrous sodium sulfate. The mixture was concentrated under reduced pressure and purified by column chromatography to obtain compound 15-4 (2.2 g, 4.02 mmol). MS [ESI]: m / z = 548.3 [M+H] + .
[0772] Step 4: Synthesis of Compound 15-5
[0773] Compound 15-4 (2.2 g, 4.02 mmol) was mixed with methanol (20 mL). Under ice bath conditions, HCl (12 N, 2 mL) was added dropwise. The reaction was carried out at room temperature, and LC-MS was used to determine the completeness of the reaction. Sodium bicarbonate was added to adjust the pH to 7-8. The reaction mixture was diluted with ethyl acetate and saturated brine. The aqueous layer was extracted with ethyl acetate, and the organic layers were combined. The organic layers were then washed with brine and dried over anhydrous sodium sulfate. The solution was concentrated under reduced pressure to obtain crude compound 15-5 (1.2 g, 3.16 mmol). MS [ESI]: m / z = 380.1 [M+H] + .
[0774] Step 5: Synthesis of Compounds 15-6
[0775] Compound 15-5 (1.2 g, 3.16 mmol) was mixed with DCM (10 mL). Triethylamine (0.48 g, 4.74 mmol) and DMAP (0.07 g, 0.6 mmol) were added under ice bath conditions. After 15 min, p-toluenesulfonyl chloride (0.72 g, 3.8 mmol) was added. The reaction was allowed to proceed at room temperature. LC-MS analysis confirmed the reaction was complete. The reaction solution was purified by column chromatography to obtain compound 15-6 (0.8 g, 1.5 mmol). MS [ESI]: m / z = 534.0 [M+H] + .
[0776] Step Six: Synthesis of Compounds 15-7
[0777] Compound 15-6 (0.8 g, 1.5 mmol), DMF (8 mL), and H₂O (0.8 mL) were mixed, followed by the addition of sodium hydrosulfide hydrate (0.16 g, 3 mmol). The mixture was purged with nitrogen, heated to 90 °C, and stirred. The reaction was monitored by LC-MS until complete. After returning to room temperature, the reaction mixture was diluted with ethyl acetate and saturated brine. The aqueous layer was extracted with ethyl acetate, and the organic layers were combined. The organic layers were washed with brine, dried over anhydrous sodium sulfate, concentrated under reduced pressure, and purified by column chromatography to obtain compound 15-7 (0.41 g, 1.06 mmol). MS [ESI]: m / z = 396.0 [M+H] + .
[0778] Step 7: Synthesis of Compounds 15-8
[0779] Compound 15-7 (0.41 g, 1.06 mmol), toluene (10 mL), and CMBP (0.97 g, 4.04 mmol) were mixed and heated to 120 °C with stirring. The reaction was monitored by LC-MS until complete. After returning to room temperature, compound 15-8 (200 mg, 0.52 mmol) was purified by column chromatography. MS [ESI]: m / z = 378.0 [M+H] + .
[0780] Step 8: Synthesis of Compounds 15-9
[0781] Compound 15-8 (200 mg, 0.52 mmol), dichloroethane (2 mL), and NBS (113.17 mg, 0.63 mmol) were mixed and reacted at 60 °C. The reaction was confirmed to be complete by LC-MS. The reaction solution was concentrated under reduced pressure and purified by column chromatography to obtain compound 15-9 (120 mg, 0.26 mmol). MS [ESI]: m / z = 456.0 [M+H] + .
[0782] Step Nine: Synthesis of Compound 15-A
[0783] Compound 15-9 (100 mg, 0.22 mmol), 1,4-dioxane (2 mL), cesium carbonate (142 mg, 0.43 mmol), Pd-PEPPSI-IPentCl (42 mg, 0.04 mmol), and (R)-3-aminotetrahydrofuran (28 mg, 0.32 mmol) were mixed. After nitrogen purging, the mixture was heated to 120 °C and stirred. The reaction was monitored by LCMS until complete. The mixture was then allowed to return to room temperature, filtered through diatomaceous earth, washed with dichloromethane, concentrated under reduced pressure, and purified by Prep-HPLC to obtain compound 15-A (10 mg, 0.02 mmol). MS [ESI]: m / z = 463.1 [M+H] + .
[0784] 1 H NMR (400MHz, CD3OD) δ7.24–7.12(m,1H),7.02–6.92(m,1H),6.90–6.82(m, 1H),4.55–4.37(m,2H),4.07–3.95(m,2H),3.90–3.80(m,1H),3.67(dd,J=9 .2,4.0Hz,1H),3.42–3.34(m,1H),3.27–3.20(m,4H),3.02–2.85(m,2H),2 .74–2.63(m,4H),2.36–2.26(m,1H),2.17–2.05(m,2H),2.03–1.80(m,3H).
[0785] Example 14: Synthesis of Compound 16-A
[0786] Step 1: Synthesis of Compound 16-1
[0787] Compound 15-4 (500 mg, 0.91 mmol), dichloroethane (5 mL), and NBS (195.0 mg, 1.1 mmol) were reacted at 60 °C. The reaction was monitored by LC-MS until complete. The reaction solution was concentrated under reduced pressure and purified by column chromatography to obtain compound 16-1 (430 mg, 0.68 mmol). MS [ESI]: m / z = 627.0 [M+H] + .
[0788] Step 2: Synthesis of Compound 16-2
[0789] Compound 16-1 (430 mg, 0.68 mmol), methanol (5 mL), and trifluoroacetic acid (1 mL) were reacted at room temperature. The reaction was monitored to be complete by LCMS. The pH was adjusted to 7–8 with saturated NaHCO3, followed by extraction with ethyl acetate. The organic layer was dried over anhydrous sodium sulfate and purified by column chromatography to obtain compound 16-2 (300 mg, 0.65 mmol). MS [ESI]: m / z = 459.0 [M+H] + .
[0790] Step 3: Synthesis of Compound 16-3
[0791] Compound 16-2 (300 mg, 0.65 mmol), dichloromethane (5 mL), DIPEA (126 mg, 0.98 mmol), DMAP (15.9 mg, 0.13 mmol), and methanesulfonic anhydride (136.8 mg, 0.78 mmol) were reacted at room temperature. The reaction was confirmed to be complete by LCMS. Compound 16-3 (350 mg, 0.58 mmol) was purified by column chromatography. MS [ESI]: m / z = 615.1 [M+H] + .
[0792] Step 4: Synthesis of Compound 16-4
[0793] Compound 16-3 (350 mg, 0.58 mmol), DMSO (5 mL), and ammonia (3 mL) were reacted at 40 °C. The reaction was confirmed to be complete by LC-MS. Subsequently, di-tert-butyl dicarbonate (149 mg, 0.68 mmol) was added, and compound 16-4 (210 mg, 0.38 mmol) was purified by column chromatography. MS [ESI]: m / z = 540.2 [M+H] + .
[0794] Step 5: Synthesis of Compound 16-5
[0795] Compound 16-4 (210 mg, 0.38 mmol), 1,4-dioxane (2 mL), cesium carbonate (253 mg, 0.77 mmol), Pd-PEPPSI-IPentCl (38 mg, 0.04 mmol), and (R)-3-aminotetrahydrofuran (50.8 mg, 0.58 mmol) were reacted after three nitrogen purgings and the temperature was raised to 120 °C. The reaction was confirmed to be complete by LC-MS. After returning to room temperature, the mixture was filtered through diatomaceous earth, washed with dichloromethane, concentrated under reduced pressure, and purified by Prep-HPLC to obtain compound 16-5 (160 mg, 0.03 mmol). MS [ESI]: m / z = 546.1 [M+H] + .
[0796] Step Six: Synthesis of Compound 16-A
[0797] Compound 16-5 (160 mg, 0.03 mmol), methanol (2 mL), and hydrochloric acid (0.5 mL, 12 N) were reacted at room temperature. The reaction was monitored to be complete by LCMS. The mixture was concentrated and evaporated to dryness. The pH was adjusted to 7–8 with saturated NaHCO3, followed by extraction with ethyl acetate. The organic layer was dried over anhydrous sodium sulfate and purified by Prep-HPLC to obtain compound 16-A (120 mg, 0.03 mmol). MS [ESI]: m / z = 446.1 [M+H] + , 1 H NMR (400MHz, CD3OD) δ7.23–7.13(m,1H),7.03–6.94(m,1H),6.92–6.83(m,1H),4.59–4.36(m,2H),4.12–3.95(m,2H),3.93–3.79(m ,1H),3.67(dd,J=9.0,3.8Hz,1H),3.39–3.32(m,2H),3.02–2.85(m,10H),2.37–2.26(m,1H),2.17–2.06(m,2H),1.99–1.84(m,3H).
[0798] Example 15: Synthesis of Compound 17-A
[0799] Compound 16-A (50 mg, 0.11 mmol), dichloromethane (2 mL), DIPEA (43.5 mg, 0.33 mmol), and acetic anhydride (17.19 mg, 0.16 mmol) were reacted at room temperature. The reaction was confirmed to be complete by LCMS. Compound 17-A (30 mg, 0.06 mmol) was prepared and purified by Prep-HPLC. MS [ESI]: m / z = 488.1 [M+H] + , 1H NMR (400MHz, CD3OD) δ7.23–7.11(m,1H),7.04–6.94(m,1H),6.91–6.81(m,1H),4.56–4.39(m,2H),4.07–3.95(m,2H),3.91–3.79(m,1H), 3.78–3.65(m,5H),3.43–3.32(m,2H),3.06–2.86(m,6H),2.38–2.27(m,1H),2.18(d,J=2.0Hz,3H),2.15–2.05(m,2H),1.99–1.87(m,3H).
[0800] Example 16: Synthesis of Compound 18-A
[0801] Compound 16-A (50 mg, 0.11 mmol), dichloromethane (2 mL), paraformaldehyde (107 mg, 0.08 mmol), and sodium cyanoborohydride (4.2 mg, 0.06 mmol) were reacted at room temperature. The reaction was monitored to be complete by LCMS. The reaction was quenched with brine, and compound 18-A (25 mg, 0.05 mmol) was prepared and purified by Prep-HPLC. MS [ESI]: m / z = 460.1 [M+H] + , 1 H NMR (400MHz, CD3OD) δ7.24–7.10(m,1H),7.02–6.93(m,1H),6.90–6.80(m,1H),4.56–4.37(m,2H),4.08–3.92(m,2H),3.90–3.80(m,1H),3.67(dd, J=9.2,4.0Hz,1H),3.42–3.32(m,2H),3.03–2.88(m,6H),2.68–2.56(m,4 H),2.38(s,3H),2.37–2.27(m,1H),2.16–2.03(m,2H),2.00–1.87(m,3H).
[0802] Referring to the synthesis method of Example 16, by replacing the corresponding parts in Example 16 with the following reactants, the following compounds can be prepared:
[0803] Example 17: Synthesis of Compound 25
[0804] Compound Int 2 (100 mg, 0.33 mmol) was dissolved in 1,4-dioxane (1 mL), and 4-(2,4-difluorophenoxy)piperidine (107 mg, 0.50 mmol), Pd-PEPPSI-IPentCl (32 mg, 0.03 mmol), and cesium carbonate (327 mg, 1.0 mmol) were added at room temperature. The reaction was carried out at 115 °C for 16 hours under a nitrogen atmosphere. After the reaction was completed, the temperature was allowed to return to room temperature. The reaction solution was filtered, and the filtrate was concentrated under reduced pressure. The crude product was purified by Prep-HPLC to give compound 25 (18.79 mg, 0.04 mmol), MS m / z (ESI): 430.95 [M+H]. + .
[0805] 1 H NMR (400MHz, DMSO) δ7.35-7.25(m,2H),7.05-6.97(m,1H),6.82(s,1H),6.15(s,1H),5.36(d,J=6.0Hz,1H),4.85(t,J=6.0Hz,2H),4.90-4.79 (m,6H),3.89-3.82(m,2H),3.03-2.93(m,2H),2.84-2.77(m,2H),2.74 -2.66(m,2H),2.11-2.02(m,2H),1.95-1.85(m,2H),1.68-1.59(m,2H).
[0806] Referring to the synthesis method of Example 17, by replacing the corresponding parts in Example 17 with the following reactants, the following compounds can be prepared:
[0807] Example 18: Synthesis of Compound 49
[0808] Compound Int 3 (90 mg, 0.30 mmol) was dissolved in 1,4-dioxane (1 mL), and 4-(2,4-difluorophenoxy)piperidine (96 mg, 0.45 mmol), Pd-PEPPSI-IPentCl (29 mg, 0.03 mmol), and cesium carbonate (295 mg, 0.90 mmol) were added at room temperature. The reaction was carried out under a nitrogen atmosphere and microwaved at 115 °C for 2 hours. After the reaction was complete, the temperature was allowed to return to room temperature. The reaction solution was filtered, and the filtrate was concentrated under reduced pressure. The crude product was purified by prep-HPLC to give compound 49 (30.55 mg, 0.07 mmol), MS m / z (ESI): 431.0 [M+H]. + .
[0809] 1H NMR (400MHz, DMSO) δ7.34-7.25(m,2H),7.06-6.98(m,1H),6.75(s,1H),6.08(s,1H),5.25(d,J=5.6Hz,1H),4.84(t,J=6.0Hz,2H),4 .54-4.41(m,4H),3.63-3.54(m,4H),3.03-2.95(m,2H),2.82-2.74(m,4H),2.73-2.66(m,2H),2.13-2.02(m,2H),1.96-1.84(m,2H).
[0810] Example 19: Synthesis of compounds 34-A and 34-B
[0811] Step 1: Synthesis of Compounds 34-A and 34-B
[0812] Compound Int 2 (160 mg, 0.53 mmol), 4-((2,4-difluorophenyl)fluoromethyl)piperidine (184 mg, 0.80 mmol), Pd-PEPPSI-IPentCl (52 mg, 0.05 mmol), and cesium carbonate (524 mg, 1.60 mmol) were dissolved in ultradry 1,4-dioxane (2 mL). The mixture was stirred at 115 °C for 16 hours under a nitrogen atmosphere. After the reaction was complete, the mixture was filtered, and the filtrate was concentrated under reduced pressure. The crude product was purified by rapid silica gel column chromatography to obtain compound 34. Compound 34 was then separated by SFC (column: DAICEL OD-H 4.6 mm * 250 mm L 5 μm, mobile phase: CO2 / MEOH [0.1% NH3 (7 M methanol solution)] = 75 / 25) to obtain compound 34-fraction 1 (compound 34-A or 34-B) and compound 34-fraction 2 (compound 34-B or 34-A).
[0813] Compound 34 - Component 1: 21.23 mg, retention time: 7.42 min. MS m / z (ESI): 447.10 [M+H] + .
[0814] 1H NMR (400MHz, DMSO) δ7.63-7.49(m,1H),7.38-7.27(m,1H),7.22-7.15(m,1H),6.79(s,1H),6. 14(s,1H),5.64-5.44(m,1H),5.26(d,J=6.0Hz,1H),4.88-4.80(m,2H),4.57-4.47(m,1H),4.4 7-4.39(m,4H),3.90-3.80(m,2H),3.12-2.89(m,2H),2.84-2.73(m,2H),2.57-2.53(m,1H),2 .47-2.42(m,1H),2.09-1.92(m,2H),1.75-1.60(m,3H),1.59-1.45(m,1H),1.34-1.26(m,1H).
[0815] Compound 34 - Component 2: 20.29 mg, retention time: 6.69 min. MS m / z (ESI): 447.00 [M+H] + .
[0816] 1 H NMR (400MHz, DMSO) δ7.63-7.49(m,1H),7.38-7.27(m,1H),7.22-7.15(m,1H),6.79(s,1H),6. 14(s,1H),5.64-5.44(m,1H),5.26(d,J=6.0Hz,1H),4.88-4.80(m,2H),4.57-4.47(m,1H),4.4 7-4.39(m,4H),3.90-3.80(m,2H),3.12-2.89(m,2H),2.84-2.73(m,2H),2.57-2.53(m,1H),2 .47-2.42(m,1H),2.09-1.92(m,2H),1.75-1.60(m,3H),1.59-1.45(m,1H),1.34-1.26(m,1H).
[0817] Referring to the synthesis method of Example 18, by replacing Int3 in Example 18 with the following reactants, the following compounds can be prepared:
[0818] Example 20: Synthesis of compounds 55-A and 55-B
[0819] Step 1: Synthesis of Compounds 55-A and 55-B
[0820] Compound Int 3 (100 mg, 0.33 mmol), 4-((2,4-difluorophenyl)fluoromethyl)piperidine (115 mg, 0.50 mmol), Pd-PEPPSI-IPentCl (32 mg, 0.03 mmol), and cesium carbonate (327 mg, 1.00 mmol) were dissolved in ultradry 1,4-dioxane (1 mL). The mixture was stirred at 115 °C for 16 hours under a nitrogen atmosphere. After the reaction was complete, the mixture was filtered, and the filtrate was concentrated under reduced pressure. The crude product was purified by silica gel column chromatography to obtain compound 55. Compound 55 was then separated by SFC (column: DAICEL IC 4.6 mm I.D. * 250 mmL 5 μm, mobile phase: CO2 / MEOH [0.1% NH3 (7 M methanol solution)] = 60 / 40) to obtain compound 55-fraction 1 (compound 55-A or 55-B) and compound 55-fraction 2 (compound 55-B or 55-A).
[0821] Compound 55 - Component 1: 20.14 mg, retention time: 4.88 min. MS m / z (ESI): 447.0 [M+H] + .
[0822] 1 H NMR (400MHz, DMSO) δ7.63-7.51(m,1H),7.38-7.27(m,1H),7.25-7.11(m,1H),6.72(s,1 H),6.08(s,1H),5.63-5.44(m,1H),5.15(d,J=6.0Hz,1H),4.87-4.78(m,2H),4.49(m,1 H),4.45-4.38(m,2H),3.64-3.51(m,4H),3.10-2.93(m,2H),2.80-2.70(m,4H),2.46-2 .42(m,2H),2.06-1.90(m,2H),1.72-1.59(m,1H),1.57-1.47(m,1H),1.33-1.25(m,1H).
[0823] Compound 55 - Component 2: 16.31 mg, retention time: 3.98 min. MS m / z (ESI): 447.0 [M+H] + .
[0824] 1H NMR (400MHz, DMSO) δ7.63-7.51(m,1H),7.38-7.27(m,1H),7.25-7.11(m,1H),6.72(s,1 H),6.08(s,1H),5.63-5.44(m,1H),5.15(d,J=6.0Hz,1H),4.87-4.78(m,2H),4.49(m,1 H),4.45-4.38(m,2H),3.64-3.51(m,4H),3.10-2.93(m,2H),2.80-2.70(m,4H),2.46-2 .42(m,2H),2.06-1.90(m,2H),1.72-1.59(m,1H),1.57-1.47(m,1H),1.33-1.25(m,1H).
[0825] Example 21: Synthesis of Compound 68
[0826] Step 1: The synthesis of compound 68-2 can be referred to Compound 14-2 in Example 11.
[0827] Step 2: The synthesis of compound 68-3 can be referred to Compound 14-3 in Example 11.
[0828] Step 3: The synthesis of compound 68-4 can be referred to Compound 14-4 in Example 11.
[0829] Step 4: The synthesis of compound 68-5 can be referred to Compound 14-5 in Example 11.
[0830] Step 5: Synthesis of Compound 68
[0831] Compound 68-5 (22.5 mg, 0.056 mmol), dihydrofuran-3(2H)-one (36 mg, 0.42 mmol), Pd / C (3 mg), methanol (4 mL), and acetic acid (30 mg) were added to a single-necked flask. The mixture was stirred for 30 min, purged with hydrogen, and allowed to react in a balloon at room temperature for 3.5 h. The reaction was monitored by LC-MS until completion. The mixture was filtered, concentrated under reduced pressure, and the crude product was purified by pre-HPLC to obtain compound 68 (2.0 mg, 4.42 μmol). MS [ESI]: m / z = 472.1 [M+H] + .
[0832] 1H NMR (400MHz, DMSO) δ7.36–7.25(m,2H),7.08–6.97(m,1H),6.79(d,J=8.6Hz,1H),6.38 (d,J=1.6Hz,1H),4.78–4.70(m,1H),4.64-4.32(m,3H),4.06–3.98(m,1H),3.93–3.79( m,2H),3.77–3.69(m,1H),3.59(t,J=5.9Hz,2H),3.55(dd,J=8.8,3.5Hz,1H),3.03–2. 88(m,2H),2.79–2.59(m,4H),2.28–2.15(m,1H),2.11–1.96(m,5H),1.92–1.70(m,3H).
[0833] Referring to the synthesis method of Example 21, by replacing the corresponding parts in Example 21 with the following reactants, the following compounds can be prepared:
[0834] Example 23: Synthesis of Compound 170-A
[0835] Step 1: Preparation of Compound 170-1
[0836] Under nitrogen protection, compound Int 1-6 (400 mg, 1.07 mmol) and 2.5 M lithium aluminum hydride THF solution (0.2 mL, 0.54 mmol) were dissolved in 4 mL of THF, and the mixture was stirred at 0 °C for 2 hours. The reaction was confirmed to be complete by LC-MS. The reaction mixture was quenched dropwise in ice water, extracted with ethyl acetate, and the organic phase was concentrated under reduced pressure. The crude product was purified by silica gel column chromatography to give compound 170-1 (171 mg, 0.475 mmol). MS [ESI]: m / z = 361.2 [M+H] + .
[0837] Step 2: Preparation of Compound 170-2
[0838] Compound 170-1 (171 mg, 0.475 mmol) was dissolved in DCM (4 mL), and triethylamine (144 mg, 1.425 mmol) was added at 0 °C and stirred for 0.5 h. Acetyl chloride (39 mg, 0.5 mmol) was then added, and the mixture was stirred at 0 °C for 2 h. The reaction was confirmed to be complete by LC-MS. The solution was concentrated under reduced pressure, and the crude product was purified by silica gel column chromatography to give compound 170-2 (97 mg, 0.24 mmol). MS [ESI]: m / z = 403.2 [M+H] + .
[0839] Step 3: Preparation of compound 170-3
[0840] Compound 170-2 (97 mg, 0.24 mmol) was dissolved in DCM (2 mL) at room temperature, followed by the addition of NBS (42 mg, 0.24 mmol) and stirring for 2 hours. The reaction was confirmed to be complete by LC-MS. The reaction solution was quenched dropwise in a saturated sodium bisulfite solution, extracted with ethyl acetate, and the organic phase was concentrated under reduced pressure. The crude product was purified by silica gel column chromatography to give compound 170-3 (60 mg, 0.125 mmol). MS [ESI]: m / z = 481.1 [M+H] + Step 4: Preparation of compound 170-A
[0841] Compound 170-3 (60 mg, 0.125 mmol), (R)-tetrahydrofuran-3-amine (17 mg, 0.2 mmol), RuPhos (6 mg, 0.0125 mmol), RuPhos Pd G3 (10 mg, 0.0125 mmol), and cesium carbonate (122 mg, 0.375 mmol) were dissolved in toluene (2 mL) and reacted at 120 °C for 12 h. The reaction was confirmed to be complete by LC-MS. The crude product was purified by pre-HPLC to give compound 170-A (14.1 mg, 0.03 mmol). MS [ESI]: m / z = 488.1 [M+H] + .
[0842] 1 H NMR (400MHz, DMSO-d6) δ7.33–7.22(m,2H),7.04–6.97(m,1H),5.77(m,1H),4.59–4.43(m,3H),4.40(m,1H),3.86(m,4H),3 .57–3.51(m,2H),3.27(m,2H),2.99–2.81(m,4H),2.17(m,1H),2.04(m,2H),2.00(m,3H),1.98–1.81(m,4H),1.66(s,1H).
[0843] Example 25: Synthesis of Compound 19-A
[0844] Step 1: Synthesis of Compound 19-2
[0845] Compound 19-1 (10 g, 57.95 mmol), 4-(2,4-difluorophenoxy)piperidine (14.83 g, 69.54 mmol), cesium fluoride (8.80 g, 57.95 mmol), and DIPEA (7.49 g, 57.95 mmol) were dissolved in DMF (100 mL), and the mixture was heated to 90 °C and reacted for 12 h. The reaction was confirmed to be complete by LC-MS. After cooling to room temperature, the mixture was extracted with ethyl acetate, and the combined organic layers were washed with saturated brine, dried over anhydrous sodium sulfate, concentrated under reduced pressure, and the crude product was purified by silica gel column chromatography to give compound 19-2 (16.2 g, 45.8 mmol). MS [ESI]: m / z = 350.2 [M+H] + .
[0846] Step 2: Synthesis of Compound 19-3
[0847] Under a nitrogen atmosphere, compound 19-2 (10 g, 28.63 mmol) and dimethylethylenediamine (10.0 g, 114.5 mmol) were dissolved in toluene (100 mL). Trimethylaluminum (4.13 g, 57.25 mmol) was slowly added dropwise in an ice bath, and the mixture was heated to 120 °C for 6 hours. The reaction was confirmed to be complete by LC-MS. After cooling to room temperature, the pH was adjusted to neutral with sodium bicarbonate. The mixture was extracted with ethyl acetate, and the organic layers were combined, washed with saturated brine, dried over anhydrous sodium sulfate, concentrated under reduced pressure, and purified by silica gel column chromatography to give compound 19-3 (6.0 g, 18.0 mmol). MS [ESI]: m / z = 334.2 [M+H] + .
[0848] Step 3: Synthesis of Compound 19-4
[0849] Compound 19-3 (6.0 g, 18.0 mmol), dichloroethane (50 mL), and NBS (3.2 g, 18.0 mmol) were added to a single-necked flask. The mixture was heated to 60 °C and reacted for 4 hours. The reaction was confirmed to be complete by LC-MS. The mixture was concentrated under reduced pressure, and the crude product was purified by silica gel column chromatography to obtain compound 19-4 (6.2 g, 15.0 mmol). MS [ESI]: m / z = 413.3 [M+H] + .
[0850] Step 4: Synthesis of Compound 19-5
[0851] Compound 19-4 (6.2 g, 15.0 mmol), (E)-3-(4,4,5,5-tetramethyl-1,3,2-dioxaboran-2-yl)acrylate (5.1 g, 22.56 mmol), DMAC (40 mL), water (4 mL), cesium carbonate (14.7 g, 45.1 mmol), and Pd(dppf)Cl2 (1.10 g, 1.50 mmol) were added to a single-necked flask. The mixture was purged with nitrogen, heated to 120 °C, and stirred for 6 hours. The reaction was confirmed to be complete by LC-MS. After cooling to room temperature, the mixture was extracted with ethyl acetate, and the organic layers were combined, washed with saturated brine, dried over anhydrous sodium sulfate, concentrated under reduced pressure, and purified by silica gel column chromatography to give compound 19-5 (4.2 g, 9.73 mmol). MS [ESI]: m / z = 432.2 [M+H] + .
[0852] Step 5: Synthesis of Compound 19-6
[0853] Compound 19-5 (4.2 g, 9.73 mmol), methanol (30 mL), and palladium on carbon (420 mg, 10% w / w) were added to a single-necked flask. The mixture was purged with hydrogen and reacted at room temperature for 12 hours. The reaction was confirmed to be complete by LC-MS. The reaction solution was filtered through diatomaceous earth, washed with methanol, concentrated under reduced pressure, and the crude product was purified by silica gel column chromatography to give compound 19-6 (3.8 g, 8.77 mmol). MS [ESI]: m / z = 434.2 [M+H] + .
[0854] Step Six: Synthesis of Compound 19-7
[0855] Compound 19-6 (3.8 g, 8.77 mmol) was added to a single-necked flask, followed by ultra-dry tetrahydrofuran (30 mL). The mixture was purged with nitrogen, and LAH (17.53 mmol) was slowly added at -78 °C. The reaction was allowed to proceed for 4 h, then slowly brought to room temperature for 2 h. The reaction was confirmed to be complete by LC-MS. The reaction solution was quenched with water in an ice bath, filtered, concentrated under reduced pressure, and the crude product was purified by silica gel column chromatography to obtain compound 19-7 (2.2 g, 5.59 mmol). MS [ESI]: m / z = 394.2 [M+H] + .
[0856] Step 7: Synthesis of Compound 19-8
[0857] Compound 19-7 (2.2 g, 5.59 mmol) and 1,4-dioxane (20 mL) were added to a single-necked flask. TMSOTf (1.2 g, 5.59 mmol) was slowly added at room temperature, and the reaction was carried out at 90 °C for 4 h. The reaction was confirmed to be complete by LC-MS. The pH was adjusted to neutral with sodium bicarbonate solution, and the mixture was extracted with ethyl acetate, washed with saturated brine, dried over anhydrous sodium sulfate, concentrated under reduced pressure, and purified by silica gel column chromatography to give compound 19-8 (1.5 g, 4 mmol). MS [ESI]: m / z = 376.2 [M+H] + .
[0858] Step 8: Synthesis of Compound 19-9
[0859] Compound 19-8 (1.5 g, 4 mmol), dichloromethane (10 mL), and NBS (0.71 g, 4 mmol) were added to a single-necked flask. The mixture was reacted at 60 °C for 4 hours. The reaction was confirmed to be complete by LC-MS. The mixture was concentrated under reduced pressure, and the crude product was purified by silica gel column chromatography to obtain compound 19-9 (1.3 g, 2.86 mmol). MS [ESI]: m / z = 454.2 [M+H] + .
[0860] Step 7: Synthesis of Compound 19-A
[0861] Under a nitrogen atmosphere, compound 19-9 (0.14 g, 0.31 mmol), 4-(2,4-difluorophenoxy)piperidine (81.44 mg, 0.38 mmol), cesium carbonate (207.41 mg, 636.57 μmol), Ruphos Pd G3 (26.65 mg, 31.83 μmol), and Ruphos (14.85 mg, 31.83 μmol) were dissolved in 1,4-dioxane (2 mL), and the mixture was purged with nitrogen and reacted at 95 °C for 12 h. The reaction was confirmed to be complete by LC-MS. The reaction solution was purified by Prep-HPLC to give compound 19-A (40 mg, 0.08 mmol), MS [ESI]: m / z = 461.1 [M+H]. + .
[0862] 1H NMR (400MHz, DMSO-d6) δ7.35–7.24(m,2H),7.05–6.97(m,1H),5.78(d,J=5.2H z,1H),4.66–4.58(m,1H),4.56–4.38(m,2H),4.11–4.01(m,1H),3.95–3.68(m ,4H),3.61–3.49(m,1H),3.32-3.28(m,2H),3.04–2.72(m,4H),2.24–2.11(m, 1H),2.04(s,2H),2.00–1.81(m,3H),1.78–1.59(m,2H),1.41(d,J=6.4Hz,3H).
[0863] Example 28: Synthesis of Compound 367
[0864] At room temperature, triethylamine (70 mg, 0.6 mmol) and acetic anhydride (56 mg, 0.5 mmol) were added to a 5 mL solution of compound Int 7 (0.2 g, 0.46 mmol) in dichloromethane, and the mixture was reacted at room temperature for 4 hours. The reaction was confirmed to be complete by LC-MS. The solution was concentrated under reduced pressure, and the crude product was purified by pre-HPLC to give compound 367 (0.18 g, 0.37 mmol). MS [ESI]: m / z = 475.1 [M+H] + .
[0865] 1 H NMR (400MHz, DMSO) δ7.38–7.24(m,2H),7.09–6.96(m,1H),6.76–6.55(m,1H),5.28–5.14(m,1H),4.92–4.79(m,2H),4.61–4. 40(m,6H),4.13–3.94(m,2H),3.82–3.72(m,2H),3.34–3.22(m,2H),2.92–2.77(m,2H),2.14–1.93(m,5H),1.93–1.79(m,2H).
[0866] Referring to the synthesis method of Example 28, by replacing the following reactants, the following compounds can be prepared:
[0867] Example 32: Synthesis of Compound 106
[0868] Compound Int 9 (1.1 g, 2.5 mmol) was dissolved in toluene (15 mL), and compound Int 2-7 (273 mg, 3.7 mmol), Cs₂CO₃ (2.4 g, 7.5 mmol), and Pd-PEPPSI-IPentCl (121 mg, 0.12 mmol) were added. The reaction was carried out under nitrogen purging at 90 °C for 16 h. The reaction was quenched with water, extracted with ethyl acetate, washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated. The crude product was purified by pre-HPLC to give compound 106 (314 mg, 0.72 mmol). MS [ESI]: m / z = 433.2 [M+H] + .
[0869] 1 H NMR (400MHz, DMSO) δ7.34-7.23(m,2H),7.04-6.96(m,1H),6.86(s,1H),5.97(s,1H),5.53(d,J=4.7 Hz,1H),4.84(m,2H),4.49(m,6H),3.97–3.89(m,2H),3.85-3.78(m,2H),3.05-2.89(m,2H),2.67(m 2H),2.06(m,2H),1.98-1.84(m,2H).
[0870] Referring to the synthesis method of Example 32, by replacing the following reactants with compound Int 9, the following compounds can be prepared:
[0871] Referring to the synthesis method of Example 32, by replacing compounds Int 9 and Int 2-7 with reactants 1 and 2 respectively, the following compounds can be prepared:
[0872] Example 38: Synthesis of Compound 376-A
[0873] Under ice bath conditions, formaldehyde aqueous solution (30 mg, 0.4 mmol) was added to a 2 mL solution of compound 370-A (0.1 g, 0.23 mmol) in dichloromethane. Sodium triacetoxyborohydride (71 mg, 0.33 mmol) was then slowly added, and the reaction was allowed to proceed for 12 hours at room temperature. The reaction was confirmed to be complete by LC-MS. The solution was diluted with water, extracted with ethyl acetate, washed with saturated brine, dried over anhydrous sodium sulfate, filtered, concentrated under reduced pressure, and the crude product was purified by Pre-HPLC to obtain compound 376-A (0.05 g, 0.1 mmol). MS [ESI]: m / z = 461.1 [M+H] + .
[0874] 1H NMR (400MHz, DMSO) δ7.41–7.25(m,2H),7.11–6.95(m,1H),6.86(s,1H),5.30(d,J=6.4 Hz,1H),4.51–4.32(m,2H),3.98–3.88(m,3H),3.84(dd,J=14.2,7.6Hz,1H),3.71(m,1 H),3.61(s,2H),3.50(dd,J=8.8,4.4Hz,1H),3.10–2.89(m,2H),2.88–2.76(m,2H),2. 74–2.58(m,2H),2.28(s,3H),2.25–2.11(m,1H),2.12–2.01(m,2H),1.96–1.77(m,3H).
[0875] Example 43: Synthesis of Compound 409
[0876] DCM (5 mL) was added to compound 408 (20 mg, 0.045 mmol), followed by mCPBA (9.3 mg, 0.054 mmol). The reaction was carried out under nitrogen atmosphere at room temperature for 30 minutes. The reaction was monitored by TCL until complete. The mixture was quenched with saturated sodium bicarbonate solution. The mixture was purified by pre-HPLC to obtain compound 409 (11 mg, 0.024 mmol). MS [ESI]: m / z = 463.1 [M+H] + .
[0877] 1 H NMR (400MHz, DMSO-d6) δ7.37–7.25(m,2H),7.07–6.95(m,1H),6.83(s,1H),6.16(s,1H),5.30(d,J=5.2Hz,1H),4.91–4.79 (m,2H),4.58–4.30(m,4H),3.62–3.44(m,2H),3.08–2.85(m,4H),2.78–2.59(m,4H),2.48–2.37(m,2H),2.17–1.81(m,4H).
[0878] Other compounds disclosed herein can also be prepared by referring to the above synthetic method.
[0879] Biological tests
[0880] Experimental Example 1: Evaluation of the reverse agonistic activity of compounds towards GPR6
[0881] Using the HEK293T cell line stably expressing the GPR6 receptor, after stimulation with different concentrations of test compounds, [the cells were analyzed / performed]... The Ultra cAMP Kit (Revvity) measures the reverse agonistic effect of compounds on the GPR6 receptor.
[0882] HEK293T-GPR6 cells in good growth condition were seeded into 6-well plates, and doxycycline was added to induce GPR6 expression. The cells were cultured for 24 h. Cells were then digested and seeded into 384-well plates at 5000 cells / well. The disclosed test compound, positive control (final concentration 10 μM CVN424), and negative control (0.1% DMSO) were added to the corresponding wells and incubated for 40 minutes. The assay reagents were added according to the kit instructions. The microplate reader was used to read the values at 665 nm and 620 nm under excitation at a detection wavelength of 320 nm.
[0883] The activity percentage (%) was calculated by plotting the signal value against the compound concentration using the activation rate formula: Activity percentage (%) = (analyte value - negative control value) / (positive control value - negative control value) * 100%, where "positive control value" is the average value of 10 μM CVN424 and "negative control value" is the average value of 0.1% DMSO. Curve fitting was performed using the nonlinear regression method in GraphPad Prism software. 50 calculate.
[0884] Table 1. Reverse agonistic activity of the compounds disclosed herein against the GPR6 receptor.
[0885] Experimental results show that the compound disclosed herein exhibits good inverse agonistic activity against the GPR6 receptor.
[0886] In addition to those described herein, various modifications to this disclosure will be apparent to those skilled in the art based on the foregoing description. Such modifications are also intended to fall within the scope of the appended claims.
Claims
1. A compound, or a stereoisomer, tautomer, polymorph, solvate, N-oxide, isotopically labeled compound, or a metabolite, prodrug, or pharmaceutically acceptable salt or ester thereof, wherein the compound has a structure as shown in Formula I: in, Ring A is selected from 3-14 membered heterocycles and 3-14 membered carbocycles, wherein the heterocycle or carbocycle is optionally composed of one or more elements each independently selected from H, D, halogen, hydroxyl, amino, cyano, nitro, C. 1-6 Alkyl, C 3-6 Cycloalkyl, 3-12 membered heterocyclic, 5-10 membered heteroaryl, C 6-10 Aryl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy groups, -C 1-6 Alkyl-OR a -C(=O)-(CH2) p -OR a -C(=O)-(CH2) p -NR a R b and -C 1-6 Alkylene-NR a R b Substituents of the substituents; Y is selected from -CR a R b -、-O-、-NR a -、-S-、-S(O)- and -S(O)2-; X 1 and X 2 Each is independently selected from CR and N; R is independently selected from H, D, halogen, hydroxyl, cyano, nitro, amino, C 1-6 Alkyl, 3-12 membered heterocyclic, 5-10 membered heteroaryl, C 6-10 Aryl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Halogenated alkyl and C 3-10 Cycloalkyl; preferably, R is independently selected from H, halogen, hydroxyl, cyano, nitro, amino, C 1-6 Alkyl, 3-12 membered heterocyclic, 5-10 membered heteroaryl, C 6-10 Aryl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Halogenated alkyl groups and C 3-10 cycloalkyl; L is selected from 4-8 membered carbocyclic rings, 3-10 membered heterocyclic groups, and 5-10 membered heteroaryl groups, wherein the carbocyclic ring, heterocyclic group, or heteroaryl group is optionally selected by one or more independently from H, D, halogen, hydroxyl, amino, cyano, nitro, C 1-6 Alkyl, C 3-6 Cycloalkyl, 3-12 membered heterocyclic, 5-10 membered heteroaryl, C 6-10 Aryl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy groups, -C 1-6 Alkyl-OR a -C(=O)-(CH2) p -OR a -C(=O)-(CH2) p -NR a R b and -C 1-6 Alkylene-NR a R b The substituents are preferably selected from one or more groups, each independently chosen from H, halogen, hydroxyl, amino, cyano, nitro, C. 1-6 Alkyl, C 3-6 Cycloalkyl, 3-12 membered heterocyclic, 5-10 membered heteroaryl, C 6-10 Aryl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy groups, -C 1-6 Alkyl-OR a -C(=O)-(CH2) p -OR a -C(=O)-(CH2) p -NR a R b and -C 1-6 Alkylene-NR a R b Substituents of the substituents; Z is selected from covalent bond, =C(R) a )-、-CR a R b -、-O-CR a R b -、C(=NSO2R b ), C(=O)NR b -NR a -, -O-, -S-, -C(=O)-, -S(=O)-, -S(=O)2-, S(=O)(=NR b ) and S(=NR b )2; R 1 Selected from H, D, halogen, cyano, C 1-6 Alkyl, C 3-6 cycloalkyl, C 1-6 Haloalkyl, C 1-6 Haloalkoxy, -C(=O)R c -C 1-6 Alkyl-C(=O)-NR a R b NR a R b OR a SR a -NR a C(=O)R b -C(=O)-OR a -SOR a -SO2R a C 6-10 Aryl, 5-10-membered heteroaryl, and 3-12-membered heterocyclic groups, wherein the alkyl, cycloalkyl, aryl, heteroaryl, or heterocyclic group is optionally selected by one or more groups, each independently selected from H, D, =O, halogen, hydroxyl, amino, cyano, nitro, C 1-6 Alkyl, C 3-6 cycloalkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Hydroxyalkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy group, -C(=O)-(CH2) p -OR a -C(=O)-(CH2) p -NR a R b and -C 1-6 Alkylene-NR a R b Substituents; preferably, R 1 Selected from H, halogen, cyano, C 1-6 Alkyl, C 3-6 cycloalkyl, C 1-6 Haloalkyl, C 1-6 Haloalkoxy, -C(=O)R c -C 1-6 Alkyl-C(=O)-NR a R b NR a R b OR a SR a -NR a C(=O)R b -C(=O)-OR a -SOR a -SO2R a C 6-10 Aryl, 5-10-membered heteroaryl, and 3-12-membered heterocyclic groups, wherein the alkyl, cycloalkyl, aryl, heteroaryl, or heterocyclic group is optionally selected by one or more groups, each independently selected from H, =O, halogen, hydroxyl, amino, cyano, nitro, C 1-6 Alkyl, C 3-6 cycloalkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Hydroxyalkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy group, -C(=O)-(CH2) p -OR a -C(=O)-(CH2) p -NR a R b and -C 1-6 Alkylene-NR a R b The substituents are preferably selected from one or more groups, each independently chosen from H, halogen, hydroxyl, amino, cyano, nitro, C. 1-6 Alkyl, C 3-6 cycloalkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Hydroxyalkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy group, -C(=O)-(CH2) p -OR a -C(=O)-(CH2) p -NR a R b and -C 1-6 Alkylene-NR a R b Substituents of the substituents; R a and R b Each is independently selected from H, D, halogen, hydroxyl, cyano, 3-12 membered heterocyclic group, 5-10 membered heteroaryl, C 6-10 Aryl, C 1-6 Alkyl, C 3-6 cycloalkyl, C 3-6 cycloalkyl-OR c C 1-6 Alkoxy, C 1-6 Haloalkyl, C 1-6 Haloalkoxy, -C(=O)R c -C 1-6 Alkyl-C(=O)-NR c R d NR c R d -NR c C(=O)R d -C(=O)-OR c -OR c -SR c -SOR c and -SO2R c The alkyl, cycloalkyl, alkoxy, haloalkyl, haloalkoxy, heterocyclic, heteroaryl, or aryl group is optionally selected by one or more groups, each independently selected from H, D, halogen, hydroxyl, amino, cyano, C 1-6 Alkyl, C 3-6 cycloalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkyl groups and C 1-6 Substituents of haloalkoxy groups; preferably, R a and R b Each is independently selected from H, halogen, hydroxyl, cyano, 3-12 membered heterocyclic group, 5-10 membered heteroaryl, C 6-10 Aryl, C 1-6 Alkyl, C 3-6 cycloalkyl, C 3-6 cycloalkyl-OR c C 1-6 Alkoxy, C 1-6 Haloalkyl, C 1-6 Haloalkoxy, -C(=O)R c -C 1-6 Alkyl-C(=O)-NR c R d NR c R d -NR c C(=O)R d -C(=O)-OR c -OR c -SR c -SOR c and -SO2R c The alkyl, cycloalkyl, alkoxy, haloalkyl, haloalkoxy, heterocyclic, heteroaryl, or aryl group is optionally selected by one or more groups, each independently selected from H, halogen, hydroxyl, amino, cyano, C 1-6 Alkyl, C 3-6 cycloalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkyl groups and C 1-6 Substituents of haloalkoxy groups; Or, R a R b The atoms bonded thereto form 3-8 membered carbon rings, 3-12 membered heterocyclic groups, or 5-10 membered heteroaryl groups, wherein the carbon ring, heterocyclic group, or heteroaryl group is optionally composed of one or more elements independently selected from H, D, halogen, hydroxyl, amino, cyano, =O, C. 1-6 Alkyl, C 3-6 cycloalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkyl groups and C 1-6 The alkyl halogen is preferably substituted by one or more groups, each independently selected from H, halogen, hydroxyl, amino, cyano, =O, C. 1-6 Alkyl, C 3-6 cycloalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkyl groups and C 1-6 Substituents of haloalkoxy groups; R c and R d Each is independently selected from H, D, halogen, hydroxyl, cyano, 3-12 membered heterocyclic group, 5-10 membered heteroaryl, C 6-10 Aryl, C 1-6 Alkyl, C 3-6 cycloalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkyl groups and C 1-6 The alkyl, cycloalkyl, alkoxy, haloalkyl, haloalkoxy, heterocyclic, heteroaryl, or aryl group is optionally selected by one or more groups, each independently selected from H, D, halogen, hydroxyl, amino, cyano, C. 1-6 Alkyl, C 3-6 cycloalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkyl groups and C 1-6 Substituents of haloalkoxy groups; preferably, R c and R d Each is independently selected from H, halogen, hydroxyl, cyano, 3-12 membered heterocyclic group, 5-10 membered heteroaryl, C 6-10 Aryl, C 1-6 Alkyl, C 3-6 cycloalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkyl groups and C 1-6 The alkyl, cycloalkyl, alkoxy, haloalkyl, haloalkoxy, heterocyclic, heteroaryl, or aryl group is optionally selected by one or more groups, each independently selected from H, halogen, hydroxyl, amino, cyano, C. 1-6 Alkyl, C 3-6 cycloalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkyl groups and C 1-6 Substituents of haloalkoxy groups; Or, R c R d The N atom attached thereto forms a 3-8 membered heterocyclic group or a 5-10 membered heteroaryl group, wherein the heterocyclic group or heteroaryl group is optionally composed of one or more elements independently selected from H, D, halogen, hydroxyl, amino, cyano, =O, C. 1-6 Alkyl, C 3-6 cycloalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkyl groups and C 1-6 The alkyl halogen is preferably substituted by one or more groups, each independently selected from H, halogen, hydroxyl, amino, cyano, =O, C. 1-6 Alkyl, C 3-6 cycloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkyl, C 1-6 Substituents of haloalkoxy groups; Ar is selected from C 6-10 Aryl and 5-10 heteroaryl, wherein the aryl or heteroaryl is optionally surrounded by one or more R 2 replace; R 2 Each is independently selected from H, D, halogen, amino, cyano, nitro, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Haloalkyl, C 1-4 Alkoxy, C 3-10 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-10 Aryl and 5-10 heteroaryl groups, wherein the alkyl, cycloalkyl, heterocyclic, aryl, or heteroaryl group is optionally composed of one or more groups each independently selected from H, D, halogen, hydroxyl, amino, cyano, and C. 1-6 Alkyl substituents; preferably, R 2 Each is independently selected from H, halogen, amino, cyano, nitro, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Haloalkyl, C 1-4 Alkoxy, C 3-10 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-10 Aryl and 5-10 quinone heteroaryl groups, preferably H, halogen, amino, cyano, nitro, or C. 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Haloalkyl, C 3-10 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-10 Aryl and 5-10-membered heteroaryl groups, wherein the alkyl, cycloalkyl, heterocyclic, aryl, and heteroaryl groups are optionally surrounded by one or more groups selected from H, halogen, hydroxyl, amino, cyano, and C. 1-6 Alkyl substituents; p is independently selected from 0, 1, 2, 3, 4, 5 and 6; The compound of formula I may optionally be substituted at any position with one or more of the following substituents: D, halogen, -OH, -CN, -COOH, -NH2, C 1-6 Alkyl and C 1-6 Halogenated alkyl groups.
2. The compound according to claim 1, or its stereoisomers, tautomers, polymorphs, solvates, N-oxides, isotopically labeled compounds, or their metabolites, prodrugs, or pharmaceutically acceptable salts or esters, wherein, Ring A is a 3-14 membered heterocycle, wherein the heterocycle is optionally composed of one or more members independently selected from H, D, halogen, hydroxyl, amino, cyano, nitro, C. 1-4 Alkyl, C 3-6 Cycloalkyl, 3-10 membered heterocyclic, 5-10 membered heteroaryl, C 6-10 Aryl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-4 Haloalkyl, C 1-4 Alkoxy, C 1-4 Halogenated alkoxy groups, -C 1-4 Alkyl-OR a -C(=O)-(CH2) p -OR a -C(=O)-(CH2) p -NR a R b and -C 1-4 Alkylene-NR a R b The substituents are preferably selected from one or more groups, each independently chosen from H, halogen, hydroxyl, amino, cyano, nitro, C. 1-4 Alkyl, C 3-6 Cycloalkyl, 3-10 membered heterocyclic, 5-10 membered heteroaryl, C 6-10 Aryl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-4 Haloalkyl, C 1-4 Alkoxy, C 1-4 Halogenated alkoxy groups, -C 1-4 Alkyl-OR a -C(=O)-(CH2) p -OR a -C(=O)-(CH2) p -NR a R b and -C 1-4 Alkylene-NR a R b Substituents; or, Ring A is a 3-10 membered carbon ring, wherein the carbon ring is optionally composed of one or more elements independently selected from H, D, halogen, hydroxyl, amino, cyano, nitro, C. 1-6 Alkyl, C 3-6 Cycloalkyl, 3-12 membered heterocyclic, 5-10 membered heteroaryl, C 6-10 Aryl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy groups, -C 1-6 Alkyl-OR a -C(=O)-(CH2) p -OR a -C(=O)-(CH2) p -NR a R b and -C 1-6 Alkylene-NR a R b The substituents are preferably selected from one or more groups, each independently chosen from H, halogen, hydroxyl, amino, cyano, nitro, C. 1-6 Alkyl, C 3-6 Cycloalkyl, 3-12 membered heterocyclic, 5-10 membered heteroaryl, C 6-10 Aryl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy groups, -C 1-6 Alkyl-OR a -C(=O)-(CH2) p -OR a -C(=O)-(CH2) p -NR a R b and -C 1-6 Alkylene-NR a R b Substituents; or, Selected from or, Selected from 3. The compound according to claim 1 or 2, or its stereoisomers, tautomers, polymorphs, solvates, N-oxides, isotopically labeled compounds, or their metabolites, prodrugs, or pharmaceutically acceptable salts or esters, wherein the compound has the structure shown in Formula I-01: Y, X 1 X 2 L, Z, Ar, R 1 As defined in claim 1 or 2; R 3 Selected from H, D, halogen, hydroxyl, amino, cyano, nitro, C 1-6 Alkyl, C 3-6 Cycloalkyl, 3-12 membered heterocyclic, 5-10 membered heteroaryl, C 6-10 Aryl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy groups, -C 1-6 Alkyl-OR a -C(=O)-(CH2) p -OR a -C(=O)-(CH2) p -NR a R b and -C 1-6 Alkylene-NR a R b r, m, and n are each independently selected from 0, 1, 2, 3, and 4, and q is selected from 0-8 (e.g., 0-4, 0, 1, 2, 3). Alternatively, the compound may have the structure shown in Formula I-1: Y, X 1 X 2 L, Z, Ar, R 1 As defined in claim 1 or 2, m and n are each independently selected from 0, 1, 2, 3, and 4; Preferably, the compound of formula I has the structure shown in formula I-1-A, I-1-B, I-1-C, I-1-D, I-1-E or I-1-F: X 1 X 2 L, Z, Ar, R 1 As defined in claim 1 or 2, Y is independently selected from -CR a R b -、-O-、-NR a -、-S-、-S(O)- and -S(O)2-; Preferably, the compound of formula I has the structure shown in formula I-2: Y, L, Z, Ar, R 1 As defined in claim 1 or 2; m and n are each independently selected from 0, 1, 2, 3, 4; More preferably, the compound of formula I has the structure shown in formula I-2-A or formula I-2-B: Y, L, Z, Ar, R 1 As defined in any one of claims 1-2; Preferably, the compound of formula I has the structure shown in formula I-3-A, I-3-B, I-3-C, I-3-D, I-3-E or I-3-F: L, Z, Ar, R 1 and R a As defined in any one of claims 1-3; m and n are each independently selected from 0, 1, 2, 3, and 4.
4. The compound according to any one of claims 1-3, or a stereoisomer, tautomer, polymorph, solvate, N-oxide, isotopically labeled compound, or a metabolite, prodrug, or pharmaceutically acceptable salt or ester thereof, wherein, Y is selected from -CR a R b -、-O-、-NR a -、-S-、-S(O)- and -S(O)2-, where R a and R b Each is independently selected from H, D, halogen, hydroxyl, cyano, C 1-6 Alkyl, C 1-6 Haloalkyl, C 3-6 Cycloalkyl, -C(=O)R c and -SO2R c Preferably, H, halogen, hydroxyl, cyano, and C are preferred. 1-6 Alkyl, C 1-6 Haloalkyl, C 3-6 Cycloalkyl, -C(=O)R c and -SO2R c More preferably, H, halogen, hydroxyl, cyano, C 1-6 Alkyl, -C(=O)R c and -SO2R c Further optimization of H, halogen, hydroxyl, cyano and C groups. 1-6 Alkyl; R c Selected from C 1-6 Alkyl and C 3-6 cycloalkyl; Preferably, Y is selected from -C(CH3)(OH)-, -O-, -NH-, -S-, -S(O)-, -S(O)2-, -N(COCH3)-, -N(COCH2CH3)-, -N(C(O)isopropyl)-, -N(CH3)-, -N(COcyclopropyl)-, -N(S(O)2CH3)-, -N(isopropyl)-, -N(cyclobutyl)- and -N(CH2CF3)-; More preferably, Y is selected from -C(CH3)(OH)-, -O-, -NH-, -S-, -S(O)-, -S(O)2-, -N(COCH3)-, -N(COCH2CH3)-, -N(C(O)isopropyl)-, -N(CH3)-, -N(COcyclopropyl)- and -N(S(O)2CH3)-; More preferably, Y is selected from -C(CH3)(OH)-, -O-, -NH-, -S-, -S(O)- and -S(O)2-.
5. The compound according to any one of claims 1-4, or its stereoisomers, tautomers, polymorphs, solvates, N-oxides, isotopically labeled compounds, or their metabolites, prodrugs, or pharmaceutically acceptable salts or esters, wherein it has one or more of the following characteristics: (1) L is selected from 4-8 membered monocyclic rings, 3-10 membered heterocyclic rings, and 5-10 membered heteroaromatic rings, wherein the monocyclic ring, heterocyclic ring, or heteroaromatic ring is optionally selected by one or more independently from D, halogen, hydroxyl, amino, cyano, nitro, C 1-6 Alkyl, C 3-6 Cycloalkyl, 3-12 membered heterocyclic, 5-10 membered heteroaryl, C 6-10 Aryl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy groups, -C 1-6 Alkyl-OR a -C(=O)-(CH2) p -OR a -C(=O)-(CH2) p -NR a R b and -C 1-6 Alkylene-NR a R b The substituents are preferably selected from one or more groups, each independently chosen from halogen, hydroxyl, amino, cyano, nitro, C. 1-6 Alkyl, C 3-6 Cycloalkyl, 3-12 membered heterocyclic, 5-10 membered heteroaryl, C 6-10 Aryl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy groups, -C 1-6 Alkyl-OR a -C(=O)-(CH2) p -OR a -C(=O)-(CH2) p -NR a R b and -C 1-6 Alkylene-NR a R b Substituents of the substituents; (2) L is selected from 4-8 membered carbon rings, 3-10 membered nitrogen-containing heterocycles, and 5-10 membered nitrogen-containing heteroaromatic rings, wherein the carbon ring, heterocyclic group, or heteroaromatic group is optionally selected by one or more independently from H, D, halogen, hydroxyl, amino, cyano, nitro, C 1-6 Alkyl, C 3-6 Cycloalkyl, 3-12 membered heterocyclic, 5-10 membered heteroaryl, C 6-10 Aryl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy groups, -C 1-6 Alkyl-OR a -C(=O)-(CH2) p -OR a -C(=O)-(CH2) p -NR a R b and -C 1-6 Alkylene-NR a R b The substituents are preferably selected from one or more groups, each independently chosen from H, halogen, hydroxyl, amino, cyano, nitro, C. 1-6 Alkyl, C 3-6 Cycloalkyl, 3-12 membered heterocyclic, 5-10 membered heteroaryl, C 6-10 Aryl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy groups, -C 1-6 Alkyl-OR a -C(=O)-(CH2) p -OR a -C(=O)-(CH2) p -NR a R b and -C 1-6 Alkylene-NR a R b Substituents of the substituents; Alternatively, L can be selected from 4-8 membered carbon rings and 3-10 membered nitrogen-containing heterocycles; (3) L is selected from 4-8 membered carbon rings, 3-10 membered nitrogen-containing heterocycles, and 5-10 membered nitrogen-containing heteroaromatic rings, wherein the carbon ring, heterocyclic group, or heteroaromatic group is optionally selected by one or more independently from H, D, halogen, hydroxyl, amino, cyano, nitro, C 1-6 Alkyl and C 3-6 The cycloalkyl group is substituted, preferably by one or more groups independently selected from H, halogen, hydroxyl, amino, cyano, nitro, C. 1-6 Alkyl and C 3-6 Substituents of cycloalkyl groups; (4) L is selected from 4-8 membered carbon rings, 3-10 membered nitrogen-containing heterocycles, and 5-10 membered nitrogen-containing heteroaromatic rings, wherein the carbon ring, heterocyclic group, or heteroaromatic ring is optionally selected by one or more independently from H, D, halogen, hydroxyl, amino, and C. 1-6 The alkyl group is substituted, preferably by one or more groups, each independently selected from H, halogen, hydroxyl, amino, and C. 1-6 Alkyl substituents; (5) L is selected from 4-8 membered monocyclic rings and 3-6 membered nitrogen-containing mono-heterocyclic rings, wherein the monocyclic ring or mono-heterocyclic ring is optionally selected by one or more groups, each independently selected from D, halogen, hydroxyl, amino, cyano, nitro and C. 1-6 The alkyl group is substituted, preferably by one or more groups, each independently selected from halogen, hydroxyl, amino, cyano, nitro, and C. 1-6 Alkyl substituents; (6) L is selected from Preferably, L is selected from (7) Z is selected from covalent bonds, =C(R) a )-、-C(R a R b -, -O-, -S-, -N(R) a -, -C(=O)-, -S(=O)- and -S(=O)2-, preferably covalent bonds, -C(R)- a R b -, -O-, -S-, -N(R) a )-, -C(=O)-, -S(=O)- and -S(=O)2-; (8) Z is selected from covalent bonds, -CF2-, -CH2-, -CH(CH3)-, -CHF-, -O-, -C(=O)-, -S(=O)2-, =CH-, =CF-, -CD2-, -CDF-, =CD-, Preferably, Z is selected from covalent bonds, -CF2-, -CH2-, -CHF-, -O-, -C(=O)-, -S(=O)2-, =CH-, =CF-, -CD2-, -CDF-, =CD-, More preferably, Z is selected from covalent bonds, -CF2-, -CH2-, -CHF-, -O-, -C(=O)-, -S(=O)2-, =CH-, =CF-, More preferably, Z is selected from covalent bonds, -CF2-, -CH2-, -CHF-, -O-, -C(=O)-, and -S(=O)2-; (9)R 1 Selected from H, halogen, cyano, C 1-6 Alkyl, C 3-6 cycloalkyl, C 1-6 Haloalkyl, C 1-6 Haloalkoxy, -C(=O)R c -C 1-6 Alkyl-C(=O)-NR a R b NR a R b OR a SR a -NR a C(=O)R b -C(=O)-OR a -SOR a -SO2R a C 6-10 Aryl, 5-10-membered heteroaryl, and 3-12-membered heterocyclic groups, wherein the alkyl, cycloalkyl, aryl, heteroaryl, or heterocyclic group is optionally selected by one or more groups, each independently selected from H, =O, halogen, hydroxyl, amino, cyano, nitro, C 1-6 Alkyl, C 3-6 cycloalkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Hydroxyalkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy group, -C(=O)-(CH2) p -OR a -C(=O)-(CH2) p -NR a R b and -C 1-6 Alkylene-NR a R b The substituents are preferably selected from one or more groups, each independently chosen from H, halogen, hydroxyl, amino, cyano, nitro, C. 1-6 Alkyl, C 3-6 cycloalkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Hydroxyalkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy group, -C(=O)-(CH2) p -OR a -C(=O)-(CH2) p -NR a R b and -C 1-6 Alkylene-NR a R b Substituents of the substituents; (10)R 1 Selected from -cyclopropyl-CH2-OH, -NH-CH(CH3)2, -O-CH(CH3)2, -NH-cyclopropyl, -NH-cyclobutyl, -NH-CH(CH3)-CH2-OH, -NH-cyclopropyl-OH -S-CH(CH3)2, -CH2-CH(CH3)2 Preferably, R 1 Selected from -cyclopropyl-CH2-OH, -NH-CH(CH3)2, -O-CH(CH3)2, -NH-cyclopropyl, -NH-cyclobutyl, -NH-CH(CH3)-CH2-OH, -NH-cyclopropyl-OH -S-CH(CH3)2, -CH2-CH(CH3)2 (11) Ar is selected from C 6-10 Aryl and 5-10 nitrogen-containing heteroaryl groups, wherein the aryl and heteroaryl groups are optionally separated by one or more R groups. 2 replace; (12)R 2 Each is independently selected from H, D, F, Cl, Br, amino, cyano, nitro, C 1-4 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-4 Haloalkyl, C 1-4 Alkoxy, C 3-8 Cycloalkyl, 3-10 membered heterocyclic groups, C 6-10 Aryl and 5-10 heteroaryl groups, wherein the alkyl, cycloalkyl, heterocyclic, aryl, or heteroaryl group is optionally composed of one or more groups each independently selected from H, D, F, Cl, Br, hydroxyl, amino, cyano, and C. 1-4 Alkyl substituents; preferably, R 2 Each is independently selected from H, F, Cl, Br, amino, cyano, nitro, C 1-4 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-4 Haloalkyl, C 1-4 Alkoxy, C 3-8 Cycloalkyl, 3-10 membered heterocyclic groups, C 6-10 Aryl and 5-10 membered heteroaryl groups, preferably H, F, Cl, Br, amino, cyano, nitro, C 1-4 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-4 Haloalkyl, C 3-8 Cycloalkyl, 3-10 membered heterocyclic groups, C 6-10 Aryl and 5-10 heteroaryl groups, wherein the alkyl, cycloalkyl, heterocyclic, aryl, or heteroaryl group is optionally composed of one or more groups each independently selected from H, F, Cl, Br, hydroxyl, amino, cyano, and C. 1-4 Alkyl substituents; (13)R 2 Each is independently selected from H, D, F, Cl, amino, cyano, nitro, C 1-4 Alkyl, C 1-4 Haloalkyl, C 1-4 Alkoxy, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 Aryl and 5-10 heteroaryl groups, wherein the alkyl, cycloalkyl, heterocyclic, aryl, or heteroaryl group is optionally composed of one or more groups each independently selected from H, D, F, Cl, Br, hydroxyl, amino, cyano, and C. 1-4 Alkyl substituents; preferably, R 2 Each is independently selected from H, F, Cl, amino, cyano, nitro, C 1-4 Alkyl, C 1-4 Haloalkyl, C 1-4 Alkoxy, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 Aryl and 5-10 membered heteroaryl groups, preferably H, F, Cl, amino, cyano, nitro, C 1-4 Alkyl, C 1-4 Haloalkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 Aryl and 5-10 heteroaryl groups, wherein the alkyl, cycloalkyl, heterocyclic, aryl, or heteroaryl group is optionally composed of one or more groups each independently selected from H, F, Cl, Br, hydroxyl, amino, cyano, and C. 1-4 Alkyl substituents; (14) Ar is a phenyl group, which is optionally substituted with one or more (e.g., 2, 3, 4 or 5) substituents each independently selected from D, F and Cl, preferably substituted with one or more (e.g., 2, 3, 4 or 5) substituents each independently selected from F and Cl; preferably, Ar is a phenyl group, which is substituted with a plurality of (e.g., 2, 3, 4 or 5) substituents each independently selected from F and Cl. (15) Ar is selected from phenyl and pyridyl, wherein the phenyl and pyridyl are substituted by a plurality of (e.g. 2, 3, 4 or 5) substituents each independently selected from D, F, Cl, methyl and methoxy, preferably substituted by a plurality of (e.g. 2, 3, 4 or 5) substituents each independently selected from F, Cl, methyl and methoxy. (16)Ar is selected from Preferably, Ar is selected from (17)X 1 and X 2 Each is independently selected from N and CR, and R is selected from H, D, halogen, hydroxyl, cyano, nitro, amino, and C. 1-4 Alkyl, C 2-4 alkenyl, C 2-4 alkynyl group, C 1-4 Halogenated alkyl groups and C 3-8 Cycloalkyl groups, preferably H, halogen, hydroxyl, cyano, nitro, amino, or C. 1-4 Alkyl, C 2-4 alkenyl, C 2-4 alkynyl group, C 1-4 Halogenated alkyl groups and C 3-8 cycloalkyl; (18)X 1 and X 2 Each is independently selected from N and CR, and R is selected from H, D, F, Cl, Br, hydroxyl, cyano, nitro, amino, methyl, ethyl, propyl, C. 1-3 Halogenated alkyl groups and C 3-6 Cycloalkyl groups, preferably H, F, Cl, Br, hydroxyl, cyano, nitro, amino, methyl, ethyl, propyl, C 1-3 Halogenated alkyl groups and C 3-6 cycloalkyl; (19)X 1 and X 2 Each is independently selected from N and CH; (20)X 1 and X 2 At least one of them is CR, and each R is independently selected from H, D, F, Cl, Br, hydroxyl, cyano, nitro, amino, methyl, ethyl, propyl, C 1-3 Halogenated alkyl, cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl; (21)X 1 and X 2 For N; or, X 1 Selected from CH, C(F), C(Cl), C(CH3), C(CN), and C(cyclopropyl), X 2 For CH; or, X 1 For CH, X 2 Selected from CH, C(F), C(Cl), C(CH3), C(CN), and C(cyclopropyl); or, X 1 Let N, X 2 For CH; or, X 1 For CH, X 2 For N; or, X 1 Selected from CH, C(F), C(Cl), C(CH3) and C(CN), X 2 For CH; or, X 1 For CH, X 2 Selected from CH, C(F), C(Cl), C(CH3), and C(CN); (22) m and n are each independently selected from 0, 1 and 2; preferably, m is selected from 0 and 1, and n is selected from 1 and 2; (23) q is selected from 0, 1 and 2, preferably q is selected from 0 and 1; or q is selected from 3 and 4; (24) r is selected from 0, 1 and 2; preferably, r is selected from 0 and 1.
6. The compound according to any one of claims 1-5, or a stereoisomer, tautomer, polymorph, solvate, N-oxide, isotopically labeled compound, or a metabolite, prodrug, or pharmaceutically acceptable salt or ester thereof, wherein the compound of formula I has the structure shown in formulas I-8-A to I-8-E, preferably the structure shown in formulas I-8-A to I-8-C, more preferably I-8-A: Y is selected independently from -CR a R b -、-O-、-NR a -, -S-, -S(O)- and -S(O)2-, preferably -O-, -N(CH3)-, -N(isopropyl)-, -N(COCH3)- and -S(O)-, more preferably -O-, -N(CH3)- and -N(isopropyl)-, and even more preferably -O-; X 1 and X 2 Each is independently selected from CR and N; R is independently selected from H, halogen, cyano, C 1-6 Alkyl and C 3-10 Cycloalkyl, preferably H; Z is selected from covalent bonds, =CH-, -CR a R b -, -O-, -S- and -C(=O)-, preferably =CH- and -CR a R b - and -O-, more preferably -CF2-, -CHF-, -O- and =CH-, and even more preferably -CF2-, -CHF- and -O-; R 1 Selected from C 1-6 Alkyl, C 3-6 cycloalkyl, NR a R b OR a SR a 5-10-membered heteroaryl and 3-12-membered heterocyclic groups, wherein the alkyl, cycloalkyl, heteroaryl or heterocyclic group is optionally selected by one or more of each independently selected from H, D, =O, halogen, C 1-6 Alkyl, C 1-6 Hydroxyalkyl, C 1-6 Halogenated alkyl groups and C 1-6 Alkyl group substitution; preferably, R 1 Selected from NR a R b OR a and SR a More preferably, R 1 For NR a R b Further preferably, R 1 for R a Selected from halogens, hydroxyl groups, 3-12 membered heterocyclic groups, 5-10 membered heteroaryl groups, C 1-6 Alkyl, C 3-6 cycloalkyl, C 1-6 Haloalkyl, -C(=O)R c and -SO2R c Preferably, R a Selected from halogens, hydroxyl groups, 3-12 membered heterocyclic groups, C 1-6 Alkyl, C 3-6 cycloalkyl, C 1-6 Halogenated alkyl groups and -C(=O)R c More preferably, R a Selected from halogens, 3-12 membered heterocyclic groups, C 1-6 Alkyl groups and -C(=O)R c ; R c Selected from C 1-6 Alkyl and C 3-6 cycloalkyl; R b Selected from H, D, halogens, hydroxyl groups, 3-12 membered heterocyclic groups, 5-10 membered heteroaryl groups, C 1-6 Alkyl, C 3-6 cycloalkyl and C 1-6 Haloalkyl groups, preferably H, D, halogens, 3-12 membered heterocyclic groups, C 1-6 Alkyl, C 3-6 cycloalkyl and C 1-6 Halogenated alkyl groups, more preferably H, D, halogens and 3-12 membered heterocyclic groups.
7. The compound according to any one of claims 1-6, or a stereoisomer, tautomer, polymorph, solvate, N-oxide, isotopically labeled compound, or a metabolite, prodrug, or pharmaceutically acceptable salt or ester thereof, wherein the compound is selected from: Preferably, the compound is selected from:
8. A compound, or a stereoisomer, tautomer, polymorph, solvate, N-oxide, isotopically labeled compound, or a metabolite, prodrug, or pharmaceutically acceptable salt or ester thereof, wherein the compound has a structure as shown in Formula I': in, A' ring is selected from C 6-14 Aromatic rings and 3-14 membered heteroaromatic rings, wherein the aromatic rings or heteroaromatic rings are optionally selected by one or more groups, each independently selected from H, D, halogen, hydroxyl, amino, cyano, nitro, C 1-6 Alkyl, C 3-6 Cycloalkyl, 3-12 membered heterocyclic, 5-10 membered heteroaryl, C 6-10 Aryl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy groups, -C 1-6 Alkyl-OR a -C(=O)-(CH2) p -OR a -C(=O)-(CH2) p -NR a R b and -C 1-6 Alkylene-NR a R b The substituents are substituted; the heteroaromatic ring contains 1-3 heteroatoms, each independently selected from N, O and S; X 1 X 2 L, Z, Ar, R 1 R a and R b As defined in any one of claims 1-6; Preferably, Selected from 9. The compound according to claim 8, or its stereoisomers, tautomers, polymorphs, solvates, N-oxides, isotopically labeled compounds, or their metabolites, prodrugs, or pharmaceutically acceptable salts or esters, wherein, Compounds of formula I' have the structures shown in formula I'-1-A or I'-1-B: R' is independently selected from H, D, halogen, hydroxyl, amino, cyano, nitro, C 1-6 Alkyl, C 3-6 Cycloalkyl, 3-12 membered heterocyclic, 5-10 membered heteroaryl, C 6-10 Aryl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy groups, -C 1-6 Alkyl-OR a -C(=O)-(CH2) p -OR a -C(=O)-(CH2) p -NR a R b and -C 1-6 Alkylene-NR a R b ; p is selected from 0-3; X 1 X 2 L, Z, R 1 R a and R b As defined in any one of claims 1-6; Preferably, R 1 Selected from 10. The compound according to claim 8 or 9, or its stereoisomers, tautomers, polymorphs, solvates, N-oxides, isotopically labeled compounds, or their metabolites, prodrugs, or pharmaceutically acceptable salts or esters, wherein, The compounds mentioned are selected from: Preferably, the compound is selected from...
11. A pharmaceutical composition comprising a preventive and / or therapeutically effective amount of the compound according to any one of claims 1-10, or a stereoisomer, tautomer, polymorph, solvate, N-oxide, isotopically labeled compound, or a metabolite or prodrug or pharmaceutically acceptable salt or ester thereof, and one or more pharmaceutically acceptable excipients.
12. The use of any one of the compounds of claims 1-10, or their stereoisomers, tautomers, polymorphs, solvates, N-oxides, isotopically labeled compounds, or their metabolites, prodrugs, or pharmaceutically acceptable salts or esters, or the pharmaceutical composition of claim 11, in the preparation of a medicament for the prevention and / or treatment of diseases, particularly GPR6 receptor-mediated diseases; preferably, the GPR6 receptor-mediated diseases are selected from: movement disorders, including Parkinson's disease, levodopa-induced dyskinesia, Huntington's disease, drug addiction, eating disorders, cognitive impairment, schizophrenia, bipolar disorder, and depression.
13. The compound of any one of claims 1-10, or its stereoisomers, tautomers, polymorphs, solvates, N-oxides, isotopically labeled compounds, or their metabolites, prodrugs, or pharmaceutically acceptable salts or esters, or the pharmaceutical composition of claim 11, for the prevention and / or treatment of diseases, particularly the prevention and / or treatment of GPR6 receptor-mediated diseases; preferably, the GPR6 receptor-mediated diseases are selected from: movement disorders, including Parkinson's disease, levodopa-induced dyskinesia, Huntington's disease, drug addiction, eating disorders, cognitive impairment, schizophrenia, bipolar disorder, and depression.
14. A method for preventing and / or treating a disease, particularly a method for preventing and / or treating GPR6 receptor-mediated diseases, said method comprising administering to an individual in need an effective amount of any one of claims 1-10, or a stereoisomer, tautomer, polymorph, solvate, N-oxide, isotopically labeled compound, or a metabolite or prodrug or pharmaceutically acceptable salt or ester thereof, or a pharmaceutical composition of claim 11.
